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Sleep disturbances, pain and depression are common in nursing home (NH) patients 
and the assessment and treatment of these conditions are challenging. In this thesis, I 
aimed to investigate clinical assessment methods of sleep in NH patients, as well as 
the effects of pain treatment on sleep in NH patients with dementia and depression. 
The thesis was based on two large-scale studies conducted in Norwegian NHs. In 
paper 1, we conducted a cross-sectional study (n=83), which investigated the degree 
to which actigraphy-based and proxy-rater based assessments of sleep in NH patients 
provide comparable clinical outcomes. We compared the sleep-related items in the 
Neuropsychiatric Inventory – Nursing Home version (NPI-NH) and the Cornell Scale 
for Depression in Dementia (CSDD) with actigraphy assessments of sleep 
disturbances. In papers 2 and 3, we conducted a multicenter, two-armed, double-
blinded, placebo-controlled, randomised clinical trial. The present thesis reports 
secondary outcomes of this RCT and includes papers that aimed to investigate the 
short-term effects (paper 2) and long-term effects (paper 3) of pain treatment on sleep 
as measured with actigraphy in NH patients with dementia and depression (n=106). 
In paper 1, the CSDD and NPI-NH measures were found to have a very small to 
small chance of capturing the sleep outcomes identified by actigraphic recordings. 
We concluded that the usefulness of proxy-rater measures of sleep is unclear, and 
further research into their clinical value is needed. The results from papers 2 and 3 of 
the thesis show that active pain treatment improved sleep compared to placebo in the 
short-term (paper 2). However, no such effect was found in the long term (paper 3). 
From baseline to week 13 of the treatment period, there was considerable attrition of 
patients due to adverse events, suggesting that more research into which analgesics 
may be most suitable in people with dementia is needed. The underlying mechanism 
of the results from papers 2 and 3 is unknown, and future research should explore this 
with a different design – using analgesics that patients with dementia and depression 




treatment. To summarise, the thesis provides insight into strengths and weaknesses of 
different assessment tools that can be used to assess sleep in NH patients. It moreover 
sheds light on the effect of pain treatment on sleep in people with dementia and 





Sammendrag på norsk 
Søvnforstyrrelser, smerte og depresjon er utbredt blant sykehjemspasienter og 
representerer en stor utfordring med hensyn til behandling. Denne avhandlingens 
formål var å undersøke kliniske evalueringsmetoder for søvn blant 
sykehjemspasienter, samt effektene av smertebehandling på søvn hos 
sykehjemspasienter med demens og depresjon. Avhandlingen er basert på to 
omfattende empiriske studier gjennomført ved norske sykehjem. I artikkel 1 
gjennomførte vi en tverrsnittsstudie (n=83) hvor vi undersøkte i hvilken grad 
aktigrafibaserte og proxyrater-baserte evalueringer av søvn blant sykehjemspasienter 
gir sammenlignbare kliniske resultater. Vi sammenlignet søvnrelaterte mål i Cornell 
Scale for Depression in Dementia (CSDD) og Neuropsychiatric Inventory – Nursing 
Home version (NPI-NH) med søvnforstyrrelser identifisert med aktigrafi. I artikkel 2 
og 3 gjennomførte vi en multisenter, toarmet, dobbelblindet, placebokontrollert, 
randomisert klinisk studie. De to siste artiklene i denne avhandlingen er basert på det 
sekundære formålet med studien, hvilket var å undersøke kortsiktige effekter (artikkel 
2) og langsiktige effekter (artikkel 3) av smertebehandling på søvn målt med aktigrafi 
hos sykehjemspasienter med demens og depresjon (n=106).  
 
I artikkel 1 fant vi at målinger med CSDD og NPI-NH hadde fra svært liten til liten 
sannsynlighet for å fange opp søvnutfall som ble avdekket ved hjelp av 
aktigrafimålinger. Vi konkluderte at det er begrenset nytte av proxyratermåling av 
søvn, og at ytterligere forskning på den kliniske verdien av slike målinger er 
nødvendig. Resultatene fra artikkel 2 og 3 avdekket at aktiv smertebehandling 
forbedrer aktigrafimålt søvn sammenlignet med placebobehandling på kort sikt 
(artikkel 2). Imidlertid er disse resultatene ikke gyldige på lang sikt (artikkel 3). Fra 
baseline til uke 13 var det betydelig bortfall av pasienter som mottok aktiv 
smertebehandling grunnet ulike reaksjoner på den aktive behandlingen, hvilket 
indikerer at det er nødvendig med forskning med hensyn til hvilken smertebehandling 




resultatene er imidlertid ukjente og fremtidig forskning bør undersøke dette 
ytterligere, da med annet design og med preparater som tåles bedre i denne 
pasientgruppen. Fremtidige studier bør også fokusere på den kliniske verdien av 
denne typen behandling. Oppsummert bidrar avhandlingen med ny innsikt i 
svakhetene knyttet til mulige evalueringsverktøy for søvn blant sykehjemspasienter. 
Videre belyser den effekten av smertebehandling på søvn, hvilket kan danne grunnlag 
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In recent decades, life expectancy has increased and the proportion of the population 
in need of nursing home (NH) services has consequently escalated (Statistics Norway 
2018). NH patients are subject to multimorbidity and belong to a very fragile group. 
Sleep disturbances, dementia, pain and depression are all common in NH patients, 
and the combination of these often-coinciding conditions represents a comprehensive 
challenge for NH care (Flo et al. 2014).   
 
Sleep is essential for good health and well-being, and sleep architecture changes from 
younger to older age. Sleep disturbances are common in people with dementia 
(McCleery 2014). Depending on the definition of sleep disturbances, study designs 
and sample populations, the prevalence of sleep disturbances varies from 25% to 
more than 60% (Neikrug et al. 2010; Ownby et al. 2014; Monane et al. 1996). Due to 
reduced ability to give valid self-report among people with dementia, however, 
identifying sleep disturbances in this population is methodologically challenging.  
 
The causes of sleep disturbances may also be complex, and pain has been suggested 
as one underlying factor contributing to such disturbances (Flo et al. 2014). The 
presence of pain is widespread among elderly patients in NHs, and the causes of pain 
are similarly manifold (Achterberg et al. 2010). Furthermore, approximately 40-50% 
of patients with dementia experience symptoms of depression (Garre-Olmo et al. 
2003). Previous research indicates that depression and pain share common signal 
pathways and neurotransmitters and are responsive to comparable treatment – a 
relationship often referred to as the pain-depression dyad (Buysse et al. 1991; Chopra 
et al. 2014). Studies conducted in people without dementia suggest that depression 
may act as a mechanism through which pain influences sleep (Nicassio et al. 2012; 





Two challenges in NH medicine serve as point of departure for this thesis. First, 
attaining valid information about subjective experiences in people with dementia or 
possible dementia may be difficult due to reduced communicative skills (Flo et al. 
2014; Husebo et al. 2014a). In order to render such assessment possible for both 
research and clinical purposes, several clinical assessment tools for measuring sleep 
have been developed. It is, however, unclear to what extent they are used in the 
clinical setting. Being able to assess sleep using clinical assessment tools in NHs can 
be very valuable, and empirical investigation that can provide insight into the 
usefulness of such tools is therefore desirable. The first challenge thus relates to sleep 
assessment. 
 
The second challenge relates to treatment that can improve sleep. Prior research has 
suggested that pain might be an important cause of sleep disturbances in NH patients 
with possible dementia (Flo et al. 2017; Chen et al. 2011), and that pain treatment 
could potentially improve sleep (Husebo et al. 2014b). However, this has not yet been 
investigated in a placebo-controlled trial. Furthermore, in the NH setting, treatment is 
often conducted by trial-and-error with different approaches. This leads to a process 
in which NH staff is continuously evaluating and redirecting when the desired result 
stalls. This may result in NH staff giving pain treatment to patients with symptoms of 
depression and disturbed sleep in the hope that this will reduce these symptoms. A 
recent publication shows that from 2000 to 2011, there was an increase from 1.9% to 
17.9% of the prescription of strong opioids like fentanyl, buprenorphine, morphine 
and oxycodone in NH patients (Sandvik et al. 2016). The effect of these medications 
is, however, unclear. Thus, insight into the effect of pain treatment on sleep in NH 
patients with dementia and depression is of high clinical and scientific importance 
from the point of view of sleep medicine as well as geriatric medicine. 
 
In this thesis, then, I aim to investigate possible clinical assessment methods of sleep 
in NH patients, as well as the effects of pain treatment on sleep in this patient group. 




three empirical inquiries. First, we investigated different methods for measuring sleep 
in NHs, and specifically the degree to which proxy-rater based assessments and the 
more objective measurement of actigraphy provided comparable results. The second 
and third inquires were investigations of i) short-term and ii) long-term effects of pain 
treatment on sleep in NH patients with comorbid depression and dementia, by means 
of a large-scale randomised placebo-controlled clinical trial (RCT).  
 
The remainder of the thesis is structured as follows. First, I outline the background of 
the study and review existing research. Second, I present the aims of the thesis. Third, 
I outline the methods employed in the three papers comprised in the thesis. Fourth, I 
present the results of the three papers. Fifth, I discuss the methods and findings of the 
three papers in light of the overarching aims of the thesis. Finally, I outline 








In this chapter, I present the background, theory and prior empirical findings of 
relevance to the present inquiry. First, I outline the research setting by accounting for 
central characteristics of NH care and the nature and characteristics of patients with 
dementia. Second, I describe the nature of sleep, as well as the specific characteristics 
of sleep in the ageing population and among patients with dementia. I also account 
for assessment of sleep in this patient group. Third, I shed light on the nature of 
depression in general and of depression in patients with dementia in particular. 
Fourth, I account for pain in general and pain in NH patients in particular. Finally, I 
outline the rationale of the thesis.  
 
The literature search upon which this chapter builds involved the following medical 
subject headings (MeSH) keywords: sleep and dementia; pain and dementia; 
depression and dementia, and a combination of these. The search was conducted in 
PubMed. While the rationale for the studies reported herein was established based on 
existing literature at the time I commenced this work, the three papers and the 
following chapters have also been informed by more recently published works. The 
most recent literature search was conducted in February 2019.  
 
2.1 Research setting: Nursing home care and patients with dementia  
 
As people above the age of 65 constitute a large and increasing proportion of the 
population, the demand for nursing and care services increases. As of the end of 
2017, there were 32 733 long-term patients living in such institutions in Norway. In 
Norway, 1% of care service recipients are below the age of 50, while 74% are 80 
years or older (Statistics Norway 2018). As many as 27 647 of the 32 733 long-term 





Patients in NHs are commonly multimorbid and fragile (Fortin et al. 2005). 
Multimorbidity is defined by Boyd et al. (2010, p. 453) as “the co-existence of two or 
more chronic conditions, where one is not necessarily more central than the other”. 
The interaction of these diseases, the related drug treatment thereof, 
institutionalisation and loss of autonomy place NH patients in a very vulnerable 
position. In NHs, approximately 50% of patients have two to five diagnoses and 
approximately 30% have six or more diagnoses (Statistics Norway 2018). 
Furthermore, a diagnosis does not necessarily represent a chronic condition, but can 
be transitory. Previous research suggests that multimorbidity is associated with 
decreased function and quality of life, as well as with increased healthcare utilisation 




Dementia is a devastating chronic syndrome of cognitive decline, which is usually 
due to one or more neurodegenerative conditions that emerge in old age (Prince et al. 
2016). It is an incurable and progressive disease and it leads to a decline in the 
individual’s cognitive and physical functions. The influence on brain function 
interferes with the individual’s ability to function at work, in everyday activities and 
in relationships (Prince et al. 2015; Alzheimer’s Disease International 2016). The 
individual’s cognitive functions typically deteriorate progressively. These include 
memory, attention, problem thinking, learning and the ability to orientate in new and 
old environments (Prince et al. 2015; Alzheimer’s Disease International 2016). As the 
disease progresses, it influences the individual’s language and ability to speak. 
Moreover, the individual may experience manifold challenges related to bodily 
changes, e.g. incontinence, muscle stiffness and balance problems (Edjolo et al. 
2014).  
 
Currently, approximately 46.8 million people worldwide suffer from dementia. 




2016). In NHs, 50-80% of patients have possible dementia (Helvik et al. 2015). The 
World Health Organization declared dementia a public priority, citing high global 
prevalence and economic impact on families, communities and health service 
providers (WHO 2016). Dementia is considered the most expensive of contemporary 
diseases, and it is minimally responsive to medication currently available (Thies et al. 
2012).  
 
Normally, a diagnosis of dementia is based on the criteria listed in the International 
Classification of Diseases, version 10 (ICD-10) (WHO 2015) and the Diagnostic and 
Statistical Manual of Mental Disorders, 5th edition (DSM-5) (American Psychiatric 
Association 2013). It is worth noting that according to Statistics Norway (2018), only 
16% of long-term patients living under institutional care are diagnosed with 
dementia. Studies investigating cognitive function through assessment scales suggest 
that approximately 50-80% of patients have dementia (Helvik et al. 2015; Røen et al. 
2017). This is a challenge, since the planning of health and social care services and 
treatment relies on diagnostic coverage (Prince et al. 2016).  
 
Neuropsychiatric symptoms (NPS) or behavioural and psychological symptoms of 
dementia (BPSD) represent central aspects of the condition (Selbæk et al. 2014). 
Such symptoms include hallucinations, delusions, depression, apathy, anxiety, 
aggression, agitation, aberrant motor activity, changes in appetite and sleep 
disturbances (Selbæk et al. 2014). NPS occur in more than 80% of people with any 
type of dementia (Lyketsos et al. 2002), and are perceived as very troublesome. One 
of these symptoms – sleep disturbances – is often the leading cause for NH admission 
(Luppa et al. 2008). The type of dementia and progression thereof will affect the 








2.1.2 Different types of dementia 
 
Since Alois Alzheimer published his historical thesis in the early 20th century, there 
has been knowledge on the histopathological signature of Alzheimer’s disease – the 
amyloid plaques (Alzheimer, 1907). There are several subtypes of dementia, of which 
the most frequent are Alzheimer’s disease, vascular dementia, and the related 
conditions of dementia with Lewy bodies and dementia in Parkinson’s disease 
(McCleery et al. 2014). Alzheimer’s disease accounts for approximately 70% of all 
dementia cases (Ott et al. 1995). Although its pathogenesis is still somewhat unclear, 
Alzheimer’s disease is characterized by neurochemical and neuropathological 
changes. Its defining features are accumulation of amyloid-β peptides into 
extracellular plaques and development of intracellular neurofibrillary tangles due to 
hyperphosphorylation and accumulation of the tau protein (Rizzi et al. 2014). Other 
important features include visible changes in brain histology and behaviour.  
 
Vascular dementia, the second most common form, represents approximately 20-25% 
of cases (Kalaria et al. 2008; Desmond 1996; Prince et al. 2016). Vascular dementia 
is a result of neuronal damage caused by a disruption in the blood vessels to the brain. 
This leads to different clinical presentations depending on which brain area is 
affected, severity and type of disruption (haemorrhagic or ischemic) (Khan et al. 
2016). When comparing the clinical courses of Alzheimer’s disease and vascular 
dementia, the development of the latter is more stepwise. Also, it is caused by distinct 
ischemic episodes (Dickson 2001). However, comorbid Alzheimer’s disease and 
vascular dementia (so-called mixed dementia) is the most common form in NH 




Sleep is essential for good health and well-being, and every human being needs it. 




from and unresponsiveness to the environment” (Kryger et al. 2017). 
Polysomnography (PSG) gives comprehensive information about both sleep 
(classification of the different sleep stages) and wakefulness (Kryger et al. 2017; 
Sateia et al. 2000). PSG involves measurement of brain activity 
(electroencephalography [EEG]), eye movement (electrooculogram [EOG]) and 
muscle tone (electromyogram [EMG]). Clinical PSG often also involves assessment 
of respiratory, limb movement and cardiac activity (Kryger et al 2017). Based on 
PSG, we can broadly distinguish between rapid eye movement (REM) sleep and non-
rapid eye movement (NREM) sleep. As defined by the American Academy of Sleep 
Medicine (AASM), NREM sleep comprises three stages: N1, N2, and N3 (Iber et al. 
2007).  
 
The change from wakefulness to stage N1 is defined as change from alpha waves (8-
13 Hz – typically 9-11 Hz in adults) to theta waves (4-7 Hz). In stage N1, one may 
also observe vertex sharp waves and slow eye movements, but these are not required 
to score sleep as N1. In addition, reduced muscle tone and reduced awareness of the 
surroundings also characterise N1. Stage N2 is characterised by theta waves 
interspersed with specific EEG features, e.g. K-complexes and/or sleep spindles. In 
addition, further reduction in muscle tone and awareness is observed (Iber et al. 
2007). N3 is also referred to as slow wave sleep (SWS) or delta sleep (deep sleep). It 
is characterised by waves with high amplitude (at least 75µV from peak-to-peak) and 
low frequency (< 2 Hz) that occupy at least 20% of the epoch (Iber et al. 2007).  
REM sleep is defined by EEG activation, similar but not identical to wakefulness and 
is not divided into stages. Furthermore, muscle tone is very low or absent in REM 
sleep (Kryger et al. 2017). The different sleep stages progress from NREM to REM, 
in a sleep cycle that lasts approximately 90 minutes. There are 4-5 cycles in one 
nocturnal sleep period. The majority of deep sleep and restorative NREM sleep takes 
place in the beginning of the sleep period, while REM sleep is more common in the 





Individuals differ with regard to how much sleep they need to maintain a normal level 
of functioning and well-being (Bjorvatn and Pallesen 2009). Many bodily functions, 
like body temperature, degree of activation and secretion of hormones, follow a 
circadian rhythm. Circadian rhythms are 24-hour physiological rhythms regulated by 
an internal pacemaker in the suprachiasmatic nucleus (SCN) in the anterior 
hypothalamus (Kryger et al. 2017). Light is the primary environmental rhythm 
modulator of the light-dark cycle (Kryger et al. 2017). The circadian 
phototransduction involves rods and intrinsically photosensitive retinal ganglion 
cells. In this process, retina converts light signals into neural signals for the SCN 
(Figueiro et al. 2017). During night and in darkness, the hormone melatonin is 
produced by the pineal gland and it signals when it is time to sleep (Figueiro et al. 
2017). Melatonin production follows a cycle and the timing of melatonin onset in the 
evening is used as a marker for the circadian clock. This marker is referred to as dim 
light melatonin onset (Figueiro et al. 2017). Exposure to light at different times will 
affect the circadian rhythm system differently. Body temperature is often used as an 
expression for circadian rhythm and its lowest point reflects the rhythm base. This 
point is commonly known as nadir. Light in the morning, after nadir, which typically 
occurs approximately two hours before a person normally wakes up without alarm, 
will advance the timing of sleep. Light in the evening, before nadir, will delay the 
timing of sleep (Figueiro et al. 2017; Kryger et al. 2017).  
 
The homeostatic process involves an accruing need for sleep as a result of the prior 
period of wakefulness (Borbély 1982). This implies that the need for sleep increases 
the longer a person stays awake, which is believed to have implications for sleep 
quality (Bjorvatn and Pallesen 2009). The homeostatic and the circadian timing 
system are results of complex interactions between several brain regions, 
neurotransmitter systems and modulatory hormones (Wulff et al. 2010). Together 
with behavioural, environmental, individual and social processes, they regulate the 
quality, timing and duration of sleep (Bjorvatn and Pallesen 2009). In summary, 




and getting stable sleep duration requires regular bed and rise times (Bjorvatn and 
Pallesen 2009).  
 
2.2.1 Sleep and ageing 
 
Approximately 40% to 70% of older adults suffer from sleep disturbances (Van 
Someren et al. 2000; Maggi et al. 1998). With increasing age, sleep becomes more 
fragmented (Bliwise et al. 2009) and there is a decline in SWS and REM sleep 
(Ohayon et al. 2004). Older people spend more sleep time in the lighter stages of 
sleep (N1 and N2), which in turn increases the possibility for waking up more often 
during the night (Ancoli-Israel and Cooke 2005). Despite this, previous research 
suggests that older adults sleep approximately seven hours at night, which is 
comparable to younger adults (Ancoli-Israel 2009).  
 
Insomnia is one of the most widespread sleep disorders among adults (Mai et al. 
2008; Ancoli-Israel and Cooke, 2005). The definition of insomnia is subjective poor 
sleep attributed to problems with sleep onset, troubled night-time sleep or too early 
morning awakening (Manjavong et al. 2016; Kryger et al. 2017). In the adult 
population, prevalence studies suggest that approximately 10-20% suffer from 
insomnia (Ohayon et al. 1997; Pallesen et al. 2001). Among the elderly, however, 
reported prevalence of insomnia ranges from 45% to 60% (Manjavong et al. 2016; 
Kryger et al. 2017). The condition is associated with feeling unrefreshed, daytime 
sleepiness, impaired daytime attention and depression (Kryger et al. 2017). 
 
As age advances, the circadian rhythms may become weaker and less synchronised 
(Dijk et al. 1995; Ancoli-Israel and Cooke 2005; Forbes et al. 2014). A shift in older 
adults’ sleep/wake cycle is also often observed. This condition is denoted advanced 
sleep phase syndrome (Campbell et al. 1995). In elderly patients, this syndrome may 
lead to sleepiness early in the evening and early morning awakening. It may result in 




Cooke 2005). Several other sleep disorders are common in older adults, including 
periodic limb movements in sleep, sleep-disordered breathing, restless legs syndrome 
and REM sleep behaviour disorder (Ancoli-Israel and Cooke 2005).  
 
2.2.2 Sleep in people with dementia 
 
As previously mentioned, identifying sleep disturbances often depends on self-report, 
which can make it difficult to identify and treat such disturbances in people with 
dementia. Different studies report varying prevalence depending on how sleep 
disturbances are defined and which measurements are used. Studies report that 
approximately 60% of NH patients experience sleep disturbances, and prevalence 
differs according to the type of dementia (Neikrug and Ancoli-Israel 2010; Ownby et 
al. 2014). Sleep disturbances are reported in 25-35% of people with Alzheimer’s 
disease (Dauvillers 2007). The prevalence of sleep disturbances in people with 
vascular dementia is similar to that of Alzheimer’s disease. However, Fuh et al. 
(2005) found higher prevalence of sleep problems among patients with cortical 
vascular dementia. Sleep disturbances are particularly prevalent in people with Lewy 
bodies and Parkinson’s disease dementia. Compared to people with Alzheimer’s 
disease, these patients have higher rates of insomnia, excessive sleepiness, 
dyssomnias and parasomnias (Bliwise et al. 2011; Rongve et al. 2010). While studies 
have identified a link between neurodegeneration and sleep disturbances, the 
mechanisms are not fully understood. Research suggests that β-amyloid (Aβ) 
accumulation affects sleep, though this is probably mediated by several other 
variables (Holth et al. 2017). This was supported by the study by Fjell et al. (2018), 
which investigated to what extent biomarkers could predict sleep over a 3-year period 
in β-amyloid positive individuals. Fjell and colleagues found that multiple variables 
predicted sleep outcomes, including higher levels of tau and YKL-40 in the 
cerebrospinal fluid, depression scores, more brain atrophy and lower memory 





Sleep disturbances can be quite severe for people with dementia, and some of them 
may experience less than an hour of undisturbed sleep at any time (Bliwise et al. 
1989). The most common sleep disturbances are increased sleep onset latency, 
fragmented sleep at night, early morning awakening, and excessive daytime 
sleepiness (McCleery et al. 2014). These are all examples of abnormalities in sleep 
regulation. In people with dementia, low amplitude of the circadian rhythm may lead 
to mistimed and poorly consolidated bouts of sleep and wakefulness. Sleep 
disturbances in this group may thus be a direct result of neurodegeneration in the 
sleep-wake circuitry (McCleery et al. 2014). When compared to the younger 
population, people aged 65 and older are at risk of experiencing changes in the core 
body temperature, melatonin rhythm and circadian rest-activity cycle. These changes 
may manifest as fragmented nocturnal sleep, multiple and prolonged awakenings and 
more daytime napping (Forbes et al. 2014). Furthermore, these changes are more 
prevalent in people with dementia (McCurry et al. 2000).  
 
In addition to circadian rhythm disturbances, several other factors may contribute to 
sleep disturbances in people with dementia. The causes of sleep disturbances are 
comparable to those in people without dementia. The causes include pain (Flo et al. 
2017; Chen et al. 2011), physical health conditions, polypharmacy (Jokanovic et al. 
2015) and depression (Giron et al. 2002; Ownby et al. 2014). Being under 
institutional care might also contribute to sleep problems. For instance, artificial light 
exposure at night due to lights from bathrooms or corridors can shift the timing of the 
circadian pacemaker (Forbes et al. 2014). Noise from staff or other patients may also 
influence the patient’s ability to sleep. Daytime light exposure is rare among NH 
patients, which may also contribute to sleep difficulties at night (Forbes et al. 2014).  
 
Furthermore, sleep disturbances in people with dementia may be due to 
neurodegeneration in the suprachiasmatic nucleus or impaired melatonin production 
and release (Kinnunen et al. 2017; Van Someren 2000; Swaab et al. 1985; Gubin et 




term care patients (Neikrug and Ancoli-Israel 2010). Moreover, research has 
documented changes in the sleep architecture of people with Alzheimer’s disease, 
including a reduction of slow wave sleep (SWS), sleep spindle activity and REM 
sleep (Montplaisir et al. 1995; 1998). There is, however, no evidence suggesting that 
these changes are associated with subjective sleep disturbances.  
  
Sleep disturbances in people with dementia have manifold and potentially severe 
consequences. In institutionalised patients, sleep disturbances may impair daytime 
function (Cricco et al. 2001), reduce quality of life, and reduce memory and 
concentration (Ancoli-Israel and Cooke 2005). Sleep disturbances in NH patients 
may also have other consequences such as increased risk of falls, hip fractures (Stone 
et al. 2004; Widera 2013), and decreased survival (Dew et al. 2003). Sleep 
disturbances in people with dementia may moreover affect the sleep of those living at 
home with a carer (McCurry et al. 2007). Previous research shows that sleep 
disturbances may result in increased caregiver distress, which in turn increases the 
possibility that patients become institutionalised (Donaldson et al. 1998; Gaugler 
2000). Improving the treatment of sleep disturbances in NH patients would not only 
benefit the condition for patients, but also reduce the strain on NH staff (Pollak and 
Perlick 1991).  
 
2.2.3 Assessing sleep disturbances in people with dementia  
 
In light of the potentially severe consequences of sleep disturbances for NH patients, 
detection and treatment should have high clinical priority. However, the assessment 
and identification of sleep disturbances in people with dementia can be challenging. 
Several methods are used to assess sleep, of which I will emphasise three: PSG, 
actigraphy and proxy-rater assessment of sleep.  
 
PSG was introduced in the 1950s, and has since been regarded as the gold standard 




people with dementia for the following reasons: 1) some patients with dementia 
might perceive it as overly invasive; 2) electroencephalography does not produce 
clear patterns of sleep stages in people with dementia, and PSG results for patients 
with dementia are consequently very difficult to score (Bliwise 1993; Ancoli-Israel et 
al. 1997).  
 
Actigraphy records and generates 24-hour objective information on wakefulness and 
sleep based on activity/inactivity, and it is usually tolerated by patients with dementia 
(Kryger et al. 2017). Actigraphy equipment consists of an accelerometer and a 
memory storage unit, and is usually a watch-like device that patients can wear on the 
wrist. It is therefore considered to be a relatively non-invasive method for assessing 
sleep. Since PSG is the gold standard for sleep measurement, actigraphy measures 
should ideally correspond with PSG measurement. Sivertsen et al. (2006) found that 
actigraphy had high sensitivity (92.5%), but that its specificity (i.e. ability to detect 
wakefulness) was 36.3% among older adults treated for chronic insomnia. Sivertsen 
et al. (2006) therefore concluded that the clinical utility of actigraphy is still 
suboptimal, at least in older adults with insomnia.  It is however noteworthy that 
Ancoli-Israel et al (2003) concluded that actigraphy is reliable for assessing sleep 
patterns in people with insomnia, evaluating sleep in people who are less likely to 
tolerate PSG (such as patients with dementia) and for studying the effects of 
treatment which intend to improve sleep, among others.  
 
Sleep diaries are important clinical tools for subjective sleep assessment in the 
broader population (Carney et al. 2012), but their validity is questionable when used 
in people with dementia. Therefore, validated proxy-rated assessment tools could be 
useful to assess sleep in this patient group. Proxy-rater measurements can provide 
valuable information about patients based on the observations of close caregivers 
who function as proxy-raters. It is, however, essential that the proxy-rater has been 




the patient’s behaviour and render the proxy-rater able to identify changes. However, 
few assessment tools are validated for measuring sleep in NH patients.  
 
One assessment tool for measuring sleep is the Sleep Disorders Inventory (SDI), 
which is an expanded version of the sleep and night-time behaviour item in the 
Neuropsychiatric Inventory (NPI) (Cummings 1997). The SDI has been tested on 
people with Alzheimer’s disease who are living at home with a caregiver 
(Tractenberg et al. 2003). The SDI is found to have good validity for patients living at 
home and has been recommended for use in sleep research (Tractenberg et al. 2003). 
Other instruments, like the Cornell Scale for Depression in Dementia (CSDD), which 
is developed to measure depression in people with dementia, also contains items 
which evaluates sleep (Alexopolous et al. 1988a; 1988b; Barca et al. 2010).  
 
2.2.4 Treatment of sleep disturbances in people with dementia  
 
Medications are often sought to alleviate sleep disturbances in people with dementia. 
There is, however, no conclusive evidence that medications are effective, and they 
can also have harmful side-effects (McCleery et al 2014; Rapaport et al. 2018). Since 
sleep disturbances in persons with dementia may originate from changes in the brain 
caused by dementia, it is not clear whether regular sleep medications are effective 
(McCleery et al. 2014; Kinnunen et al. 2017; Van Someren 2000). Furthermore, 
research suggests that treating sleep disturbances increases amyloid deposition, and it 
is therefore possible that treating sleep disturbances may slow the progression of 
dementia (Holth et al. 2017). Different sleep disturbances call for different types of 
treatment, and there is need for more research that differentiates between types of 
sleep disturbances in this patient group and the treatment thereof. 
 
Several studies have examined how bright light therapy may affect sleep in people 
with dementia (Fetveit et al. 2004; Skjerve et al. 2004; Forbes et al. 2014). However, 




patient group (Forbes et al. 2014). Meanwhile, a more recent meta-analysis 
investigating the effect of bright light on sleep problems found a positive effect on 
sleep problems (van Maanen et al. 2016). Chiu et al. (2017) found that light therapy 
had a positive effect on behavioural disturbances, total sleep time and depression. A 
Cochrane review investigating the effect of different pharmacotherapies found no 
indication of improvements for ramelteon (selective melatonin receptor agonist for 
treatment of insomnia [Neubauer et al. 2008]) and melatonin. However, the use of 50 
mg Trazodone (triazolopyridine antidepressant used for treatment of insomnia 
[Mendelson, 2005]) showed increased nocturnal sleep time and sleep efficiency in 
patients with Alzheimer’s disease (McCleery et al. 2014).  
 
The difficulty of detecting and treating sleep disturbances in people with dementia 
suggests a need to investigate methods and treatments that can potentially improve 
the lives of these patients. As highlighted by Kinnunen et al. (2017), sleep is one of 
the cornerstones of human well-being. There is a pressing need for treatments that 
work and that can be used over the longer time periods. In light of this, clinical trials 
investigating potential treatments are highly needed. 
 
2.3 Depression  
 
According to DSM-5 criteria for major depressive disorder, the following symptoms 
have to be present during the same two-week period and represent a change from 
previous functioning: 1) depressed mood or 2) loss of interest or pleasure (American 
Psychiatric Association 2013). Symptoms include loss of appetite, energy, reduced 
concentration, sleep disturbances and pronounced fatigue. Changes in sleep profile 
are reported among 90% of the people experiencing an acute depressive episode 
(Wulff et al. 2010). Worldwide, approximately 300 million people of all ages suffer 






2.3.1 Depression in people with dementia  
 
In people with dementia, the occurrence of depressive symptoms is found to be 
approximately 40-50% (Garre-Olmo et al. 2003). Depression occurs more often in 
people with vascular dementia and dementia with Lewy bodies, compared to people 
with Alzheimer’s disease (Ballard et al. 2000; Borroni et al. 2008). In people with 
dementia, depression is often persistent or follows a fluctuating course (Borza et al. 
2014). With increasing dementia severity, depression is more prevalent, which in turn 
causes increased suffering and reduced quality of life (Gonzalez-Salvador et al. 
2000). Furthermore, some studies indicate that people with dementia and depression 
may be at risk of worse outcomes after undergoing medical treatment, and have 
increased mortality compared to those without depression (Bellelli et al. 2008; Rapp 
et al. 2011).  
 
2.3.2 Assessment of depression in people with dementia  
 
Diagnosing depression in people with dementia is difficult because of an overlap 
between the symptoms of depression and the early stages of dementia (Enache et al. 
2011). The symptoms observed in the early stages of dementia progression, such as 
reduced memory or lack of initiative, are also symptoms of depression (Brailean et al. 
2016). The above-mentioned CSDD is a reliable and valid assessment tool for 
measuring depression in this population. The CSDD consists of 19 items measuring 
five different domains related to depression. These domains are mood, behavioural 
disturbances, physical signs, cyclic functions and ideational disturbance (Alexopolous 
et al. 1988a; 1988b; Barca et al. 2010). The CSDD is often administered using proxy-
raters who are familiar with the patient. Jeon et al. (2015) compared and analysed 
CSDD scores from proxy-raters against expert diagnoses by means of ROC curves. 
They concluded that the clinical utility of the CSDD is questionable. In contrast, 
Hancock et al (2015) concluded that the CSDD was useful as a brief screening test 




2.3.3 Treatment of depression in people with dementia  
 
In 2017, the Norwegian Directorate of Health published guidelines for the treatment 
of depression in people with dementia (Norwegian Directorate of Health 2017). 
These recommendations correspond with other national guidelines. As first-line 
treatment, non-pharmacological treatment is recommended. This includes 
psychological treatment, person-centred care and reminiscence therapy. Studies 
investigating these interventions give some support that they reduce depressive 
symptoms in people with dementia and depression (Kales et al. 2015; Testad et al. 
2014; Orgeta et al. 2015). When non-pharmacological treatment has been attempted 
and no effect is seen, or depressive symptoms persist, pharmacological treatment is 
recommended. However, the decision to start treatment should be based on an 
evaluation of patients’ comorbidity, preferences and polypharmacy. It should also 
involve a careful evaluation of risk versus potential benefits. However, systematic 
reviews and meta-analyses investigating the efficacy of antidepressants for 
depression in people with dementia conclude that there is little support to recommend 
this treatment (Bains et al. 2002; Nelson et al. 2011; Leong et al. 2014). A study 
conducted by Banerjee et al. (2011) included 326 patients with depression and 
dementia. In this study, patients were allocated to receive mirtazapine, sertraline or 
placebo for 39 weeks with follow-up at week 13 and 39. In all three groups, CSDD 
scores had improved significantly in week 13, and this was unchanged from week 13 
to the follow-up at week 39. Taken together, studies investigating the efficacy of 
antidepressants highlight that there is no robust evidence to support treatment with 
antidepressants in this patient group. In light of these studies, investigating other 




The International Association for the Study of Pain (IASP) defines pain as “an 




tissue damage, or described in terms of such damage” (IASP 2017). Thus, it is a 
subjective experience. It is common to classify pain into two main types: nociceptive 
and neuropathic pain. According to the IASP, nociceptive pain denotes “pain that 
arises from actual or threatened damage to non-neural tissue and is due to activation 
of nociceptors”. Nociceptive pain includes somatic pain (pain derived from the 
musculoskeletal system) and visceral pain (pain related to the internal organs) (IASP 
2017). Neuropathic pain is related to the nervous system and is a result of a lesion or 
disease of the somatosensory system (IASP 2017; Dworkin 2012).  
 
2.4.1 Pain in people with dementia  
 
Pain is very common in people with dementia, and 40-60% of NH patients are 
estimated to experience daily pain (Achterberg et al. 2010). Pain may remain 
undetected, since people with dementia experience reduced ability to communicate 
and evaluate pain symptoms (Flo et al. 2014). Because pain is difficult to assess and 
recognise in people with dementia, pain is acknowledged as a major clinical 
challenge in this patient group. Therefore, it is important that a caregiver who is 
familiar with the patient observes the patient and is aided by validated assessment 
tools in the attempt to identify pain. The consequences of untreated pain may be 
manifold. Pain is associated with reduced quality of life, decline of activities of daily 
living, physical and mobility disability (Flo et al. 2014).   
 
2.4.2 Assessment of pain in people with dementia  
 
Several assessment tools have been developed for measuring pain in people with 
dementia, and such tools are designed to capture potential changes in patients’ typical 
behaviour when experiencing pain (Corbett et al. 2012; Sandvik 2017). Although pain 
is a subjective experience, in the NH setting, pain is often assessed by a proxy or a 
stand-in for the patient. In many cases, this is the patient’s primary nurse or another 




Hadjistavropoulos et al. (2010), however, the best clinical practice for pain 
assessment is to use the patient’s own self-reported data, when such information is 
possible to provide. The guidelines of the American Geriatric Society (AGS) Panel 
on Persistent Pain in Older Persons recommends evaluation of facial expressions, 
verbalisation and vocalisations, body movements, changes in interpersonal 
interactions, changes in activity patterns or routines and/or mental change (AGS 
2002). When NH patients experience persistent pain, functional and mental capacities 
may decline (Husebo et al. 2012). Manifold outcomes are associated with pain in NH 
patients, including reduced quality of life (Cordner et al. 2010), increased agitation 
(Husebo et al. 2011), depression and anxiety (Snow 2006). 
 
 2.4.3 Pain treatment in people with dementia  
 
A systematic review shows that when comparing people with and without dementia, 
people with dementia receive fewer analgesics (Tan et al. 2015). However, more 
recent research indicates that this discrepancy is decreasing and that that there has 
been an overall increase in the use of opioid analgesics (Sandvik et al. 2016; Tan et 
al. 2016). The most used non-opioid analgesic in NH patients with dementia is 
paracetamol. Sandvik et al. (2016) found that 48% of patients were prescribed 
paracetamol in 2011, which had increased from 23% in 2003. A central question is 
whether the treatment is effective. A double-blind, placebo-controlled crossover 
study investigating pain treatment (acetaminophen [paracetamol] 650 mg four times a 
day versus as-needed administration of acetaminophen) found no significant 
differences in discomfort scores between the different trial arms (Buffum et al. 2004). 
Chibnall et al. (2005) investigated the effect of acetaminophen on behaviour, well-
being, and psychotropic medication use in NH patients with moderate to severe 
dementia. They concluded that NH patients who received active pain treatment spent 
more time in social interaction and work-like activity. The authors therefore 
concluded that untreated pain inhibits activity in NH patients. Erdal et al. (2018) 




treatment (paracetamol and buprenorphine combined) compared to placebo. 
However, when conducting sub-group analyses, Erdal et al. (2018a) found a 
significant reduction in pain for those patients who received active paracetamol 
versus placebo. Taken together, the inconsistency of these results suggests that more 
research is necessary to investigate this relationship further.   
 




To the best of my knowledge there are no studies investigating the degree to which 
proxy-rater assessment tools identify sleep disturbances, as compared to actigraphy 
assessment, in the NH setting. The NPI-NH contains a sleep-related item that can be 
used to assess sleep. In addition, the CSDD, which is developed and validated to 
evaluate depression in this patient group, contains several items regarding sleep. It is 
likely that these items provide some information regarding how the NH staff 
considers the patients’ sleep.  
 
Towards this backdrop, the first rationale of this thesis was as follows:  
1) Identifying and treating sleep disturbances in NH patients should be a clinical 
priority.  
2) Few studies have investigated the sleep of NH patients as measured with 
proxy-rater assessment tools and actigraphy.  
3) It is valuable to compare the different methods in order to assess their 
strengths and weaknesses. This could provide new knowledge regarding the 








Papers 2 and 3 
Research on the previously mentioned pain-depression dyad suggests that pain and 
depression often coexist and exacerbate each other (Goldenberg et al. 2010; Bair et 
al. 2003). Moreover, pain and depression share joint signal pathways and 
neurotransmitters, and respond to comparable treatments (Chopra et al. 2014; Buysse 
et al. 1991). In previous research on neuropsychiatric symptoms, sleep is found to 
cluster with depression, anxiety and eating and appetite disturbances (Aalten et al. 
2003; Hollingwoth et al. 2006; Cheng et al. 2012; Selbaek et al.2012), which gives 
support for the link between sleep and depression. Pain may lead to depression, 
which in turn may influence the patient’s sleep (Flo et al. 2017; Niacassio et al. 2012; 
Valrie et al. 2008). Among patients with depression, as many as 90% have sleep 
complaints like frequent awakenings during the night, early morning awakenings 
and/or difficulties initiating sleep (Hamilton et al. 1989; Perlis et al. 1997; Franzen et 
al. 2008). Senba (2015) points out that chronic pain often coexists with insomnia, and 
that sleep and pain symptoms are considered to be reciprocally interacting (Senba 
2015; Finan et al. 2013; Lautenbacher et al. 2005). Smith et al (2005) found that 
approximately 50% of the patients with insomnia suffer from chronic pain (Smith et 
al. 2004). In clinical cases, it is well known that insomnia exacerbates pain and 
experimental studies have shown that sleep deprivation increases pain sensitivity 
(Finan et al. 2013; Sivertsen et al. 2015).  People with dementia and depression may 
be lying in bed, experiencing difficulty falling asleep or maintaining sleep because 
they are in pain. At the same time, these patients have reduced capacity to express 
their symptoms due to dementia. In such cases, the patients may receive sleep 
medication, when they are in fact experiencing pain. Secondary analyses from a 
cluster-randomised controlled trial showed that pain management had beneficial 
effects on mood symptoms, depression, apathy and sleep in people with agitation and 
dementia (Husebo et al. 2014). However, this was not a placebo-controlled trial, and 
only participants with clinically significant agitation were included. Taken together, 




disturbances are linked and exacerbate each other, as visualized in Figure 1 below. 




Figure 1: The relationship between pain, depression and sleep in patients with dementia 




Towards this backdrop, the second rationale of this thesis was as follows:  
1) Depression, pain and sleep may interact and reciprocally influence each other. 
Specifically, pain may lead to sleep problems, either through a direct route or 
mediated by depression. 
2) Giving pain treatment may therefore enhance sleep in people with dementia 






3. Aims   
 
The aim of this thesis was threefold. Its first aim was to investigate the degree to 
which actigraphy-based and proxy-rater-based assessments of sleep in NH patients 
provide comparable clinical outcomes. Its second and third aim was to investigate i) 
the short-term and ii) the long-term effects of pain treatment on sleep in people with 
comorbid dementia and depression. The thesis comprises three papers, which have 
the following aims:  
 
Paper 1:  
The first paper of the thesis is entitled Clinically Significant Discrepancies between 
Sleep Problems Assessed by Standard Clinical Tools and Actigraphy. It aimed to 
investigate different methods to assess sleep in NH patients. In addition, it aimed to 
investigate the degree to which actigraphy-based and standard proxy-rater-based 
assessments of sleep in NH patients provide similar results. The paper was published 
in BMC Geriatrics in 2017. 
 
Paper 2:  
The second paper of the thesis was entitled Effects of Pain Treatment on Sleep in 
Nursing Home Patients with Dementia and Depression – A Multicenter Placebo-
Controlled Randomised Clinical Trial. It aimed to investigate the short-term effects 
of pain treatment on sleep in NH patients with dementia and depression in a placebo-
controlled randomised clinical trial with objective sleep measurements. The paper 
was published in the International Journal of Geriatric Psychiatry in 2018.  
 
Paper 3:  
The third paper of the thesis was entitled Long-term Pain Treatment Did Not Improve 
Sleep in Nursing Home Patients with Comorbid Dementia and Depression: A 13-
week Randomized Placebo-Controlled Trial. It aimed to investigate the long-term 




depression in a placebo-controlled randomised clinical trial with objective sleep 






In this chapter, I give an account of the research design and methodological choices 
of the studies. First, I give a brief introduction to the datasets on which the thesis 
builds. Second, I outline the assessment tools used in the thesis. Third, I discuss the 
methods used in paper 1. Fourth, I discuss the experimental design of the RCT upon 
which papers 2 and 3 build.  
 
4.1 A brief introduction to the datasets  
 
Prior to the presentation of the research design and methodological choices, I 
introduce the two empirical studies from which the datasets are derived. Paper 1 uses 
data from the COSMOS study (COmmunication, Systematic pain treatment, 
Medication review, Organized activities and Safety) (Husebo et al. 2019). The 
COSMOS trial was approved by the Regional Committee for Medical and Health 
Research Ethics West Norway (REK 2013/1765), and was registered at 
www.clinicaltrials.gov (NCT02238652). The COSMOS study is a four-month 
cluster-randomised trial with follow up at month nine. The primary outcome was 
quality of life in NH patients after a complex intervention. The study, which included 
67 NH units, took place in Norway between January 2014 and December 2015. I was 
not involved in the COSMOS data collection process, and the secondary analyses of 
baseline data in paper 1 was not initially part of the COSMOS study design.  
 
Papers 2 and 3 use data from the DEP/SLEEP.PAIN.DEM study – a multicenter, 
randomised, placebo-controlled trial. The Norwegian Medicines Agency (EudraCT 
2013-002226-23) and the Regional Ethics Committee West (REC-West 2013/1474) 
granted approval to the DEP/SLEEP.PAIN.DEM study. The study’s Clinical Trial 





The present thesis builds on the sleep data from this trial. The following assessment 
tools are used in the papers: actigraphy, the Mini Mental Status Examination 
(MMSE), the CSDD and the NPI-NH. I conducted the entire data collection for the 
RCT reported in papers 2 and 3 together with Ane Erdal, whose PhD thesis was based 
on the primary outcome (depression).  
 
4.2  Assessment tools used in the thesis 
 
In the following, I will describe the assessment tools used in the present thesis – 




We used the Actiwatch Spectrum (Philips Respironics) for actigraphy measurement 
and Actiware 6 (Respironics) for sleep scoring. We set the sensitivity setting to 
medium, and the sleep/waking status was determined by the actiware software for 
each one-minute epoch. A trained technician conducted the process of scoring the 
activity protocols. A standardised hierarchical approach was used in order to set rest 
intervals for the actigraphy data. The following approach was used: 1) event markers 
when possible; or 2) light and activity data; or 3) light or activity data. We only 
implemented alternatives 2 and 3 if there was a clear differentiation between active 
and rest periods. If not, we excluded the actigraphy protocol. This approach applies to 
all three papers.  
 
4.2.2 Neuropsychiatric inventory – Nursing Home version  
 
The NPI-NH evaluates 12 neuropsychiatric symptoms in people with dementia; 
respectively: delusions; hallucinations; agitation; dysphoria; anxiety; apathy; 
irritability; euphoria; disinhibition; aberrant motor behaviour; and night-time 




process of the COSMOS study, neuropsychiatric symptoms were assessed in an 
interview with the patient’s primary caregiver using the NPI-NH. The NPI-NH 
produces an item score by multiplying the frequency and the severity of symptoms. 
Several studies have investigated the underlying factor structure of the NPI-NH and 
found the presence of three behavioural sub-syndromes: mood/apathy, psychosis, and 
hyperactivity. The sleep item was found to cluster with depression, anxiety and eating 
and appetite disturbances in the mood/apathy cluster (Aalten et al. 2003; 
Hollingworth et al. 2006; Cheng et al. 2012; Selbaek et al. 2012). The NPI-NH was 
used in paper 1 to assess sleep. 
 
4.2.3 Cornell Scale for Depression in Dementia 
 
The CSDD is validated to measure depression in people with dementia (see Appendix 
2). When using the CSDD, the proxy-rater gives a score for each of the 19 items 
ranging from zero (no depression) to two (severe symptoms), or the letter “a”, which 
implies that the symptom is not possible to evaluate. A total score is provided by 
adding all the results together. This provides a total score ranging from zero to 38 
(which is consistent with very severe depression). Barca et al. (2015) investigated the 
factor structure of the CSDD among 1682 patients with mild to severe dementia and 
identified five clusters of symptoms: mood, physical, cyclic, retardation and 
behaviour. The cyclic factor included multiple awakening, difficulty falling asleep 
and early morning awakening. All factors except mood and cyclic factors were found 
to increase as dementia progresses (Barca et al. 2015). A recently conducted meta-
analysis and systematic review found optimal sensitivity using a cut-off of equal or 
over 6 (sensitivity 0.91 and specificity 0.73), and optimal specificity using a cut-off 
of equal or over 8 (sensitivity 0.78 and specificity 0.84) (Goodarzi et al. 2017). The 
CSDD was used in paper 1 to investigate the correspondence between sleep items and 
actigraphy. In addition, the CSDD was used in the screening process of the 





4.2.4 Mini Mental Status Examination  
 
The MMSE is a brief cognitive screening test with a 30-point scale that consists of 20 
tasks (see Appendix 3), which gives indications of probable dementia (Creavin et al. 
2016). The MMSE is administered in direct interview with the patient. When using 
the MMSE, there are several important limitations that need to be acknowledged. 
Daily fluctuations in mood, vision, hearing ability, hunger, sleepiness, comfort, pain, 
stress, the temperature in the room, and the cooperation with interviewer are all 
aspects that may influence the answers from the responder. In addition, educational 
level, age and gender may also influence the answers (Creavin et al. 2016; De Silva et 
al. 2008; Finney et al. 2016). Some of these aspects can be handled before the 
interview begins, such as room temperature or hunger. We used the MMSE to assess 
patients’ cognitive function in all three papers. MMSE scores from 0 to 10 suggest 
severe dementia, 11 to 20 point to moderate dementia, 21 to 25 suggest mild 
dementia, and scores of 26 to 30 indicate no dementia (Perneczky et al. 2006).  It is 
important to highlight that the MMSE test can not be used alone to diagnose dementia 
(Creavin et al. 2016), and in the papers included in the present thesis we only use the 
MMSE results as an indication of probable dementia.  
 
4.2.5 Mobilisation-Observation-Behaviour-Intensity-Dementia-2 Pain Scale 
 
Mobilisation-Observation-Behaviour-Intensity-Dementia-2 Pain Scale (MOBID-2) is 
a validated, staff-administered instrument for measuring pain in people with 
advanced dementia (Husebo et al. 2007) (see Appendix 4). The score is based on the 
patient’s pain behaviour in connection with standardised guided movements when the 
patient is lying in bed. In addition, it evaluates pain behaviour related to internal 
organs, head and skin (Husebo et al. 2007). A total score, ranging from 0 to 10, of 
which 10 represents the worst possible pain, is generated through an evaluation of all 
observations. The cut-off to indicate clinically relevant pain is a score of ≥ 3 (Husebo 








The study in paper 1 has a cross-sectional design. We conducted secondary analyses 
on baseline data from the COSMOS trial (Husebo et al. 2015; 2019). The COSMOS 
dataset is comprehensive, and we used its baseline data on patient characteristics, 
sleep outcomes as measured by actigraphy and scores from the various proxy-rater 
instruments. This enabled us to compare sleep assessments by the different measures 
for each of the patients included in the study.  
 
4.3.2 Settings, participants and data collection 
 
The COSMOS trial was conducted at Norwegian NHs, and 700 patients were invited 
to participate. A research team containing of five persons (two PhD candidates, two 
research assistants and a medical professor) performed the data collection in 
cooperation with NH staff and patients. The research team included eight different 
NHs in the study. The intervention lasted four months, with data collection conducted 
at baseline, and after four and nine months, respectively. The intervention consisted 
of a standardised educational program. In paper 1, we include data assessed at 
baseline – before any intervention occurred. The nurses who functioned as proxy-
raters for the patients were instructed in the use of the different assessment scales 
prior to the evaluation.  
 
From this study population, 545 participants from 67 NH units at the eight NHs were 
included. Both urban/rural and large/small municipalities were included in order to 
gain a representative distribution of NHs. Inclusion criteria are listed in the sub-
section immediately below. After applying the inclusion criteria, we included 107 




excluded, either because of missing data or due to actigraph malfunction. Thus, the 
final sample included 83 patients, for whom actigraphy measurement was completed 
and CSDD and NPI-NH scores were collected. 
 
4.3.3 Inclusion and exclusion criteria  
 
The following inclusion criteria were applied for the COSMOS trial: 
- NH patients who were ≥ 65 years old,  
- with life expectancy > 6 months,  
- who were not diagnosed with schizophrenia 
The following patients were excluded from the actigraphy measurement:  
- patients who had paralysis in the arms or upper body,  
- or who had any form of chronic movement disorder 




In order to compare actigraphy-based and proxy-rater-based assessments of sleep, we 
had to define what constitutes disturbed sleep in this population. We applied the 
quantifiable criteria described in the DSM-5 diagnostic features for insomnia 
(American Psychiatric Association 2013). These cut-off points were used to define 
sleep disturbances as measured with actigraphy: sleep onset latency (SOL) > 30 
minutes; wake after sleep onset (WASO) > 30 minutes; early morning awakening 
(EMA) > 30 minutes. In addition, we used a cut-off of number of wake bouts (NoW) 
≥ 3 and a cut-off for sleep efficiency (SE) < 85% (Lacks and Morin 1992).   
 
To provide proxy-rater-based assessments of sleep, we used the sleep-related items in 
the Neuropsychiatric Inventory – Nursing Home version (NPI-NH) and in the Cornell 




item number 11 – night-time behaviour. It is important to note that the NPI-NH is the 
short version of the instrument. It is different from the more comprehensive version, 
which is named the NPI (see Appendix 1 for the NPI-NH).  
 
When scoring the sleep-related item in the NPI-NH, proxy-raters were asked the 
following questions (reprinted from paper 1):  
 Does the patient have sleep problems?  
 Is s/he awake during the night?  
 Does s/he wander during night-time, getting dressed, or going into the room of 
others? 
We calculated a product score for each patient. It was based on the frequency score 
for each symptom (score 1–4) and the corresponding severity score (score 1–3). In 
line with previously conducted studies, we used a cut-off at product score ≥ 4 to 
define the presence of sleep disturbances (Garcia-Alberca et al. 2013; Chwiszczuk et 
al. 2016).  
 
We used the CSDD to measure sleep as observed and judged by proxy-raters. In the 
category “cyclic functions”, the instrument includes the following three questions 
regarding sleep (reprinted from paper 1):  
 Item 13: “Does the patient have difficulty falling asleep?” 
 Item 14: “Does the patient have multiple awakenings during sleep?”  
 Item 15: “Does the patient have early morning awakenings? 
 
We scored the items as follows:  
 For item 13, we gave a score of 0 if the patient had no problem, a score of 1 if 
the patient only had difficulty falling asleep a few nights in the past week and 
2 if there was difficulty every night. 
 For item 14, we gave a score of 0 if the patient had no problem and a score of 




patient got out of bed in the middle of the night and/or had woken up every 
night in the past week.  
 For item 15, we gave a score of 0 if the patient had no problem. If the patient 
woke up early, but then went back to sleep a score of 1 was given. We gave a 
score of 2 if the patient woke up earlier than usual and could not go back to 
sleep.  
 
We used a cut-off score of ≥ 1 to describe sleep disturbances recognised by proxy-
raters for items 13 and 14. For item 15, we used a cut-off score of = 2. We used item 
13 as a measure of problems with sleep onset latency (SOL), item 14 as a measure of 
problems related to number of wake bouts (NoW), and item 15 as a measure of 
problems with early morning awakening (EMA). These measures was used when 
comparing the CSDD items and actigraphy measurements. It should be noted that the 
CSDD is not validated to measure sleep or sleep disturbances, but is a measure of 
depression. However, the questions listed above could still elicit valuable information 
about patients’ sleep, as it is designed to identify depression-related sleep problems. 
To my knowledge, no prior studies have used the CSDD for this purpose.  
 
4.3.5 Statistical analyses 
 
The empirical investigation compared the results from two methods of measuring 
sleep: actigraphy and the proxy-rater based approach. We calculated descriptive 
statistics for all relevant variables. Furthermore, in order to investigate whether the 
measures yielded comparable results, we conducted three analyses. First, we 
conducted McNemar’s tests to investigate if there were significant variances between 
the relevant measures. Cohen’s kappa tests were used to investigate the degree of 
similarity between the pairs of relevant measures from actigraphy, the NPI-NH and 
the CSDD, respectively. Third, we conducted sensitivity and specificity analyses for 
all of the pairs of measures. For the sensitivity and specificity analyses, we developed 




plotting the true positive rate against the false positive rate for the diagnostic test. 
Each ROC curve has an AUC (area-under-the-curve) value, which indicates the 
performance for each pair of measures. AUC values can be assessed as follows: a 
value of 1 = a perfect test, a value of 0.97 = a very good test, values below 0.75 = not 
clinically useful and values close to 0.5 = no discriminatory value (Fan et al. 2006).  
 




Papers 2 and 3 are based on a large-scale, double-blinded, multicenter placebo-
controlled randomised clinical trial. It reports the effects of pain treatment 
(paracetamol/buprenorphine) on actigraphy-measured sleep in people with dementia 
and depression. The results on sleep are secondary outcomes of an RCT that 
comprises both depression-related and sleep-related outcomes.  
 
In paper 2, Effects of Pain Treatment on Sleep in Nursing Home Patients with 
Dementia and Depression – A Multicenter Placebo-Controlled Randomised Clinical 
Trial, we used actigraphic sleep data collected for 14 consecutive days. The first 
week served as baseline measurement while the second week was the experimental 
period. Thus, paper 2 investigated the short-term effects of pain treatment.  
 
In paper 3, Long-Term Pain Treatment Did Not Improve Sleep in Nursing Home 
Patients with Comorbid Dementia and Depression: A 13-week Randomized Placebo-
Controlled Trial, we used actigraphic sleep data collected in the week before 
treatment commenced (baseline) and during week 13 of the treatment/placebo period. 






4.4.2 Setting, participants and data collection  
 
The RCT was conducted between August 2014 and September 2016. I conducted the 
data collection together with Ane Erdal. We collaborated with physicians and nurses 
working at the 47 NHs. I will describe this process in detail, because it gives insight 
into how we took care of patients’ interests and ensured high data quality.  
 
The data collection process started with contacting the municipal agency for elderly 
and nursing homes with a short presentation of the project. Agency managers who 
were favourable to the project forwarded e-mails to managers at the different NHs. 
We in turn contacted the NHs directly and agreed on a date for the first visit at the 
NH, where we gave a 45 minute presentation of the project to management, 
physicians and nurses at the NH. Any questions or misgivings were followed up 
directly. These meetings were a good opportunity to get acquainted with staff and 
gave them a chance to discuss the project with us.  
 
We then set a date for the second visit, during which we screened all patient journals 
in line with the list of inclusion and exclusion criteria. If there was sufficient time, we 
conducted a CSDD assessment. We took steps to discuss potential inclusion of 
patients who had scored equal to or above 8 on the CSDD. We discussed this with 
both the NH staff and the patient. If the patients were positive and the NH staff 
recommended inclusion, we called the patient’s next of kin/legal guardian and 
explained the study protocol to them. We explained the study aims, intervention and 
time use. In cases were the next of kin was positive to inclusion, we distributed a 
letter with comprehensive information about the study. We asked the next of kin to 
give presumed consent if they thought that the patient would be positive to inclusion 
if s/he were able to understand the study more thoroughly. Next of kin/legal guardian, 





After informed or presumed consent was given, we contacted the NH and set a date 
for the third visit. We tried to make the visits as unobtrusive as possible for NH staff. 
This implies that we visited the NH when the primary nurse who was familiar with 
the patient was working. In the following process, we coordinated all of our meetings 
so that the assessment would put minimal strain on the NH staff. We aimed to 
conduct all relevant measurement during the third visit. When conducting the 
measurements, we sat with the nurse and provided guidance on the proxy 
measurement. This was done in order to avoid any confusion regarding the 
assessment tools and to ensure high compliance from the staff. The process took 
approximately 1.5 to 4 hours per patient. Since the nurses who served as proxy-raters 
had to be taken out of regular work during data collection, it arguably put a strain on 
the rest of the NH staff and their patients. Neither proxy-raters nor NH staff received 
any compensation for their participation.  
 
During the third visit, patients who had CSDD scores below six were excluded. When 
all measurements were done and we had an overview of the medication list, we met 
with the NH physician. Based on the study protocol and the generated data thus far, 
we suggested either paracetamol or buprenorphine transdermal patch. We asked for 
the physician’s opinion on inclusion and for any contraindications that would make 
inclusion unfeasible. We also emphasised that the physician was responsible for the 
treatment. If judged as necessary, we conducted interaction analyses using the online 
tool www.interaksjoner.no (formerly known as DRUID). If the physician agreed to 
inclusion and analgesics treatment, the medication was noted in the patient’s 
medication chart with start and end date, type of medication and a number from the 
medicine package that indicated the allocation to treatment group. We told the 
physician and NH staff to be cautious regarding any potential change. We also told 
them to contact us 24/7 if there were any changes, or if there were any doubts 
regarding the treatment that implied that the medication should be discontinued 




instructed to open in the event that they needed to know immediately whether the 
patient received active or placebo treatment.  
 
During the fourth visit, we conducted the measurements for week six, which is not 
included in this thesis. During the fifth visit, we conducted the measurements for 
week 13. All of this was done in the same manner at 47 NHs in 11 different 
municipalities in Norway. During this period, data collection was a full time job for 
Erdal and me. We did the data collection independently of our supervisors and other 
research team members, but informed them about the number of patients included 
and any potential problems we faced during the process. 
 
4.4.3 Inclusion and exclusion criteria  
 
Patients were included if they were ≥ 60 years, long-term NH patients with > 4 weeks 
of stay. Importantly, depression and dementia were both inclusion criteria. We used 
the CSDD to assess depression. We required a CSDD score ≥ 8 for inclusion and 
allowed a fluctuation between 8 to 6 from screening to baseline. A cut-off point of 
8/9 has the best accuracy for setting a diagnosis of depression in line with ICD-10 
criteria (Barca et al. 2010). In papers 2 and 3, we used MMSE to assess possible 
dementia, and to be included, patients had to have a score of ≤ 20 (Perneczky et al. 
2006; Kuhull et al. 1994).  
 
In the actigraphy sub-project, we excluded patients if they did not want to wear an 
actigraph; were immobile or had involuntary movement; had paralysis in the arms or 
upper body or any form of chronic movement disorder; or were bed-ridden. 
Moreover, patients were excluded if they had cognitive impairment connected to 
other diagnoses than vascular dementia, Alzheimer’s disease, frontotemporal 
dementia, dementia with Lewy bodies, vascular dementia or mixed dementia; severe 
pain (MOBID-2 pain score ≥ 7); contraindication or clinically significant drug 




severe aggression (with NPI-NH aggression item ≥ 8); severe hepatic or renal failure; 
anaemia (haemoglobin < 8.5 mmol/L in men, < 7.5 mmol/L in women); uncontrolled 
epilepsy; severe illness not compatible with study participation; or planned treatments 
for any opioid analgesic additional to or exceeding buprenorphine 5 µg/hour (for a 
tabular overview, see Table 1 in paper 2).  
 
Of the 2323 patients from 47 NHs who were screened for potential inclusion, 162 
were eligible to participate in the broader DEP.PAIN.DEM study. Of those 162 
patients, the actigraphy sub-project reported on in papers 2 and 3 included 106 
participants. Of the 106 patients, 49 were randomly assigned to the placebo group and 
57 to the active treatment group. The flow chart in Figure 2 shows the full screening 







Figure 2: Flowchart showing screening and inclusion for paper 2 and 3 (reprinted 
from paper 2)  
 
It is noteworthy that pain was not an inclusion criterion in the intervention study. This 
choice was made for several reasons. One of the reasons was that pain is particularly 
difficult to assess in people with dementia. In the RCT, we assessed pain with the 
assessment tool Mobilisation-Observation-Behaviour-Intensity-Dementia-2 Pain 
Scale (MOBID-2). The instrument has good validity, interrater reliability, internal 
consistency and responsiveness (Husebo et al. 2014). This assessment tool was used 
to investigate how pain developed during the 13 weeks (with measurement at weeks 




a pain score of ≥ 7 or more at baseline. It would arguably have been unethical to 
include patients with high pain scores, since we would have had to be sure that these 
patients actually received active pain treatment rather than placebo. Furthermore, 
based on the above-mentioned pain-depression dyad, which suggests that pain and 
depression often coexist and exacerbate each other (Chopra et al. 2014), we assumed 
that depression could be an expression of pain. Finally, by not using pain as an 
inclusion criterion, we have larger variation in pain scores. This allows us to compare 
patients with and without probable pain, as measured with the MOBID-2. For these 




The patients received either paracetamol tablets/placebo tablets or buprenorphine 
transdermal system patch/placebo transdermal system patch. Paracetamol is one of 
the most used analgesic-antipyretic agents; however, the mechanism behind its effect 
is not fully understood (U.S. Food & Drug Administration 2017; Felleskatalogen 
2017). Buprenorphine resembles morphine, but it is a partial agonist; its maximum 
effect is less than that of morphine, and it antagonises the effect of other opioids (U.S. 
Food & Drug Administration 2017; Felleskatalogen 2017). We allocated patients who 
were already taking paracetamol ≤ 1 g/day prior to inclusion to active or placebo 
paracetamol tablets tablets max. 3 g/day. The study treatments were prescribed in 
addition to the basic dose by the NH physician. We assigned patients to active or 
placebo buprenorphine transdermal system 5 µg/h (max. 10 µg/h) if they were taking 
non-opioid analgesics/paracetamol > 1 g/day, and/or NSAID/buprenorphine (5 µg/h). 
It is important to emphasise the results from a previously conducted study by Husebo 
et al. (2014), in which the intervention group (n=175) were subject to an eight-week 
stepwise protocol for treating pain. The medications used were paracetamol, 
pregabalin, morphine and buprenorphine. The study suggested that the 




received an opioid were withdrawn from the study as a consequence of adverse 
events (Sandvik et al. 2014). 
 
We also assigned patients who had difficulty swallowing tablets to step 2 (see Table 
1). On a fixed day every week, the buprenorphine transdermal patch/placebo patch 
was changed. This is in line with administrative guidelines (Felleskatalogen, 2019). 
Patients who were taking buprenorphine transdermal 5 µg/h prior to inclusion were 
given the study treatment as an additional 5 µg/h transdermal patch (active or 
placebo). After inclusion and study treatment start-up, patients continued their usual 
medical treatment (including any regular or “as needed” (PRN – pro re nata) 
analgesic. No new PRN were allowed. 
 
*Except low-dose acetylsalicylic acid 
 
Table 1: Overview of how patients were assigned to treatments (reprinted from paper 
3).  
 
We advised clinicians to keep doses of psychotropic and analgesic drugs stable 
during the study period. This was done in an attempt to achieve stability and control 
over potential confounding variables. If any clinical changes occurred, they were to 
 
 
 Regular analgesic treatment Randomly  
assigned   















analgesics/paracetamol > 1 g/day, 
and/or NSAID*/or no analgesics - 
but with difficulty swallowing 
tablets  
 

















be treated adequately. If this treatment interfered with the study, we excluded the 
patients in question and registered the reason for exclusion. 
 
4.4.5 Outcomes  
  
The outcome measures were different sleep parameters as measured with actigraphy. 
In paper 2, the sleep-related outcomes were total sleep time (TST), sleep efficiency 
(SE), sleep onset latency (SOL), wake after sleep onset (WASO), early morning 
awakening (EMA) and number of wake bouts (NoW). In paper 3, we used the same 
sleep-related outcomes, but in addition, we measured daytime total sleep time (DTS). 
In paper 2, we registered activity continuously for 14 consecutive days, during which 
the intervention started on day eight. Thus, the first week of measurement constitutes 
the baseline. In paper 3, activity was registered continuously for seven consecutive 
days in week 13 of the treatment period, and compared to baseline data (which was 
one week prior to intervention, as in paper 2).  
 
4.4.6 Statistical analyses 
 
In paper 2, we calculated descriptive statistics for all relevant variables, which 
provided an overview of the characteristics of patients’ sleep in the entire sample, as 
well as in each of the experimental groups. Furthermore, we conducted a mixed 
within-between subjects ANOVA (placebo versus active treatment and pre-treatment 
versus post-treatment) for all sleep outcomes. In addition, we assessed differences 
between pre- and post-treatment sleep outcomes within each treatment group, using 
paired t-tests for each of the experimental groups separately.  
  
We also conducted several sub-group analyses for all sleep outcomes. The first sub-
group analyses, mixed within-between subjects ANOVA, investigated only patients 




group analyses, we compared the effect of active and placebo treatment for patients, 
whose MOBID-2 score was ≥ 3, i.e. patients who experienced pain at baseline. 
Finally, in the last sub-group analyses, we compared the effect of active 
buprenorphine to that of active paracetamol. We used IBM SPSS Statistics 22 for all 
the statistical analyses in paper 2.  
 
In paper 3, we similarly calculated descriptive statistics for all relevant variables and 
compared across the experimental groups. We chose linear mixed models that 
investigated the long-term effects (from baseline to week 13) of pain treatment for the 
main analyses in paper 3. This is because mixed models allow for regression-based 
analyses of treatment effects even in the case of considerable attrition, as long as data 
is missing at random (Bennett 2001). Thus, we can retain individuals with missing 
data at one time point in the analyses, which was valuable due to the attrition from 
baseline to week 13.  
 
In addition to the main model, we conducted similar mixed model analyses for three 
sub-groups. First, we investigated patients with MOBID-2 score ≥ 3. Second, we 
investigated patients with SE < 85%. Third, we compared patients receiving active 
paracetamol and active buprenorphine treatment, respectively. We also conducted a 
2x2 ANOVA analysis that included only data from the 58 patients who had complete 
data from week 13. We did this to explore if different analyses would give the same 







5. Main results  
 
In this chapter, I briefly outline the main results of the three published papers. I 
summarise the results from Clinically Significant Discrepancies between Sleep 
Problems Assessed by Standard Clinical Tools and Actigraphy (paper 1), Effects of 
Pain Treatment on Sleep in Nursing Home Patients with Dementia and Depression: A 
Multicenter Placebo-Controlled Randomised Trial (paper 2) and Long-Term Pain 
Treatment Did Not Improve Sleep in Nursing Home Patients with Comorbid 
Dementia and Depression: A 13-week Randomized Placebo-Controlled Trial (paper 
3) in the three sub-sections below. 
 
5.1 Paper 1 
 
 Sleep disturbances were common among NH patients (n=83), and our results 
suggest that they were even more prevalent than what is found in earlier 
studies. 
 Patients spend on average 12 hours and 20 minutes in bed.  
 Using the NPI-NH, NH staff categorised 20.5% of patients as having sleep 
disturbances. This was significantly lower than the comparable objective 
actigraphy measurement of sleep, which indicated that 89.2% had sleep 
efficiency below 85% (p<0.001) 
 Significantly more sleep disturbances relating to SOL, NoW and EMA were 
detected by actigraphy than by the CSDD sleep items (for all variables, 
p<0.001). 
 The CSDD and NPI-NH measures had from very small to small probability for 
capturing the sleep outcomes detected by actigraphy recordings. 
 When sleep was assessed with common clinical tools like the NPI-NH and the 
CSDD, sleep disturbances appeared to be underreported or unrecognised by 




5.2 Paper 2 
 
 In the full sample (n=106), SE (from 69.9% to 72.2%), SOL (from 31.7 min to 
24.6 min), and EMA (from 50.1 min to 40.5 min) improved for the active 
treatment group compared to the placebo group from baseline to week 1 (SE: 
p=0.003; SOL: p=0.047; EMA: p=0.043). 
 In the sub-group of patients with pre-existing sleep disturbances (SE < 85%) 
identified at baseline (n=89), the analyses revealed similar results as for the 
main effects. In addition, TST (from 477.7 min to 497.6 min) improved 
significantly for the active treatment group compared to the placebo group 
(TST: p=0.014).   
 There were no significant differences between active and placebo treatment for 
any of the sleep outcomes for the sub-group of patients who experienced pain 
at baseline (n=46).  
 There was a significant increase in TST (from 502.3 min to 534.0 min) for 
patients who received active buprenorphine (n=30) compared to those who 
received active paracetamol (n=25) (TST: p=0.016).  
 
5.3 Paper 3 
 
 We found no statistically significant differences between patients who 
received active pain treatment and those who received placebo treatment when 
analysing the full sample (n=106) from baseline to week 13. 
 In the sub-group of patients with pain at baseline, i.e. MOBID-2 scores ≥ 3 
(n=46), there were no statistically significant differences between the patients 
who received active treatment and those who received placebo treatment. 
 The analyses for the sub-group of patients with SE < 85% (n=90) showed no 
statistically significant differences between the patients who received active 




 The analyses for the sub-group of patients receiving the two different types of 
active pain treatment (n=57) revealed that TST (from 508.7 min to 580.6 min) 
and SE (from 68.7% to 77.4%) were both improved after 13 weeks for patients 
who received active buprenorphine compared with patients who received 







In this chapter, I discuss the findings of the three papers. First, I discuss strengths and 
weaknesses of the methods employed in the studies. Second, I discuss interpretations 
and implications of the results. Finally, I discuss ethical considerations related to the 
empirical investigation.   
 
6.1 Discussion of the methods 
 
The studies aimed to investigate the degree to which actigraphy-based and proxy-
rater based assessments of sleep in NH patients provide comparable clinical 
outcomes, and the short-term and long-term effects of pain treatment on sleep in NH 
patients with dementia and depression.  
 
We based paper 1 on secondary cross-sectional analyses of baseline data from a 
comprehensive RCT (Husebo et al. 2019) and papers 2 and 3 on a placebo-controlled, 
double-blinded RCT. In the sample for paper 1, we included both people with and 
without dementia. In papers 2 and 3, we included only people with possible dementia 
as measured with MMSE. All of the three studies employ actigraphy to measure 
sleep, and we recorded all socio-demographic variables from patients’ medical 
journals. In addition, we used the MMSE and the CSDD in all of the studies. In paper 
1, we used the NPI-NH, and in papers 2 and 3 we used the MOBID-2 to measure 
pain.  
 
The comprehensive work related to conducting the three studies in the clinical setting 
demonstrates the complexity of the challenges that NH staff faces every day trying to 
give the best possible care for patients. The nature of the studies, their different 




to employ a set of different statistical analyses. In the following, I discuss the selected 
research design and methods for the each of the papers.  
 




We based this paper on secondary analyses of baseline data, which implies that the 
study has a cross-sectional design. Given a representative selection, cross-sectional 
studies are often used to study prevalence, i.e. the number of cases in a population at 
a given point in time (Mann 2003). They can, however, also be used in comparative 
designs. Knowledge on the prevalence of sleep disturbances in NH patients is crucial 
for clinicians, since it provides information on the likelihood of sleep being a concern 
for the patient.  
 
Cross-sectional studies have several advantageous characteristics: they can generate 
information about many different variables and they can be effective in order to 
generate hypotheses (Rothman et al. 2008). However, their application is less useful 
to study causal and longitudinal relationships. Validated assessment tools or 
questionnaires are often used in cross-sectional studies (Mann 2003). In paper 1, we 
measured the sleep-related items in the NPI-NH and the CSDD and other descriptive 
data at the same time (baseline). The variables generated from the actigraphy data, 
however, reflect the mean score from activity/inactivity measured for seven 
consecutive days. Thus, we based the baseline score in actigraphy on average sleep 








Selection bias  
 
The COSMOS study population of 545 patients distributed across 67 NH units is a 
reasonably representative selection. The actigraphy sub-project included 83 patients 
for whom we had NPI-NH, CSDD and actigraphy measurements. Since we 
conducted actigraphy measurement in a sub-project comprised in the COSMOS 
project, we had to make a choice regarding which patients to include. We primarily 
made the decision based on the inclusion criteria. However, due to financial issues, 
i.e. the high monetary cost associated with acquiring actigraphs, we could not offer 
actigraphs to all patients who could potentially be included. Ideally, we would be able 
to offer actigraphs to more patients. The chosen solution was to offer actigraphs to 
the first ten patients in every NH unit. Thus, there was no true randomisation process 
in the selection of patients who were offered actigraphy measurement. The absence of 
true randomisation increases the risk of selection bias. We explored the likelihood of 
selection bias by investigating if there were statistically significant differences in 
baseline scores for relevant variables (age, MMSE sum score, CSDD sum score, 
gender, NPI-NH sum score) between the actigraphy sample (n=83) and the remainder 
of the study sample (n=462). We found no statistically significant differences, which 
suggests that the included patients were representative for the population under 
investigation on observed characteristics. We therefore concluded that the risk of 
selection bias was reasonably low. 
 
Challenges with the use of proxy-raters  
 
We used proxy-raters to collect data using the NPI-NH and the CSDD. As previously 
mentioned, a proxy-rater is a person who knows the patient well and who is 
consequently able to answer on the patient’s behalf (Pickard and Knight 2005). 
Proxy-raters are usually used when a respondent is not able to give valid self-report, 




however, a risk that using proxy-raters may increase the chance of information bias. 
This occurs in instances in which the rater consciously or unconsciously gives 
incorrect information, which in turn is registered as part of the data (Rothman et al. 
2008). The answers given by the proxy-rater may be influenced by the rater’s own 
perceptions and feelings (Snow et al. 2005). In addition, the results from the NPI-NH 
and the CSDD may be affected by recall bias. The answers given on the different 
assessment tools rely on the rater ability to recall past events (Althubaiti 2016). This 
can be challenging when assessing sleep using tools such as the NPI-NH and the 
CSDD.  
 
Night-time workers, who had primary insight into patients’ sleep during the night, 
conveyed information about patients to daytime workers, who in turn reported on 
patients’ sleep to the research team. This is how it is typically done in Norwegian 
NHs. Every morning, NH staff members sit down together and discuss each patient 
(whether any changes have occurred, how the patient has been sleeping etc.). In the 
event of no oral report being given, daytime staff reviews the report written by the 
night-time workers. This could potentially lead to information bias, for example due 
to misinterpretation or poor communication. We cannot correct for this in our 
research design, and it should consequently inform the interpretation of our results. If 
the COSMOS study was designed with the aim of the current study in mind, we 
would have done this differently, for instance the study would have benefitted from 
proxy-rating by night-time workers.  
 
Weaknesses related to the use of the CSDD to measure sleep 
 
One may also question the validity of the CSDD for measuring sleep disturbances, 
since the instrument is primarily developed to assess depression in people with 
dementia. While we are fully aware that these questions are not validated to measure 




relevant information about the proxy-rater’s perception of patients’ sleep. 
Interestingly, Jeon et al. (2015) demonstrated that the CSDD has limited value when 
administered by NH staff. This goes against prior findings suggesting that the 
instrument has high validity and reliability (Barca et al. 2010). Jeon et al. (2015) 
argued that the complexity of the scale and the time required collecting relevant 
information (in order to enable NH staff to assess the questions) were too 
comprehensive for proper use in a busy NH setting. It is reasonable to assume that 
this also applies to the use of the sleep-related items in the CSDD. It should be noted 
that the conclusions drawn by Jeon et al. (2015) are built on one single study, and 
there is arguably need for further empirical investigation of this question. Taken 
together, this implies that we need to interpret the results from the CSDD assessment 
with these limitations in mind.  
 
Comparing proxy-rated sleep with actigraphy-based sleep outcomes 
 
In paper 1, we used actigraphy as the reference point, which implies that we view it 
as a “gold standard” compared to the sleep-related items in the CSDD and the NPI-
NH. However, one can argue that actigraphy only gives an overview of activity 
versus inactivity. In light of what we know about the population under investigation, 
who lives under institutional care with little room for activity, the results from paper 
1 must be interpreted with caution. In addition, it should be noted that previously 
conducted studies show that actigraphy is less accurate in distinguishing sleep from 
wakefulness when sleep efficiency is reduced (Kushida et al. 2001; Sivertsen et al. 
2006). Importantly, when detecting wakefulness, actigraphy has low specificity 
(36.3%), while its sensitivity for detecting sleep is high (95.2%). In paper 1, 89.2% 
had sleep efficiency below 85%, which implies that sleep as measured with 
actigraphy may overestimate the amount of time patients are actually sleeping. 
Moreover, as stated in paper 1, this means that the sensitivity for sleep as measured 
with the sleep-related items in the CSDD and the NPI-NH may be even lower than 




Furthermore, in relation to paper 1, the nature of the study does not allow for 
concluding on the question of whether the divergence between actigraphy recordings 
and proxy-rater assessments was due to the rating instruments or due to the raters. 
However, this would be an interesting topic for future research.  
 
6.1.2 Discussion of the methods used in papers 2 and 3 
 
Randomisation and blinding process 
 
Papers 2 and 3 are based on a 13-week double-blind, placebo-controlled, randomised 
clinical trial. RCTs are considered to provide the most reliable evidence on the 
effectiveness of interventions (Kendall 2003; Akobeng 2005), because their 
characteristics largely eliminate the risk of confounding factors influencing the 
outcome. No members of the research team were involved in the production of the 
randomisation list. There was no use of stratification factors. While randomisation 
can limit the chance of selection bias, it does not guarantee that the experimental 
groups are identical with regard to patient characteristics (Akobeng 2005). This 
implies that there can still be unobserved, confounding variables. In the attempt to 
avoid confounding variables, stratification factors are widely used. Examples of such 
factors can be important and different prognostic features that may serve to generate 
separate block randomisation lists (Akobeng 2005). All of the included patients in the 
DEP.PAIN.DEM project were offered actigraphs if they fulfilled all of the above-
mentioned inclusion criteria and none of the exclusion criteria for the actigraphy sub-
project. This implies that the patients were randomised to active or placebo treatment 
before we knew if they were included in the sleep sub-project (see the flow chart on 
p. 46). 57 patients who were randomised to active treatment and 49 patients 
randomised to placebo treatment was included in the sleep sub-project. We found no 
statistically significant differences between the two groups (active versus placebo) 




randomisation holds reasonably well despite this minor asymmetry in the two 
experimental groups. 
 
To ensure double blinding of the study, a statistician provided the research team with 
a blinded, sequential list of pack identification numbers. We assigned patients 
consecutively to the next pack number in the list when they were included in the 
study. The packages with active/placebo buprenorphine transdermal system or 
paracetamol were identical. The paracetamol tablets were purchased from Kragerø 
Tablettproduksjon AS, Norway, while Mundipharma Research Limited, UK provided 
buprenorphine transdermal system. These companies were otherwise not involved in 
the study. It was not possible for patients, NH staff or members of the research team 
to know if the patient received placebo or active treatment. If the patient or NH staff 
had known which treatment the patients received, it could affect the assessment and 
by extension the results.  
 
Internal validity and bias 
 
Internal validity is a central measure of the quality of RCTs. Studies have high 
internal validity when it is possible to attribute observed differences between the 
groups to the intervention under investigation (Akobeng 2008). Two important types 
of error threaten internal validity: systematic errors and random errors. In clinical 
trials, there are four main sources of systematic error: selection bias, performance 
bias, detection bias and attrition bias (Akobeng 2008; Keirse and Hanssens 2000). 
Successful randomisation eliminates selection bias, which results in the control group 
and the treatment group being very similar in relevant characteristics at baseline 
(Kendall 2003; Akobeng 2008). Thus, one would expect that treatment effects are not 





Performance bias occurs when there are systematic differences in the provision of 
care to the groups under investigation, or the exposure to other factors that could 
influence measured outcomes (Akobeng 2008). For instance, if NH staff in our study 
had not been blinded regarding which patients were in each of the treatment groups, it 
could influence their treatment of the patients. This could in turn have influenced 
patients’ sleep. Performance bias is slightly different from the well-known 
Hawthorne effect, i.e. that participants may consciously or unconsciously modify 
their behaviour due to being observed (Goodwin et al. 2017). The fact that we blinded 
NH staff mitigates the risk of performance bias in our study.  
 
Detection bias refers to systematic differences between groups with regard to how 
outcomes were assessed, in particular the assessment of subjective outcomes. If raters 
have knowledge about treatment allocation, it could influence their assessment of the 
condition of patients (Akobeng 2008). We avoided such issues in papers 2 and 3 by 
using objective outcomes (actigraphy) and masking NH staff regarding the allocation 
of treatments. This limits the potential effect of both performance bias and detection 
bias. Since the study is double-blinded and the randomisation was successful, we 
conclude that these issues pose no significant threats to internal validity in papers 2 
and 3.  
 
Attrition bias occurs when there are systematic differences between the experimental 
groups with regard to the loss and withdrawal of participants (Akobeng 2008). In the 
period investigated in paper 2, i.e. from baseline to week one, two patients were 
withdrawn from the study because of adverse reactions to buprenorphine. Such 
limited attrition is very unlikely to result in systematic differences. However, in paper 
3, 48 patients dropped out from baseline to week 13 of the treatment period. This 
creates a risk of systematic differences between patients who dropped out and those 
who completed the study period. However, as discussed in the following, we used 




Dealing with missing data 
 
In paper 3, we based the main empirical investigations on linear mixed model 
analyses. Such analyses are appropriate in light of the substantial missing data for 
actigraphy measurement in week 13. Mixed model analyses make it possible to 
conduct regression-based analyses for treatment effects, even in the event of 
considerable attrition. This is due to the method allowing for retaining data for 
subjects that have missing data for one or more important variables (Bennett 2001). 
However, the usefulness of the method and its ability to tackle the problems related to 
attrition rely on the type of missing data, i.e. data must be missing at random.  
 
To examine if this assumption held, we investigated and compared baseline 
characteristics (age, gender, CSDD score, MOBID-2 score, NPI-NH score and 
MMSE score) between patients who dropped out of the study (n=48) and those who 
completed the study (n=58). The results showed no statistically significant 
differences in any of the relevant baseline characteristics. This strengthens the case 
for assuming that the data was missing at random. The implication is that one can 
infer that potential treatment effects do not rely on the mechanism that caused the 
missing data (Bennett 2001). However, we should note with caution that there could 
be other systematic differences, for instance in these patients’ reactions to treatment, 
or in other unobserved factors that appeared after we conducted baseline 
measurement.  
 
Sleep as a secondary outcome 
The study was not designed with sleep as its primary outcome. This implies that we 
did not include only patients with sleep disturbances or differentiate between 
different kinds of sleep disturbances. Instead, we included all patients who met the 
inclusion criteria, regardless of whether they had sleep disturbances or not, and of the 




types of treatment, which was not taken into account in the design of the study. 
However, the aim of papers 2 and 3 was to investigate the short-term and long-term 
effectiveness of pain treatment on sleep in people with dementia and depression. The 
results for the depression outcome in the broader study, which is reported by Erdal et 
al. (2018a), showed that analgesic treatment did not reduce symptoms of depression. 
These results have implications for the interpretation of the results included in the 
present study. As previously mentioned, studies investigating the relationship 
between sleep, pain and depression in people without cognitive impairment have 
shown that depression can be a mechanism through which pain leads to sleep 
disturbances (Niacassio et al. 2012; Valrie et al. 2007). Our rationale was that there is 
an interactive relationship between depression, pain and sleep, and that they may 
reciprocally influence each other. Since symptoms of depression were not reduced in 
the group of patients who received active pain treatment (Erdal et al. 2018a), the 
results from papers 2 and 3 can mainly be seen as generating new hypotheses for 
further research.  
 
Type I and II error 
 
In papers 2 and 3, we risk type 1 errors due to our reliance on multiple outcome 
measures (SE, SOL, EMA, WASO, NoW, TST, DTS). Using multiple outcomes 
without correcting for multiple comparisons increases the risk that significant effects 
are found for one or more outcomes, even when in fact there are none. As stated on p. 
668 in paper 2, “we did not correct for multiple comparisons in our study. However, a 
simple Bonferroni correction would be overly conservative and would increase the 
risk of type II errors. Therefore, we urge the reader to take the lack of such correction 
into account in the interpretation of the findings of the study.”  
 
The Bonferroni correction, discussed by e.g. Zhang et al. (2001), implies dividing the 
p-value significance threshold (0.05) by the number of hypotheses tested (in the case 




critical value of p = 0.0083. In our main results, this would imply that only the SE 
result, i.e. one of three statistically significant results, would remain significant. 
However, as pointed out by Feise (2002, p. 2), an objection to such adjustment is that 
“if you reduce the chance of making a type I error, you increase the chance of making 
a type II error”. Such an approach could be too conservative. An alternative approach 
would be to merge these measures into one global test statistic (see e.g. Pocock 
1997). However, these measures cannot easily be transformed in this way, since they 
are a combination of measures capturing short time periods (e.g. EMA), long time 
periods (e.g. TST), percentages (e.g. SE) and numbers/frequency (e.g. NoW).  
 
Regarding adjustments of p-values, such efforts are complicated by the fact that our 
investigation includes repeated measures, as pointed out by Bender and Lange 
(2001). Finally, it is possible to treat each of the outcome variables as different facets 
of the phenomenon worthy of equal interest in the empirical investigation (cf. Pocock 
1997). There are several previous studies with comparable designs (e.g. Fetveit and 
Bjorvatn 2004; Taibi et al. 2009) that report a similar set of outcome variables 
without correcting for multiple comparisons. It is, in any case, important to consider 




The results of an internally valid RCT may be limited if the study results are not 
applicable to the broader population of patients. External validity concerns the degree 
to which the results of a study provide evidence than can be generalised beyond the 
study and applied in other similar clinical circumstances (Akobeng 2008). If external 
validity is high, results can be generalised into similar settings in the “real world” 





The comprehensive combination of inclusion and exclusion criteria in papers 2 and 3 
is cause for some concern. In particular, the inclusion criteria requiring that patients 
had to be depressed according to the CSDD and not prescribed any opioid analgesics 
(5 µg/h buprenorphine transdermal prior to inclusion was permitted) made it difficult 
to recruit patients to the study. Furthermore, the patients had to have dementia 
according to the MMSE (cut-off score < 20). Combined, these criteria account for 
1596 of the 2323 excluded patients. Therefore, the final sample is quite sub-selected 
relative to the broader population. 
 
When conducting mixed model analyses, we estimated intraclass correlation 
coefficients (ICC), which give an indication of the dependency of the patients 
belonging to the same NH. That is, ICCs provide information on the dependency of 
patient observations within the same NH (same medical doctor, same nurses etc.) 
(Twisk 2006). Our preliminary ICC analyses showed that observations within units 
were not significantly clustered within the NH units. We therefore conducted mixed 
models with random intercept. In the present study, it could be argued that NH 
patients with depression and dementia are the relevant population to which the results 
may be generalised.  
 
Based on this evaluation, we conclude that the studies have reasonably good internal 
and external validity, although there are some issues discussed above that should 
inform the interpretation and evaluation of the results.  
 
6.2 Discussion of the results 
 
In the following, I discuss important aspects of the results in the three papers: First, I 
discuss the clinical usefulness of proxy-rater assessment. Second, I discuss how to 
identify sleep disturbances in NHs. Third, I discuss the subjective value of the 
improvement in sleep outcomes. Finally, I discuss whether we should recommend 




6.2.1 Are proxy-rater assessments of sleep clinically useful? 
 
Paper 1 suggests that sleep disturbances were underreported or unrecognised in 
proxy-rater assessments by NH staff. This is an important finding, since it raises 
questions about the usefulness of this approach for detecting sleep disturbances in NH 
patients. It therefore leaves us questioning whether proxy-rater tools are adequate for 
assessing sleep in people with dementia.  
 
Valid proxy-rater assessment of sleep disturbances could provide useful information 
for the treatment of such disturbances. Selbæk et al. (2012) investigated the 
Norwegian version of the NPI-NH and concluded that it is reliable and valid for 
assessing psychiatric symptoms in NH patients. In paper 1, we investigated one of the 
items from the NPI-NH – item 11, which assesses sleep disturbances. Even though 
measuring sleep with actigraphy also has its limitations, the divergence between the 
outcomes is striking.  
 
One of the results from paper 1 shows that patients spend on average 12 hours and 20 
minutes in bed (from lights off in the evening to lights on in the morning). This is in 
line with previous findings (Fetveit and Bjorvatn 2002). Spending this amount of 
time in bed may enhance the likelihood of pain, wound development, hunger, and the 
feeling of being isolated. The study design does not allow us to investigate whether 
the patients were in bed for that amount of time because they wanted to, or if it was 
necessary due to institutional constraints. Either way, it may be harmful spending 
such an amount of time in bed, and obviously one cannot expect the patient to be 
sleeping for such a long period. In light of the time spent in bed, it is not surprising 
that almost 90% of patients had SE below the cut-off of 85%. We compared 
actigraphy measurement of SE with measurements of item 11 in the NPI-NH, which 
reads: “Does the patient have sleep problems? Is s/he awake during the night? Does 




comparison could yield suboptimal results, since SE is likely based on an inflated 
amount of time spent in bed, which translates into low SE.  
 
Actigraphy data do not provide information on several factors captured by item 11 in 
the NPI-NH, such as whether patients wander during night-time or go into other 
patients’ rooms. However, patients engaging in such behaviours would likely be 
assessed by proxy-raters as having night-time sleep difficulties. Thus, their NPI-NH 
item 11 score would correspond with low actigraphic SE. Therefore, we argue that 
the comparison between the two measurements at least provide some valuable 
information for clinicians and researchers.  
 
The CSDD items used in paper 1 are validated for measuring depression rather than 
sleep, but contain quite specific items regarding sleep. Yet, the results show 
significant discrepancies between the sleep-related items in the CSDD and 
actigraphy. This contrasts with findings by Fetveit and Bjorvatn (2002), who found 
consistency between NH staff observations of SOL and EMA and actigraphic 
measurements. We should note that NH staff who were proxy-raters in the Fetveit 
and Bjorvatn (2002) study observed and noted rise and bed times, which is arguably 
likely to provide more awareness of patients’ sleep. For this reason, those results are 
not quite comparable to the findings from paper 1 in this study. Meanwhile, the 
results from Fetveit and Bjorvatns’s study suggest that increased focus on patient’s 
bed routines may improve proxy-rated sleep assessment. 
 
An additional issue with the proxy-rater sleep measurement is that daytime workers 
served as proxy-raters. However, the information about patients’ sleep had been 
conveyed to them from night-time workers, who were likely to observe disturbed 
sleep in mobile or vocalizing patients. This communication might be influenced by 
several unobserved factors, such as the relationship between the workers, time 
pressure, noise, bias and so on. Moreover, it might be that information about the 




represented in information conveyed to the daytime workers. The proxy-raters thus at 
best reported indirect perceptions of patients’ night-time sleep. Nevertheless, this may 
represent how patients’ sleep is assessed in the nursing home setting. 
To summarise, actigraphy, the CSDD and the NPI-NH are not optimal tools for 
measuring sleep in people with dementia. The CSDD is developed to measure 
depression, while the NPI-NH is developed to measure the presence and severity of 
different neuropsychiatric symptoms including sleep. To use actigraphy as a 
reference is also questionable. In paper 1, we used several cut-offs to identify sleep 
disturbances. However, when the patients spend more than 12 hours in bed, the 
meaning of the different sleep parameters and cut-offs become uncertain. So when 
this sub-section asks whether proxy-rater assessments are clinically useful, it is 
important to acknowledge the weaknesses associated with the different assessment 
methods used in paper 1.  
 
Furthermore, we cannot assume that sleep is assessed on a regular basis in the NH, 
and there is currently no optimal method to assess sleep in this patient group. In paper 
1, we state that the NPI-NH and the CSDD are common clinical tools. However, to 
what degree these instruments are actually used is uncertain. However, based on 
experience, we expect that to the extent that sleep is assessed, the NPI-NH and the 
CSDD are used or looked at for inspiration. Currently, actigraphy is arguably the best 
method to measure sleep objectively in people with possible dementia (Ancoli-Israel 
et al. 1997; 2003). As pointed out in paper 1, when sleep was measured with the NPI-
NH and the CSDD, sleep disturbances were clearly underreported or unrecognised by 
NH staff, when compared to actigraphy. It is, however, unclear whether this reflects 
that the instruments poorly measure sleep, that the cut-offs used in the actigraphy 








6.2.2 How should NH staff identify sleep disturbances?  
 
Our studies demonstrate the difficulty of the dual tasks of identifying and treating 
sleep disturbances in NH patients. Since proxy-rater measurement has low degree of 
agreement with actigraphy, it makes us question what else can be done. NHs are 
demanding workplaces, and it would be very valuable to have reliable assessment 
tools for NH staff to use in the everyday pursuit of good, evidence-based care and 
medical treatment to patients.  
 
Our findings leave us questioning the value of the sleep-related items in the CSDD 
and the NPI-NH to measure sleep in NH patients. Although some studies recommend 
actigraphy as a supplement to proxy-rater assessment (see e.g. Most et al. 2012), it is 
likely too time-consuming and costly for measuring sleep in NH patients.  
 
A potentially beneficial instrument in research and the clinical setting is the SDI – an 
expanded version of item 11 in the NPI-NH. A study conducted by Tractenberg et al. 
(2003) showed that the instrument correlated with actigraphy-derived sleep 
measurement, except for 24-hour measurement of TST and DTS. However, in that 
study, live-in caregivers evaluated sleep in persons with Alzheimer’s disease who 
were living at home. A potentially fruitful avenue for future research would be to 
examine the clinical utility of the SDI also in the NH setting. A potentially beneficial 
idea would be to have systematic routines for observations during night shifts, also 
including sleep diaries.   
 
6.2.3 Pain treatment increased sleep as measured with actigraphy, but did patients 
sleep better?  
 
In the RCT reported in papers 2 and 3, we used actigraphic measurements to 




pain treatment improved sleep (specifically, SE, SOL and EMA) in the shorter term, 
but these effects did not sustain in the longer term. However, we found an increase in 
TST (short-term and long-term) and SE (long-term) in patients receiving active 
buprenorphine treatment compared to active paracetamol. The rationale behind 
papers 2 and 3 was based on growing support of the hypothesis that pain, depression 
and sleep disturbances are linked and exacerbate each other (Senba et al 2015; 
Chopra et al. 2014; Finan et al. 2013), and may be alleviated by pain treatment 
(Husebo et al. 2013). However, neither pain nor sleep disturbances were inclusion 
criteria in the present RCT. If pain and sleep disturbances had been inclusion criteria, 
it would allow us to examine the relationship more thoroughly. Furthermore, our 
research design does not allow us to ascertain how symptoms of depression may have 
influenced the effect of pain treatment on sleep, since we did not compare patients 
with and without such symptoms. Importantly, however, as discussed in section 4.4.3, 
using the additional inclusion criteria of pain and sleep disturbances would cause 
other problems. These include threats to generalisability as a consequence of an even 
more sub-selected sample, and challenges for the randomisation of active and placebo 
medication, since allocating patients with pain to placebo medication would be 
ethically questionable. 
 
In addition, we cannot conclude that the significant improvement shown with 
actigraphy represents a subjective improvement for the patient. To examine this, it 
would have been necessary to rely on self-reported data in cases where this was 
possible to collect. In cases where such self-reported data had not been attainable, it 
would have strengthened the study to include sleep diaries. As discussed above, 
proxy-raters should seek to observe patients during the night. This could potentially 
give additional and valuable information on patients’ subjective sleep experiences.  
 
Among the patients included in our RCT, some may have experienced pain and 
others not. As shown in papers 2 and 3, we had to screen 2323 patients from 47 NHs 




MMSE and depression as measured with the CSDD. Having pain and sleep 
disturbances as additional inclusion criteria would necessitate screening even more 
patients, which in turn would have demanded even more resources in the data 
collection process. Since we did not have pain as an inclusion criterion, we conducted 
sub-group analyses in which we only included patients who experienced pain at 
baseline. However, no effect of pain treatment on sleep was found. Importantly, the 
sub-group of patients with pain, dementia and depression was small (n=46), and these 
are secondary analyses.    
 
It should be noted that the prescription of all opioids to NH patients in Norway has 
increased from 11% in 2000 to 24% in 2011 (Sandvik et al. 2016). Buprenorphine, 
which arrived on the Norwegian market in 2005, has been found to be prescribed to 
10.5% of 1542 Norwegian NH patients with dementia (Sandvik et al. 2016). In a 
recent study that investigates opioid prescription use in NH residents with advanced 
dementia, the prevalence of strong opioid prescription was 19.3%. As pointed out by 
Sandvik et al. (2016), there was a stark increase in the prescription of strong opioids 
like fentanyl, buprenorphine, morphine and oxycodone to NH patients from 2000 to 
2011. Despite the use of opioids, 79.4% of those patients were still experiencing signs 
of pain (Griffioen et al. 2017). These findings suggest that more studies investigating 
the potential effect of these medications in this particular patient group are necessary.  
 
A potential explanation for the results in papers 2 and 3 is sedation. Sedation is a 
common adverse effect of buprenorphine which has been found to affect 
approximately 29% of the patients over the age of 65 with and without dementia 
(Pergolizzi et al. 2017). Erdal et al. (2018b) found that nine participants receiving 
active treatment were excluded from our RCT because of symptoms of sedation. 
Furthermore, patients who received buprenorphine had a significant reduction in 
daytime activity as measured with actigraphy (Erdal et al. 2018b). This indicates that 





To summarise, we found that pain treatment had an effect on sleep outcomes in the 
short term; however, the underlying mechanism is unclear. We cannot conclude 
unequivocally why we found such effects. It is moreover uncertain whether the 
changes were of subjective value for patients, which is a highly important question 
Although we did find changes in a positive direction in several sleep parameters 
among patients who received active treatment in the short-term, we do not have 
conclusive evidence that patients in fact slept better.    
   
6.2.4 Can pain treatment be recommended to improve sleep? 
 
Although our results show that pain treatment had beneficial effects on some sleep 
parameters in the short-term, we cannot generally recommend pain treatment for 
improving sleep in these patients. This would require more conclusive evidence that 
the treatment actually improved sleep. Furthermore, an important aspect to take into 
account is the comprehensive attrition between week one of the treatment period and 
week 13 in our study. The total attrition was 48 patients, and it was most prevalent in 
the group of patients who received active buprenorphine (n=22) as compared to 
active paracetamol (n=13). The results from Erdal et al. (2018b) also highlight this – 
in particular the finding of significantly higher discontinuation due to adverse events 
in patients who received buprenorphine. This could be an indication that low 
tolerance for buprenorphine was one of the reasons for attrition. If so, this is a further 
argument against the use of such medication to improve sleep.  
 
Treating sleep disturbances in this very fragile group of patients is challenging and 
important. Successful treatment may improve daytime functioning and quality of life, 
and it may possibly slow the progression of dementia (Kinnunen et al. 2017). The 
previously mentioned Cochrane review investigated the effect of light therapy for 
improving cognitive function, activities of daily living, sleep, challenging behaviour, 
and psychiatric disturbances in dementia (Forbes et al. 2014). Another recent 




ramelteon) compared to placebo for sleep disorders in people with dementia 
(McCleery et al. 2014). However, the conclusions are quite disappointing. In the first 
review, no effect was found of light therapy on sleep. In the second review, a distinct 
lack of evidence to help guide drug treatments was discovered. A concern is that if 
the source of sleep difficulties is due to changes in the brain caused by dementia, it is 
not clear if treatment with common drugs is effective in this particular patient group 
(McCleery et al. 2014). Meanwhile, positive effects of bright light treatment was 
reported in an above-mentioned meta-analysis of the effect of such treatment on 
different types of sleep problems, including sleep problems associated with dementia 
(Van Maanen et al. (2016) . Moreover, a recent meta-analysis, which only included 
RCTs on the effects of light therapy in dementia and mild cognitive impairment, 
reported moderate effect sizes on both behavioural disturbances and depression and a 
small effect size on total sleep (Chiu et al. 2017).  
 
6.3 Ethical considerations 
 
Patients with different levels of cognitive impairment took part in the studies. Doing 
research that includes people with cognitive impairment gives rise to research-ethical 
concerns, since these patients have reduced ability to understand the aim of the 
studies and the effort required to partake. Prior to data collection, we discussed 
patients’ medical decision-making capacity with NH staff familiar with them. Based 
on this evaluation, we attempted to modify information about the studies and the 
effort required to be part of the study.  
 
For patients evaluated to lack the ability to give informed consent, presumed consent 
was obtained through direct conversation with their legal guardians. Legal guardians 
(usually family members) were encouraged to evaluate if they thought the patients 
would like to take part if they had had the ability to understand fully the aim of the 
study. This implies that we cannot be sure that some patients included in the study did 




In light of this, one could argue that it might not be appropriate to conduct research in 
this fragile group. However, one can conversely argue that exactly because this 
patient group is fragile, the potential value of generating effective treatment justifies 
the burden on participants. With regard to paper 1, the Regional Committee for 
Medical and Health Research Ethics West Norway approved the COSMOS trial 
(REK 2013/1765). The trial is registered at www.clinicaltrials.gov (NCT02238652). 
With regard to papers 2 and 3, the Norwegian Medicines Agency (EudraCT 2013-
002226-23) and the Regional Ethics Committee West (REC-West 2013/1474) 
approved the DEP/SLEEP.PAIN.DEM study. The study’s Clinical Trial number is 
NCT02267057.  
 
The World Medical Association has developed the Declaration of Helsinki (World 
Medical Association Declaration of Helsinki 2013). This declaration is a statement of 
ethical principles for medical research involving humans. The declaration states that 
“medical research with a vulnerable group is only justified if the research is 
responsive to the health need or priorities of this group and the research cannot be 
carried out in a non-vulnerable group. In addition, this group should stand to benefit 
from the knowledge, practices or interventions that result from the research” (World 
Medical Association Declaration of Helsinki 2013). In addition, the Declaration states 
that when research is conducted with people who cannot provide informed consent, 
such consent has to be provided from a legally authorised representative. In our data 
collection process, we made it clear that that we wanted close contact with nurses 
who knew the patients well and who were sensitive to any signs from the patients 
implying that they did not want to partake. From baseline to week 13, 48 of 106 
patients dropped out of the study. Importantly, this number also reflects that we were 
following the process closely and that the risk/benefit balance was carefully 
considered.      
 
A violation of the DEP/SLEEP.PAIN.DEM protocol was discovered during the first 




DEP.PAIN.DEM trial, the Norwegian Medicines Agency approved the use of 
buprenorphine in the stepwise protocol, with the condition that no participants would 
receive an opioid analgesic as part of the trial unless they already received other 
scheduled analgesic treatment (e.g. paracetamol). However, as described in Table 1 in 
section 4.4.4, we allowed for prescribing buprenorphine/placebo transdermal system 
to participants who did not use any analgesic, but had difficulty swallowing tablets. 
This procedure is in line with common clinical procedures and previously published 
papers (Husebo et al. 2013). In retrospect, we found that three patients had received 
active buprenorphine while not having received analgesics at baseline, as shown in 
Table 2.  
 
 1 2 Total 
Treatment 
(1=active, 2=placebo) 
57 49 106 
Type of drug 
(1=buprenorphine, 2=paracetamol) 
58 48 106 
Received buprenorphine 
(1=active, 2=placebo) 
31 27 58 
Received active buprenorphine and 
no analgesics at baseline 
(1=yes, 2=no) 
3 28 31* 
*Note: In Table 5 in paper 2, we report results for 30 patients who received active buprenorphine. The reason 
for the discrepancy between the number reported here (n=31) and the number reported in Table 5 (n=30), is 
that one patient dropped out in week 1. This is also accounted for in paper 2.  
 
Table 2: Allocation of patients to treatments in the SLEEP.PAIN.DEM actigraphy 
sub-project 
 
This information was provided to the Norwegian Medicines Agency and the Regional 
Committee for Medical and Health Research Ethics. One of the three participants 
who received buprenorphine had pain according to the MOBID-2 (≥ 3). However, we 




patient. However, when the violation was discovered, the primary investigator of the 
study (Bettina Husebo) and my main supervisor (Elisabeth Flo) contacted the 
University of Bergen, the Norwegian Medicines Agency (SLV) and the Regional 
Committee for Medical Health Research Ethics (REK). In correspondence with the 
SLV, Flo and Husebo stated the following: “The error described above occurred 
prior to Blytt being employed as a research scholar and commencing her data 
collection. During her time as a Ph.D.student, Blytt was informed that the study’s 
exclusion and inclusion criteria were REK and SLV approved. Blytt followed all 
study procedures conscientiously; procedures that have previously been established 
in scientific publications and approved by the REK and SLV.”  
 
The violation could nevertheless have had potentially harmful effects for the patients. 
As reported by Erdal et al. (2018b), patients who received active buprenorphine had 
4.7 times increased risk of discontinuation compared to the placebo group. Patients 
were excluded because of adverse events, such as agitation, somnolence and nausea. 
Erdal et al. (2018b) concluded that buprenorphine is poorly tolerated in patients with 
dementia.  
 
After reviewing the case and the reported data, the SLV concluded as follows (see 
Appendix 5): “(…) the Norwegian Medicines Agency is satisfied that both the PI and 
the ethics committee confirm that the patient safety in the trial has been safeguarded. 
We do not currently intend to pursue this matter further.”  
 
The empirical investigations of papers 2 and 3 aimed to provide insight that could 
improve the sleep of NH patients with dementia. Importantly, the research 
contribution should exceed the potential burden for patients included in the studies, as 
discussed in the method chapter. Several patients reacted to the buprenorphine 
treatment and their reactions were so impactful that we needed to exclude them from 
the study. As reported by Erdal et al. (2018b), 89 patients were prescribed 




active treatment and 45 to placebo. Compared to six patients in the placebo group, 
treatment with active buprenorphine transdermal system was discontinued in 23 
patients. Nine patients discontinued from the active treatment within the first 14 days 
compared to two patients in the active treatment. Among those patients who did not 
tolerate active treatment, approximately half of the patients reported several types of 
adverse events (Erdal et al. 2018b). The most common cause of adverse events was 
psychiatric (personality changes, anxiety, agitation, confusion and hallucinations). 
This implies that for some patients in the study, the burden of taking part may have 
been excessive. However, the results presented in Erdal et al. (2018b) reflect the 
effort done by NH staff, Ane Erdal and myself in order to supervise the treatment, 
and to keep patients safe. In the event that adverse events occurred, patients were 
quickly withdrawn from the study. However, it should be noted that prior to 
conducting the study, there was little reason to expect that these negative effects 
would be widespread. The study design was assessed by the Regional Ethical 
Committee and the prospective impact on participants was judged as being justifiable.   
 
Doing research in this very fragile and vulnerable group of patients is very important. 
Becoming old and depending on other people for personal hygiene, care and 
treatment represent a large challenge for NH patients. Thus, contributing knowledge 
for better or more evidence-based treatment in this particular group is important, and 
we believe that despite this violation, the burden on patients has been justifiable.  
 
6.4 A brief comment on the publication strategy 
 
Regarding the publication of the findings in the thesis, it should be noted that the 
papers 2 and 3 that report sleep-related results from SLEEP.PAIN.DEM were 
published before the papers reporting the primary outcome of depression 
(DEP.PAIN.DEM), conducted by Erdal et al. (2018). The reason for this was 
practical. When the data collection process was finished and data was prepared for 




could argue that it would have been ideal to publish the findings for the primary 
outcome of the DEP.PAIN.DEM trial first. However, those findings were not 
published until June 2018, while papers 2 and 3 included in this thesis were published 
already in December 2017 and February 2018, respectively. Thus, due to financial 
constraints, it would not have been practically feasible to delay the publication of the 
papers comprised in this thesis until the papers reporting primary outcomes were 
published. However, the analyses presented in papers 2 and 3 were informed by the 
ongoing and of preliminary analyses of the primary outcomes (as reported in Erdal et 








This thesis contributes new and valuable knowledge on sleep in NH patients and the 
clinical challenges related to sleep in the NH setting.  
 
Paper 1 revealed that sleep disturbances were common in NH patients as measured 
with actigraphy, but that sleep disturbances were clearly underreported or 
unrecognised by NH staff when using common clinical tools like the NPI-NH and the 
CSDD. However, we cannot know if the divergence between the different 
measurements is due to the raters or the rating instruments. These findings suggest 
that the clinical usefulness of proxy-rater assessments of sleep is questionable. NH 
staff should show awareness to potential sleep difficulties among residents in order to 
identify and potentially treat such challenges.   
 
Paper 2 revealed that short-term pain treatment improved sleep (specifically, SE, 
SOL and EMA) in NH patients with dementia and depression. For patients with poor 
sleep at baseline, we found improvement also for TST. Furthermore, patients 
receiving active buprenorphine transdermal patch had significantly longer TST 
compared to patients who received active paracetamol. A potential explanation could 
be sedation, which is a well-known side-effect of opioids.  
 
Paper 3 revealed that pain treatment did not improve sleep in the longer term. Thus, 
the effects of such treatment found in the short-term did not sustain. However, we 
found that compared to paracetamol, TST and SE increased among patients who 
received active buprenorphine transdermal patch treatment. While our results do not 
yield conclusive evidence upon which novel treatment can be unequivocally 
recommended, the findings represent a step forward in the understanding of sleep in 





7.1 Clinical implications and future perspectives  
 
In light of the findings from paper 1, the current evaluation of sleep in patients with 
dementia seems unsatisfactory. However, the financial cost and effort cost of 
measuring sleep in the NH using actigraphy are arguably excessive. Sleep diaries are 
an alternative method that could potentially provide valuable information on patients’ 
sleep. The SDI instrument has also shown good correlation with actigraphy, when the 
population is people with dementia living at home with a caregiver. Future research 
that further investigates the clinical utility of these tools in the NH would be 
beneficial. In addition, night-time workers should have a bigger role in evaluating 
sleep and report issues in a standardised manner.  
 
Although our results show some increase in sleep in the short-term and increase sleep 
when comparing active buprenorphine and active paracetamol, our research design 
does not allow us to draw conclusions regarding the underlying mechanism. Future 
research investigating the relationship between pain, depression and sleep should 
attempt to include patients with pain, sleep complaints and depression to examine this 
relationship more thoroughly. Furthermore, it would strengthen the study to include 
both actigraphy and sleep diaries by proxy as sleep assessment methods.  
 
However, as shown in paper 3, as well as by Erdal et al. (2018a), there was 
considerable attrition from baseline to week 13 in the group of patients who received 
active buprenorphine. The findings by Erdal et al. (2018b) are based on a relatively 
low number of participants, pain was not an inclusion criterion and they are based on 
secondary data. Still, one should consider whether it would be inappropriate to use 
buprenorphine in future studies investigating this relationship. It is important to 
highlight that although paper 2 indicates that sleep as measured with actigraphy 
increased in the group who received active treatment compared to placebo, and we 




treatment – we do not recommend pain treatment to improve sleep. When evaluating 
the results from paper 3 alongside the results from Erdal et al. (2018b), we contend 
that more research is necessary regarding which opioids might be better tolerated in 
this vulnerable patient group. This is important to evaluate before new studies 
investigating the relationship between pain, sleep and depression in people with 
dementia are conducted.  
 
Systematic assessment of pain, sleep and depression should be part of the everyday 
routines in the NH, and assessment through self-report could be attempted as part of 
this effort. This should inform which treatments are considered and followed up with 
re-assessment after treatment is started. Such assessment would provide information 
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   Exempted from public disclosure cf. 
 Offl §13 første ledd, jf. fvl. §13 første ledd nr2, 
jf. lml. §30  
    
Your ref.: Date: Our ref.: Officer: 
  Bettina Husebø 9 April 2018 13/10588-21 Maria Almlöf 
STATEMENT FROM THE NORWEGIAN MEDICINES AGENCY REGARDING A CLINICAL TRIAL 
 
The Norwegian Medicines Agency (NOMA) has been contacted by Prof. Bettina S. Husebø, who is 
Principal Investigator (PI)  for the DEP.PAIN.DEM trial, EudraCT no. 2013-00226-23. The contact was 
related to a request for information made by the committee members of Kjersti Marie Blytt’s 
dissertation “Sleep in Nursing Home Patients:  Clinical Assessment and the Effects of Pain Treatment 
on Sleep.”  Prof. Husebø requested NOMA’s comments on identified inconsistencies in the conduct 
of the clinical trial, the details of which can be found in letter to the committee members dated 
2018-03-29. In addition to this letter, the NOMA has also received copies of the attachments (1-4), 
and the original request from the dissertation committee (dated 2018-03-22).  
 
NOMA has the following comments to the identified issues (please refer to the numbering of the 
issues as stated in the above mentioned letter of 2018-03-29): 
 
Regarding item 1 – identified discrepancy between NOMAs conditional approval and the allocation 
of patients who had not previously used pain treatment to the buprenorphine treatment arm: 
  
The inclusion of trial subjects against the approved procedures stated in the protocol is a protocol 
violation. This is an error which may have serious consequences for the subject safety and/or the 
robustness of the data generated in a trial.  An error of this kind should normally have been detected 
during routine monitoring of the trial. It is our understanding that the protocol deviation was 
identified only after the work was published. According to the letter to the committee members, it 
has been concluded by the concerned ethics committee that the deviation does not have ”discernible 
serious consequences for the patients” (quote). NOMA takes note of the standpoint of the ethics 
committee.  Any NOMA conclusion regarding the subject safety or robustness of the data generated 
in the trial would have to come from a Good Clinical Practice inspection of the trial. It is currently not 
the intention of the NOMA to perform such an inspection.  
 
Regarding item 2 – we confirm that the approved version of the protocol includes an exclusion 
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Regarding item 3 – the original submission of the clinical trial application included a version of the 
protocol which contained the following inclusion criterion related to pain: “Patients suffering from 
pain and require continuous treatment with analgesics”. After a round of correspondence with the 
NOMA, the pain criterion was removed by the applicant with the following justification: “We did not 
intend to make the presence of pain an inclusion criteria, due to the difficulty of assessing pain in 
patients with dementia, and this point has now been removed from the list of inclusion criteria in 
section 3 of the revised study protocol.” The comment to this in the conditional approval letter by the 
NOMA was: “the presence of pain has been omitted as inclusion criteria due to difficulties to assess 
pain in patients with dementia. In light of this we presume that patients without analgesics at 
enrolment will not be allocated to buprenorphine treatment due to the risk of dependency”.  
 




Although the identified discrepancy between the approved protocol and the included patients is a 
protocol violation with potential serious consequences for the patients’ safety and/or the robustness 
of the data generated in the clinical trial, the Norwegian Medicines Agency is satisfied that both the 
PI and the ethics committee confirm that patient safety in the trial  has been safeguarded. We do not 
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Clinically significant discrepancies between
sleep problems assessed by standard
clinical tools and actigraphy
Kjersti Marie Blytt1,2,3* , Bjørn Bjorvatn1,3, Bettina Husebo1,2,4 and Elisabeth Flo5
Abstract
Background: Sleep disturbances are widespread among nursing home (NH) patients and associated with
numerous negative consequences. Identifying and treating them should therefore be of high clinical priority.
No prior studies have investigated the degree to which sleep disturbances as detected by actigraphy and by
the sleep-related items in the Cornell Scale for Depression in Dementia (CSDD) and the Neuropsychiatric Inventory –
Nursing Home version (NPI-NH) provide comparable results. Such knowledge is highly needed, since both
questionnaires are used in clinical settings and studies use the NPI-NH sleep item to measure sleep disturbances.
For this reason, insight into their relative (dis)advantages is valuable.
Method: Cross-sectional study of 83 NH patients. Sleep was objectively measured with actigraphy for 7 days, and
rated by NH staff with the sleep items in the CSDD and the NPI-NH, and results were compared. McNemar's tests
were conducted to investigate whether there were significant differences between the pairs of relevant measures.
Cohen's Kappa tests were used to investigate the degree of agreement between the pairs of relevant actigraphy,
NPI-NH and CSDD measures. Sensitivity and specificity analyses were conducted for each of the pairs, and receiver
operating characteristics (ROC) curves were designed as a plot of the true positive rate against the false positive
rate for the diagnostic test.
Results: Proxy-raters reported sleep disturbances in 20.5% of patients assessed with NPI-NH and 18.1% (difficulty
falling asleep), 43.4% (multiple awakenings) and 3.6% (early morning awakenings) of patients had sleep
disturbances assessed with CSDD. Our results showed significant differences (p<0.001) between actigraphy
measures and proxy-rated sleep by the NPI-NH and CSDD. Sensitivity and specificity analyses supported these
results.
Conclusions: Compared to actigraphy, proxy-raters clearly underreported NH patients' sleep disturbances as
assessed by sleep items in NPI-NH and CSDD. The results suggest that the usefulness of proxy-rater measures
of sleep may be questionable and further research is needed into their clinical value. The results highlight the
need for NH staff to acquire and act on knowledge about sleep and sleep challenges among NH patients.
Trial registration: Registered at www.clinicaltrials.gov (registration number NCT02238652) on July 7th 2014
(6 months after study initiation).
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Background
In nursing homes (NH), wherein approximately 50–80%
of patients have dementia [1–4], sleep disturbances are
widespread and severe [5]. Advanced age is associated
with a decrease in total sleep time [5], slow-wave sleep
and rapid eye movement (REM) sleep [6]. Moreover, ap-
proximately 60% experience sleep disturbances at night-
time [7]. Disturbed sleep is associated with multiple
negative consequences and predicts an increased risk of
developing depression among the elderly [8]. Previous
studies have shown that disturbed sleep may lead to re-
duced quality of life and impaired cognitive daytime
functioning in elderly people with and without dementia
[9, 10]. As argued by Flo et al. [11], these outcomes may
be especially important for the elderly, since such symp-
toms may be misinterpreted as dementia or more severe
dementia. Since so many institutionalized patients are
affected by dementia, the consequence may be that they
often are no longer able to give valid self-report, a pre-
requisite for adequate symptom assessment and treatment
[12]. Therefore, they depend on the ability of health care
professionals to evaluate and treat their distressing symp-
toms, including sleep disturbances.
Identifying and treating sleep disturbances in this fragile
and multimorbid group should be of high clinical priority.
However, evaluating sleep in NH patients with dementia
is a methodological challenge [13]. Meanwhile, most tools
rely primarily on interviewing NH staff members, who
function as proxy-raters for the patients. This renders the
reliability of such measurement uncertain [14], while their
relatively low cost and effort in use, make them attractive
in the clinical setting.
Wrist-worn actigraphic recordings are considered the
most reliable instrument for objectively measuring
sleep in this patient group [15, 16]. However, there is a
high cost associated with the use of such equipment.
Most et al. [17] compared the subjective assessments
tools Pittsburgh Sleep Quality Index, Sleep Disorders
Questionnaire, Athens Insomnia Scale and actigraphy.
The study showed that the value of sleep questionnaires
is limited in early and moderate stage Alzheimer dis-
ease and recommended actigraphy as a supplement in
detecting sleep disturbances. Meanwhile, Tractenberg
et al. [18] showed that scores from the Sleep Disorders
Inventory (SDI) correlated with actigraphy data, except
for 24-h total sleep time and daytime total sleep time.
Hoekert et al. [19] similarly found a high degree of cor-
relation between actigraphy and measures in the Sleep
Inventory for Normal and Pathological States. However,
the assessment tools mentioned above are not routinely
used in NH settings to assess sleep. Thus, it is of high
importance to investigate the accuracy of proxy-rater
tools that are commonly used in both the research set-
ting and the clinical setting, and the relative advantages
and disadvantages of actigraphy and proxy-rater tools,
respectively.
To our knowledge, no prior studies have investigated
the relationship between clinically significant sleep
disturbances as detected by actigraphy and by the sleep-
related items in the Cornell Scale for Depression in
Dementia (CSDD) and the Neuropsychiatric Inventory –
Nursing Home version (NPI-NH), respectively. This is
highly needed, since both of the questionnaires are used
in clinical settings and several studies use the NPI-NH
sleep item to measure sleep disturbances among NH pa-
tients [20–23].
Consequently, the aim of this study was to investigate
the degree to which actigraphy-based and proxy-rater-
based assessments of sleep in NH patients provided com-
parable clinical outcomes. This allows for an assessment
of their relative advantages and disadvantages. The study
thus provides insight into similarities and differences in
the measurement of sleep disturbances by means of these
two approaches, which may provide crucial information
for future clinical assessment procedures and research.
Methods
Design and setting of the study
The present study was based on baseline data from the
COSMOS trial [24]; a 4-month cluster-randomized and
controlled effectiveness-implementation hybrid trial
with follow-up at month 9. The study was conducted in
Norway from January 2014 to December 2015. To gain
a representative distribution of NHs, urban/rural and
big/small municipalities were invited. NH patients
≥65 years old, with and without dementia, with life ex-
pectancy >6 months, not diagnosed with schizophrenia,
were eligible for inclusion. Patients with any form of
chronic movement disorder or any form of paralysis in
the arms/upper body were excluded from the actigra-
phy registrations.
Measurements
At baseline, a research team responsible for the COSMOS
trial informed and supervised NH staff in the different
assessment tools. Only NH staff members who knew the
patients were asked to partake in the assessment. Socio-
demographic variables were collected from patients’
medical records.
Sleep was objectively assessed using the Actiwatch
Spectrum (Philips Respironics). Since NH patients are
quite inactive, the actigraphs were placed on the pa-
tients’ dominant/mobile wrist to increase the possibility
of detecting movement. Previous studies have found no
difference between data collected from actigraphs
placed on different locations [25, 26]. NH staff was
instructed to push the event button at bed and rise
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times (light off in the night/light on in the morning),
both by verbal and written instruction.
We used the following scoring protocols: rest inter-
vals were set using a standardized hierarchical approach
based on (1) event markers, (2) light and activity data,
and (3) light or activity data. To ensure inter-scorer re-
liability, 30 of the actigraphy recordings were scored
twice by two independent scorers, and compared in
terms of total time in bed and total sleep time. To be
included, participants would have to complete at least
five night recordings. Sleep/wake status was determined
for each one-minute epoch using the Actiware 6
(Respironics) scoring program and validated algorithm,
with the sensitivity set to medium. The scoring was
used to generate the following variables: sleep onset
latency (SOL), wake after sleep onset (WASO), early
morning awakening (EMA), number of wake bouts
(NoW),
To define disturbed sleep in this population we
followed the quantifiable criteria described in the DSM-
5 diagnostic features for insomnia [27]. Hence, we used
the following cut-off points to define sleep disturbances
as measured with actigraphy: SOL >30 min; WASO
>30 min; EMA > 30 min. In addition, we used NoW ≥3.
In accordance with Lacks and Morin [28], we used a
cut-off of <85% for sleep efficiency, i.e. time spent asleep
divided by time spent in bed [13].
Sleep was subjectively assessed with the NPI-NH,
which is a proxy-rater inventory assessing twelve
neuropsychiatric symptoms associated with dementia
[29]. In the present study, we used item 11 – nighttime
behavior – to ascertain sleep disturbances as observed
and judged by proxy-raters. Proxy-raters were guided
by questions formulated as follows: “Does the patient
have sleep problems? Is s/he awake during the night?
Does s/he wander during night-time, getting dressed, or
going into the room of others?” Each symptom was
scored for frequency (score 1–4) and severity (score 1–3),
subsequently a product score was calculated thereof. In
line with Garcia-Alberca et al. [20] and Chwiszczuk et al.
[23], we used a product score ≥ 4 as a cut-off to define the
presence of sleep disturbances.
Sleep was also assessed by the CSDD, a proxy-rater in-
strument for the measurement of depression, which is
validated both for people with and without dementia
[30–32]. Questions regarding sleep fall under the cat-
egory of “cyclic functions” and comprise item 13 (“Does
the patient have difficulty falling asleep?”), item 14
(“Does the patient have multiple awakenings during
sleep?”) and item 15 (“Does the patient have early morn-
ing awakenings?”). For item 13, a score of 1 was given if
the patient only had difficulty falling asleep a few nights
in the past week and 2 if there was difficulty every night.
For item 14, the patient was given a score of 1 if sleep
was restless and occasionally disturbed. If the patient
got out of bed in the middle of the night and/or had
woken up every night in the past week, a score of 2 was
given. For item 15, a score of 1 was given if the patient
woke up early, but then went back to sleep. A score of
2 was given if the patient woke up earlier than usual
and could not go back to sleep. A cut-off score of ≥1
was used to define sleep disturbances identified by
proxy-raters for item 13 and 14. For item 15 a cut-off
score of 2 was used. Item 13 was used as a measure of
problems with SOL, item 14 as a measure of NoW, and
item 15 as a measure of EMA, in the comparisons be-
tween the CSDD items and actigraphy measurements.
The rating is in line with the guidelines by Alexopoulos
et al. [30].
Cognitive function was assessed by the Mini Mental
State Examination (MMSE), which is a 30-point validated
scale that consists of 20 tasks. Scores from 0 to 10 indicate
severe impairment, 11 to 20 is consistent with moderate
impairment, 21 to 25 is consistent with mild impairment,
and scores of 26 to 30 suggest no impairment [33, 34].
Statistical analyses
Descriptive statistics were calculated for all relevant
variables. McNemar’s tests were conducted to investi-
gate whether or not there were significant differences
between the pairs of relevant measures. Cohen’s Kappa
tests were used to investigate the degree of agreement
between the pairs of relevant actigraphy, NPI-NH and
CSDD variables. Sensitivity and specificity analyses
were also conducted for each of the pairs of measures.
Furthermore, receiver operating characteristics (ROC)
curves were calculated, as a plot of the true positive
rate against the false positive rate for the diagnostic
test. The AUC values of the ROC curves serve to evalu-
ate the performance for each of the pairs of measures.
AUC values can be assessed as follows: a value of 1 sig-
nifies a perfect test, a value of 0.97 signifies a very good
test, values below 0.75 are not considered clinically
useful, and values close to 0.5 have no discriminatory
value at all [35].
The actigraphy measures were chosen as the reference
standard and the analyses measured the degree to which
the CSDD and NPI-NH measures captured the same as
did the actigraphy measures. To test whether the final
actigraphy sample (n = 83) differed systematically from
the remainder of the study sample (n = 462), we con-
ducted independent samples t-tests comparing the mean
scores of the two samples for the following variables:
age, sex, MMSE score, CSDD scores (difficulty falling
asleep; early morning awakening; multiple awakenings)
and NPI-NH score (sleep item). We conducted the
statistical analyses using IBM SPSS Statistics 22.
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Ethics
Informed written consent was obtained through direct
conversation with patients. If the patient lacked the ability
to give consent, we obtained it through direct conversa-
tion with the patient’s legal guardian. The legal guardian
gave presumed consent on behalf of the patient. This is in
line with local legislation. The trial was approved by the
Regional Committee for Medical and Health Research
Ethics, West Norway (REK 2013/1765) and registered at
www.clinicaltrials.gov (NCT02238652).
Results
A total of 700 NH patients were invited to participate
in the COSMOS study, of which 545 participants from
67 NH units were included. The first 10 patients in
every NH unit were evaluated for inclusion in the acti-
graph subproject. The actigraphy subproject included
107 patients, 24 of whom were excluded due to acti-
graph malfunction or because of missing data. The final
sample thus included 83 patients who wore actigraphs
and had complete CSDD and NPI-NH scores. For the
variables outlined above, there were no statistically sig-
nificant differences between the scores for the actigra-
phy sample and the remainder of the study sample.
Patient characteristics are summarized in Table 1.
Sleep disturbances in NH patients as assessed by
actigraphy
The mean number of actigraphy-registered nights per
patient was 6.6 (SD = 1.1). Mean time spent in bed was
12 h and 20 min (SD = 1 h 43 min). Mean sleep effi-
ciency was 64.1% (SD = 19.2), and 89.2% of the patients
had sleep efficiency <85%. Mean SOL was 57.9 min
(SD = 80.1) and 45.8% had SOL >30 min. Mean WASO
was 151.8 min (SD = 80.2), i.e. approximately 2.5 h, and
97.6% had WASO >30 min. Mean EMA was 54.5 min
(SD = 66.5), and 59.0% of the patients had EMA > 30 min.
Mean NoW was 32.1 (SD = 13.4), with a mean length of
5.1 min (SD = 3.1). All actigraphy results are summa-
rized in Table 2.
Sleep disturbances assessed with NPI-NH compared with
actigraphy
Proxy-raters reported sleep disturbances in 20.5% of pa-
tients assessed with NPI-NH. McNemar’s test comparing
sleep efficiency measured with actigraphy and proxy-
rater sleep (NPI-NH-SS ≥ 4) showed a significant differ-
ence (p < 0.001) between the measures (see Table 3).
This was supported by the Cohen’s Kappa analysis,
which showed very low agreement between the measures
(k = .029).
In the NPI-NH measurements, we found one false
positive (i.e. instances where proxy-raters reported
sleep disturbances when actigraphy did not) and 57
false negatives (i.e. instances where proxy-raters did not
report sleep disturbances when actigraphy did). Com-
pared with the sleep efficiency measure, the sensitivity
of the NPI-NH proxy-rater sleep measure was 21.9%
(95% CI = 13.4% - 33.4%). The specificity of the meas-
ure was 88.9% (95% CI = 50.7% - 99.4%). Thus, the
positive likelihood ratio of the test was 1.97, while the
negative likelihood ratio of the test was 0.88. The AUC
value of the ROC curve was 0.554.
Sleep disturbances assessed with CSDD compared with
actigraphy
McNemar’s test for actigraphy SOL >30 min (45.8%) and
the CSDD “difficulty falling asleep” (18.1%) item showed
a significant difference (p < 0.001) between the measures
Table 1 The table shows descriptive statistics on prevalence
(mean values and standard deviations) for socio-demographic
variables, NPI-NH1 sum score = Neuropsychiatric Inventory –
Nursing Home version, CSDD2 = Cornell Scale for Depression in
Dementia. MMSE3 = Mini Mental State Examination. SD = standard
deviation
Descriptive statistics (n = 83)
Age (mean, SD) 86.6 (8.1)
Female (percentage) 75.9% (n = 63)
CSDD2 sum score (mean, SD) 6.0 (5.9)
MMSE3 sum score (mean, SD) 10.4 (7.5)
MMSE score 20 or below (number, percentage) 59 (86.8%)
MMSE score > 20 (number, percentage) 9 (13.2%)
Number of medications (mean, SD) 7.5 (3.7)
Table 2 Actigraphically measured sleep parameters, mean values
with standard deviations
Sleep parameters (n = 83)
Time spent in bed (hours:min), mean (SD) 12:20 (1:43)
Observation nights, mean (SD) 6.6 (1.0)
Sleep efficiency (%), mean (SD) 64.1 (19.2)
Sleep efficiency below 85% 89.2% (n = 74)
SOL (min), mean (SD) 57.9 (80.1)
Patients with SOL above 30 min 45.8% (n = 38)
WASO (min), mean (SD) 151.8 (80.2)
WASO above 30 min 97.6% (n = 81)
EMA (min), mean (SD) 54.5 (66.5)
EMA above 30 min 59.0% (n = 49)
NoW mean (SD) 32.1 (13.4)
NoW equal or above 3 98.8% (n = 82)
Length of wake bouts (min), mean (SD) 5.1 (3.1)
Bedtime (hours:min), mean (SD) 20:20 (2.21)
Wake up time (hours:min), mean (SD) 8:57 (1:29)
SOL refers to sleep onset latency. WASO refers to wake after sleep onset. EMA
refers to early morning awakening. NoW refers to the number of wake bouts
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(see Table 3). This was supported by the Cohen’s Kappa
analysis, which showed very low agreement between the
measures (k = .105). In the CSDD SOL measurements,
there were six false positives and 29 false negatives.
Compared with the actigraphy measure, the sensitivity
of the CSDD “difficulty falling asleep” measure was
23.7% (95% CI = 12.0% - 40.6%). The specificity of the
CSDD was 86.4% (95% CI = 72.0% - 94.3%). Thus, the
positive likelihood ratio of the test was 1.74, while the
negative likelihood ratio of the test was 0.88. The AUC
value of the ROC curve was 0.550.
McNemar’s test comparing EMA > 30 min measured
with actigraphy (59%) and the CSDD “does the patient
have early morning awakenings?” (EMA) item (3.6%)
showed a significant difference (p < 0.001) between the
measures (see Table 3). This was supported by the
Cohen’s Kappa analysis, which showed very low agree-
ment between the measures (k = .051). In the CSDD
EMA measurements, there were no false positives, but
46 false negatives. Compared with the actigraphy meas-
ure, the sensitivity of the CSDD EMA measure was
6.1% (95% CI = 1.59% - 17.9%). The specificity of the
measure was 100% (95% CI = 87.4% - 100%). Thus, the
positive likelihood ratio of the test cannot be calculated,
while the negative likelihood ratio of the test was 0.94.
The AUC value of the ROC curve was 0.531.
McNemar’s test comparing NoW ≥3 measured with
actigraphy (98.8%) and CSDD “multiple awakenings dur-
ing sleep” item (43.4%) showed a significant difference
(p < 0.001) between the measures (see Table 3). This was
supported by the Cohen’s Kappa analysis, which showed
a very low agreement between the measures (k = .019).
In the CSDD NoW measurements, there were no false
positives, but 45 false negatives. Compared with the
NoW as measured by actigraphy, the sensitivity of the
CSDD “multiple awakenings during sleep” measure was
44.4% (95% CI = 33.5% - 55.9%). The specificity of the
measure was not possible to calculate, due to the low
number of observations. Thus, the positive likelihood ra-
tio cannot be calculated, but the negative likelihood ratio
of the test was 0.56. The AUC value of the ROC curve
was 0.722.
Discussion
The aim of this study was to investigate the degree to
which actigraphy-based and common proxy-rater-based
assessments of sleep in NH patients provided compar-
able clinical outcomes. This allows for an assessment of
their relative merits, when the costs, efforts and benefits
of their use are taken into account. Taken together, the
analyses (McNemar’s test, Cohen’s Kappa and sensitiv-
ity/specificity analyses, all of which are reported in Table
3) revealed that there were highly significant differences
(p < 0.001) between the measures with respect to their
ability to capture the various sleep outcomes (SOL,
EMA and NoW). The Cohen’s Kappa values suggested
low degrees of agreement between the measures for all
pairs of variables. This was also supported by the sensi-
tivity, specificity and likelihood ratio analyses, and the
corresponding ROC-curves. The results overall revealed
that the CSDD and NPI-NH measures had from very
small to small probability for capturing the sleep out-
comes detected by actigraphic recordings. This is of key
importance since it implies that sleep disturbances may
go undetected and thereby untreated among NH pa-
tients. These results should be viewed in the context of
the nature of the two measures: While actigraphy in-
volves the use of equipment which implies relatively
high cost in use, proxy-rater tools are used mostly for
screening purposes with low cost and effort.
Using NPI-NH, staff categorized 20.5% of the patients
as having sleep disturbances. This was significantly
lower than the objective actigraphy measure of sleep,
by which 89.2% had sleep efficiency below 85%. Since
the study included both patients with and without
dementia, it is important to notice that the NPI-NH
was developed for use among people with dementia.
However, in the total sample, 87% of patients had an
MMSE score < 20, which is compatible with dementia
[34]. Only 13% had an MMSE score > 20, and the mean
MMSE score in this sub-group was 23.6. Based on this,
we can assume that most of the patients in the total
sample have mild cognitive impairment or dementia.
For this reason, we have included the NPI-NH scores
of all patients in the present study. Comparing sleep
Table 3 Significant differences between actigraphy measured wrist activity compared to percentages of patients’ sleep outcome
measured with proxy-rated CSDD and NPI-NH
Actigraphy CSDD NPI-NH p k
SOL above 30 min or CSDD-DFA ≥ 1 45.8% (n = 38) 18.1% (n = 15) <0.001 .105
EMA above 30 min or CSDD-EMA ≥ 2 59.0% (n = 49) 3.6% (n = 3) <0.001 .051
NoW ≥3 or CSDD-MA ≥ 1 98.8% (n = 82) 43.4% (n = 36) <0.001 .019
SE below 85% or NPI-NH-SS ≥ 4 89.2% (n = 74) 20.5% (n = 17) <0.001 .029
SOL refers to the Sleep Onset Latency measure using actigraphy. EMA refers to the Early Morning Awakening measure. NoW refers to the Number of Wake Bouts
measure. SE refers to the Sleep Efficiency measure. CSDD-DFA refers to the Difficulty Falling Asleep measure in the Cornell Scale for Depression in Dementia
(CSDD). CSDD-EMA refers to the Early Morning Awakening measure in the CSDD. CSDD-MA refers to the Multiple Awakenings measure in the CSDD. NPI-NH-SS re-
fers to the Subjective Sleep measure in the Neuropsychiatric Inventory – Nursing Home version. k = Cohen’s Kappa
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efficiency with the NPI-NH sleep item is not optimal,
since sleep efficiency is a measure of time spent asleep
divided by time spent in bed, while the NPI-NH more
broadly captures general sleep disturbances. However,
sleep efficiency is often used as an indicator of sleep qual-
ity [36, 37]. Thus, it can be argued that the sleep item in
NPI-NH to some extent should capture sleep quality and/
or disturbances. The excessive time in bed reported in our
study, which is an important determinant for the calcula-
tion of sleep efficiency, is in accordance with previous
studies [13, 16].
Actigraphy detected significantly more sleep distur-
bances relating to SOL, NoW and EMA than did CSDD
sleep items. These results thus also indicate that NH
staff underreport or do not recognize patients’ sleep dif-
ficulties, as captured by actigraphy. In contrast, Fetveit
and Bjorvatn [13] found that NH staff observations
(diaries) of SOL and EMA were consistent with acti-
graphic recordings. However, the way these parameters
are measured is not comparable with the measurements
of the present study. NH staff diaries are based on obser-
vation during a given period, and the observation is
recorded in writing. It is noteworthy, however, that
nocturnal awakenings registered by NH staff in the study
by Fetveit and Bjorvatn [13] showed little correlation
with actigraphy-recorded WASO. This is in line with the
present findings, which also indicated that NH staff
noticed fewer awakenings compared with actigraphy.
Is the divergence between the actigraphy recordings
and proxy-rater assessments due to the raters or due to
the rating instruments? A potential reason could be lack
of knowledge about sleep among NH staff. This could in
turn result in lower perceptiveness in recognizing sleep
disturbances. In addition, the proxy-raters were not ne-
cessarily night workers. It is possible that observations
from night workers were not properly conveyed to the
day shift staff. Furthermore, many patients in Norwegian
NHs lie in bed during night-time with the cot side of the
bed in the upward position. The consequence is that
many patients are unable to exit the bed at night. Com-
bined with a reduced capacity for verbal expression due
to dementia, this may reduce their interaction with the
night shift workers, which could lead to an impression
of sleeping even when patients might be awake.
In line with previous research, the results of the present
study showed that sleep disturbances are very common
among NH patients. Interestingly, the findings indicate
that sleep disturbances as measured with actigraphy are
even more prevalent now than what was found in earlier
studies. Fetveit and Bjorvatn [13] found mean sleep effi-
ciency of 75% among NH patients, with 72% of the pa-
tients displaying sleep efficiency below 85%. A pioneering
study by Ancoli-Israel et al. [38] found that patients on
average slept 39.5 min per hour in any hour of the night,
and 50% woke up 2 to 3 times per hour. The patients in
the present study displayed a mean sleep efficiency of 64%
and as many as 89.2% of the patients had sleep efficiency
below 85%.
It is beyond the scope of this study to explore the
discrepancy between results regarding actigraphy sleep
parameters herein and results from earlier studies.
However, a recent report shows that the proportion of
NH patients with comprehensive assistance needs has
increased from 2009 to 2015. This suggests that the
NH population is generally in poorer condition now
than earlier [39]. This is notable since previous studies
have shown that a decreased ability to sleep is associ-
ated with comorbidities [40]. This development may
potentially explain some of the discrepancy between
prior studies and the present study.
The sample size of 83 patients with actigraphy assess-
ment in the present study is larger than previous stud-
ies using actigraphy to assess sleep in this population
[13, 16, 41, 42]. The low agreement between actigraphy
and proxy-rater measures may simply indicate that the
CSDD and the NPI-NH fail to capture sleep difficulties.
In light of recent research that indicates that when the
CSDD is administered by NH staff, its clinical utility is
highly questionable, the discrepancy found in the present
study also questions the use of proxy-raters to ascertain
symptoms [43]. However, it is noteworthy that we do not
recommend actigraphy as the primary tool for evaluating
sleep in the NH setting. This would arguably be costly and
time consuming, and thus not feasible as a screening tool.
However, the results are suggestive of a need for more
precise instruments for measuring sleep among NH pa-
tients, which could be used in a low-cost and valid man-
ner by proxy-raters.
Limitations
Previous studies indicate that actigraphy is less accurate in
distinguishing sleep from wakefulness when sleep effi-
ciency is reduced [22, 35]. Therefore, actigraphy recor-
dings may overestimate sleep relative to sleep diaries and
polysomnography [44, 45]. Taking this into consideration,
the total amount of sleep may be less and even more frag-
mented than what is suggested by the results from the
present study. This means that the sensitivity for sleep in
the NPI-NH and CSDD may be even lower than estimated
herein. Meanwhile, polysomnography is not an optimal
form for assessing sleep in this patient population. It is
difficult to score since electroencephalography does not
produce clear patterns of sleep stages in demented pa-
tients [15]. Secondly, there is a low tolerance in this group
for wearing such equipment [13]. Actigraphy is therefore
considered the best method for assessing sleep objectively
in this population [15, 16].
Blytt et al. BMC Geriatrics  (2017) 17:253 Page 6 of 8
Conclusion
The study revealed that when sleep was measured with
common clinical tools like NPI-NH and CSDD, sleep dis-
turbances were clearly underreported or unrecognized by
NH staff as compared with actigraphy. The results thus
suggest that the usefulness of proxy-rater measures of
sleep may be questionable and further research is needed
into its clinical value. Our results do not allow us to con-
clude whether the divergence in results are due to the
raters or the rating instruments. However, in order to en-
able NH staff to treat sleep disturbances, the first step is
to identify that the patient has a problem. The results
therefore highlight the need for NH staff to acquire and
act on knowledge about sleep and potential sleep chal-
lenges in the population of NH patients, which in turn
may increase the likelihood for adequate treatment.
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Objective: To investigate the effects of pain treatment on sleep in nursing home (NH)
patients with dementia and depression.
Methods: A multicenter, 2‐armed, double‐blinded, placebo‐controlled, randomized clinical
trial conducted between August 2014 and September 2016. One hundred six long‐term patients
from 47 NHs in Norway with dementia and depression according to the Mini‐Mental State
Examination and the Cornell Scale for Depression in Dementia were included. Patients received
stepwise pain treatment in which those who did not use analgesics were randomized to receive
either paracetamol (3 g/day) or placebo tablets; those who already used pain treatment were
allocated to buprenorphine transdermal system (max. 10 μg/h/7 days) or placebo transdermal
patches. Sleep was assessed continuously for 14 days by actigraphy, 1 week of baseline
measurement, and 1 week of ongoing treatment. The following sleep parameters were evaluated:
total sleep time, sleep efficiency (SE), sleep onset latency (SOL), wake after sleep onset, early
morning awakening (EMA), and number of wake bouts.
Results: In the intervention group (paracetamol/buprenorphine), SE (70%‐72%), SOL
(32‐24 min), and EMA (50‐40 min) improved compared with the control group (SE, 70%‐67%;
SOL, 47‐60 min; EMA, 31‐35 min). Treatment effects were significant (P < .01, P < .05, and
P < .05, respectively).
Conclusion: Compared with placebo, pain treatment improved sleep as measured with
actigraphy. This implies that sleep, pain, and depression in NH patients should be critically
evaluated and that pain treatment should be considered to be a potentially beneficial treatment.
KEYWORDS
actigraphy, dementia, depression, nursing home, pain treatment, sleep
1 | INTRODUCTION
Approximately 60% of nursing home (NH) patients experience nightime
sleep disturbances,1,2 and 50 to 80% of NH patients have dementia.3-5
Previous studies have reported that NH patients with dementia have
more disturbed nightime sleep compared with NH patients without
dementia.6 The capacity to maintain either sleep or wakefulness is fur-
ther impaired as dementia progresses.6 Sleep disturbances among NH
patients can be attributed to medical disorders, polypharmacy,7 pain,8,9
and depression.2,10 Sleep disturbances in this population may have
serious consequences, as they increase the risk of falls11 and hip
fractures,12,13 decrease survival,14 and impair daytime functioning (eg,
reducedmemory, concentration, reaction time, and loss of autonomy).15
Studies indicate that approximately 20 to 30% of NH patients have
depression.16 The close interrelation between pain and depression is
often referred to as the pain‐depression dyad.17 This implies that both
conditions share common signal pathways and neurotransmitters and
that they are responsive to comparable treatments.17 Depression is also
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associated with sleep disturbances, especially among people with cog-
nitive impairment.18,19 Previous research suggests overlapping neural
networks for depression, sleep disturbance, and dementia.20 Among
various neuropsychiatric symptoms, sleep and depressive symptoms
are often considered to coincide as a “mood‐cluster.”21
Pain represents an important cause of poor sleep for people with
and without dementia.22 Previous studies indicate that there is a
bidirectional relationship between pain and sleep disturbances.23
Approximately 60% of NH patients experience pain every day.24 The
prevalence may vary, however, as pain can be difficult to evaluate in peo-
ple with dementia, who have reduced ability to describe their symptoms.
It is therefore important that NH staff seek to identify pain through
appropriate methods25 and exclude pain as a factor contributing to sleep
disturbances before prescribing sleep medications. Overall, the presence
of pain, dementia, and depression, together with sleep disturbances, may
lead to a downward spiral regarding health and well‐being.15,19
In a cluster‐randomized clinical trial conducted by Husebo et al,26
a stepwise protocol of treating pain was found to improve mood, sleep,
and depression in people with dementia and agitation. The study did,
however, not include objective sleep measurements and was not
placebo‐controlled. Consequently, the aim of the present study was
to investigate the effect of pain treatment on sleep in NH patients with
dementia and depression in a placebo‐controlled randomized clinical
trial with objective sleep measurements.
We hypothesized that pain treatment would improve total sleep
time (TST), sleep efficiency (SE), sleep onset latency (SOL), waking after
sleep onset, early morning awakening (EMA), and number of bouts
awake. In addition, we conducted several subgroup analyses. In 1 sub-
group analysis, the aim was to investigate the effects of pain treatment
on different sleep outcomes for patients with poor sleep at baseline,
defined as SE < 85%. In a second analysis, the aim was to investigate
if pain treatment improved sleep more in patients who were in pain
at baseline, defined as Mobilization‐Observation‐Behaviour‐Intensity‐
Dementia‐2 Pain Scale (MOBID‐2) score ≥ 3. In a final analysis, we
aimed to investigate if there were any differences within the active
treatment group, ie, between patients receiving active buprenorphine
and active placebo, respectively.
2 | METHODS
This study used data collected in the period from 1 week before the
intervention until 1 week after the intervention. The study is part of
a 13‐week, multicenter, parallel‐group, double‐blind, placebo‐con-
trolled randomized trial: “Efficacy of Pain Treatment on Depression in
Patients with Dementia—A Randomized Clinical Trial of Efficacy:
DEP.PAIN.DEM.” The study was conducted in Norway from August
2014 to September 2016.
The NHs were located in 11 municipalities in both urban and rural
areas and both larger and smaller Norwegian towns. Data collection
was conducted by 2 researchers, who recruited NHs through direct
contact with NH management. Inclusion and exclusion criteria are
listed in Table 1. At the participating NHs, the researchers were
granted access to patient medical records to perform prescreening. In
cases where no recent (<14 days old) blood analyses (electrolytes,
hemoglobin, serum creatinine, and serum alanine aminotransferase)
were available, new analyses were requisitioned. Patients who were
not excluded in the medical record review were screened for depres-
sion by using the Cornell Scale for Depression in Dementia (CSDD)27
and for dementia by using the Mini‐Mental State Examination
(MMSE).28 If the inclusion criteria (CSDD ≥ 8 and MMSE < 20) were
fulfilled, the patient was reassessed after written consent had been
given. A drop from ≥8 to ≥6 in CSDD was permitted between screen-
ing and baseline. If a patient fulfilled all of the inclusion criteria and
none of the exclusion criteria, and inclusion and study treatment were
approved by the physician responsible for the patient, the patient was
enrolled in the study (see the flow chart in Figure 1 for an overview of
enrolment and reasons for exclusion).
A fixed‐dose regimen was used in the study period. The patients
were offered a 1‐g tablet/placebo at breakfast, lunch, and supper
(8 a.m. noon and 6 p.m.). The patients received a stepwise pain treat-
ment, in which those who were taking paracetamol ≤1 g/day prior to
inclusion were allocated to paracetamol tablets/placebo tablets. The
study treatment was prescribed in addition to the basic dose. Patients
who were taking nonopioid analgesics/paracetamol >1 g/day, and/or
NSAID/buprenorphine, but had difficulty with swallowing tablets were
assigned to the buprenorphine/placebo transdermal system. In line
with the administrative guidelines, the buprenorphine transdermal
patch/placebo patch was changed on a fixed day every week. For
patients who were taking buprenorphine transdermal 5 μg/h prior to
inclusion, the study treatment was given as an additional 5‐μg/h trans-
dermal patch (active or placebo). After inclusion, all patients continued
their usual medical treatment (including any regular or “as needed”
[PRN] analgesic). To ensure stability and control in the study, the
clinicians were advised to keep doses of psychotropic and analgesic
drugs unchanged during the study period. If any clinical changes
occurred, eg, new conditions or injuries, they were to be treated ade-
quately. All withdrawals and reasons were registered.
All sleep‐related outcomes were assessed with Actiwatch
Spectrum (Philips Respironics). Activity was registered continuously
for 14 consecutive days, during which the intervention started on
day 8. Data were thus recorded for all sleep parameters for duration
of 1 week before and 1 week after the study treatment commenced.
The actigraphs were placed on the dominant/mobile wrist. To enable
better scoring of the patients' actual time spent in bed, the NH staff
were instructed (verbally and written) to register bedtimes and rising
times by pushing the event button on the actigraph (light off/lights on).
Key points
• Sleep disturbances are very common among people with
dementia.
• Compared with placebo, pain treatment improved sleep
in NH patients with dementia and depression, as
measured by actigraphy.
• Sleep, pain, and depression in NH patients should be
evaluated systematically, and pain treatment should be
considered as a potentially beneficial treatment.
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The Actiware 6 (Respironics) was used for sleep scoring. Sensitivity
was set to medium, and sleep/waking status was determined for each
1‐minute epoch. A trained technician scored all the activity protocols.
A standardized hierarchical approach was used to set rest intervals
for the actigraphy data, using (1) event markers when possible, or (2)
light and activity data, or (3) light or activity data. Alternatives 2 and
3 were only implemented if there was a clear differentiation between
active and rest periods; if not, the actigraphy protocol was excluded.
Depression was assessed by using the validated CSDD. The CSDD
consists of 19 items measuring 5 domains of depression (mood, behav-
ioral disturbances, physical signs, cyclic functions, and ideational distur-
bances). A cut‐off point of 8/9 has demonstrated the best accuracy for
FIGURE 1 Flow chart screening and inclusion
2323 patients from 47 NHs 
screened for eligibility
137 did not consent
562 took opioid analgesics (5 µg/h buprenorphine
transdermal prior to inclusion was permitted)
895 did not have depression (CSDD < 8)
99 had blood tests indicating renal/hepatic failure or anemia
56 had life expectancy less than 6 months
139 did not have dementia (MMSE 20)
54 died prior to enrolment
65 had a psychiatric disorder which warranted exclusion
87 had short-term placement or moved
14 had allergy to study treatment
30 were under 60 years of age
14 due to changes in psychotropic drugs
9 due to other reasons 
Enrolled in the main study:
162
Actigraphy sub-project:
7 had Parkinson’s disease
11 did not consent
8 removed the actigraph
30 other reasons (incl. missing 
data, malfunctioning actigraphs, 
etc.)
Enrolled in the sleep 
sub-project:
106
57 active treatment 49 placebo
TABLE 1 Inclusion and exclusion criteria in the actigraphy subproject
Inclusion Criteria Age ≥ 60 years
Long‐term nursing home placement with >4‐week stay
Dementia (MMSE ≤ 20)
Depression (CSDD ≥ 8, >3‐week duration)
Exclusion criteria Life expectancy < 6 months
Severe medical disease that could interfere with study participation
Severe liver and/or renal impairment
Anemia (Hb < 8.5 mmol/L) or electrolyte imbalance (Na+ and K+)
Suicide risk (any attempts during the last year)
History of severe psychiatric disease prior to dementia onset
Severe aggression (NPI‐NH aggression item score ≥ 8, with aggression as the predominant symptom)
Severe pain (MOBID‐2 ≥ 7)
Uncontrolled epilepsy
Contraindication or clinically significant drug interaction to the assigned study treatment
Change in psychotropic drugs
Regular use of any opioid analgesic other than, or exceeding, buprenorphine 5 mcg/h
Did not want to wear an actigraph
Immobile patients (paralysis, or otherwise bedridden)
Patients with involuntary movement (eg, Parkinson disease)
Less than 5 nights of actigraphy recordings
Abbreviations: CSDD indicates Cornell Scale for Depression in Dementia; MMSE, Mini‐Mental State Examination; MOBID‐2, Mobilization‐Observation‐
Behaviour‐Intensity‐Dementia‐2 Pain Scale; NPI‐NH, Neuropsychiatric Inventory‐Nursing Home Version.
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diagnosing depression according to the International Statistical
Classification of Diseases and Related Health Problems 10th Edition
criteria.27 The assessment was conducted by using only information
provided by NH staff members who knew the resident very well.
Pain was assessed by the MOBID‐2, a validated staff‐administered
instrument for measuring pain in people with advanced dementia.25
The instrument provides a total score based on all of the observations
ranging from 0 to 10, where 10 represents the worst possible pain.25 A
score of ≥3 has been used as a cut‐off to indicate clinically relevant
pain.25
Cognitive function was assessed by using the validated MMSE.28
The MMSE is a brief, cognitive screening test with a 30‐point scale
that consists of 20 tasks and was developed to distinguish potential
dementia from normal functioning.29 Five patients started the MMSE
screening and scored very poorly and subsequently withdrew from
the MMSE screening. This led to missing data. For these patients,
cognitive function was assessed by proxy through conversations with
primary doctors and nurses as an alternative to MMSE screening.
The patients were randomly allocated to each arm in a 1:1 ratio,
using computer‐generated random numbers. The randomization list
was produced by a statistician, without any involvement of the
research team. There was no use of stratification factors. The research
team was provided with a blinded, sequential list of pack identification
numbers, and the patients were consecutively assigned to the next
pack number in the list upon inclusion. The study was double‐blinded,
and all researchers, patients, and NH staff were masked regarding the
group allocation.
Descriptive statistics were calculated for all relevant variables.
Comparisons of sleep parameters pre‐ and posttreatments were per-
formed as a mixed within‐between subjects ANOVA (placebo versus
active treatment and pretreatment versus posttreatment). Differences
between pre‐ and posttreatments within each treatment group were
assessed with paired t tests for each of the experimental groups
separately. Furthermore, we conducted additional 2 × 2 mixed
within‐between subjects ANOVA analyses. One of these analyses
investigated patients who had sleep disturbances at baseline, defined
as SE < 85%,30 and compared the effect of active and placebo
treatments for those patients. A second analysis compared the effect
of the treatments for a subgroup of patients whose MOBID‐2 score
was ≥3, ie, patients who had pain at baseline. The last analysis investi-
gated patients in the active treatment group and thus compared the
effect of active buprenorphine to that of active paracetamol. The
statistical analyses were conducted by using IBM SPSS Statistics 22.
Each patient's medical decision‐making capacity was discussed
with the patient's primary nurse at the NH. Attempts were made to
adjust the information for patients who had reduced capacity to give
consent (MMSE score from 16 to 19).31 In addition, the researchers
contacted all of the eligible patients' legal guardians. If the legal guard-
ians gave presumed consent on behalf of the patient, they received
written and oral information together with a consent form that they
signed and mailed back. The study was approved by the Regional
Ethics Committee (REC‐West 2013/1474). The study's clinical trial
number is NCT02267057.
3 | RESULTS
In total, 2323 patients were screened for eligibility, of whom 162 were
eligible to participate as part of the broader study. The final sample of
the actigraphy subproject included 106 participants (see Figure 1). Of
the 106 patients, 49 were randomly assigned to the placebo group
and 57 to the active treatment group. In the active treatment group,
2 patients dropped out due to their reaction to the treatment. In the
total sample of patients with actigraphs, the mean age was 85.5 years
(SD = 7.3), 76%were female, themean CSDD scorewas 11.2 (SD = 3.7),
the mean MMSE score was 7.6 (SD = 6.0), the mean MOBID‐2 score
was 2.8 (SD = 2.1), and 54.7% had a MOBID‐2 score ≥ 3. Sleep charac-
teristics pre‐ and posttreatments for patients in both experimental
groups, as well as the interaction effect for each sleep outcome, are
shown in Table 2.
In the total sample (n = 106), SE, SOL, and EMA all improved for
the active treatment group compared with the placebo group (see
Table 2). The analysis of the treatment for the subgroup of patients
with preexisting sleep disturbances (SE < 85%) identified at baseline
TABLE 2 Within‐ and between‐group effects of the placebo and active treatments on different sleep outcomes
Placebo Group (n = 49) Active Group (n = 55) Interaction Effectc
Mean (SD) Pre*‐Post** P Valuea Effect Sizeb Mean (SD) Pre*‐Post** P Valuea Effect Sizeb F value P Value
TST (min) 509.9 (113.6)‐498.8 (126.5) .164 0.20 515.6 (136.7)‐526.9 (119.7) .235 0.16 3.25 .074
SE (%) 70.0 (13.1)‐67.5 (14.8) .036 0.31 69.9 (14.8)‐72.2 (12.5) .039 0.29 9.11 .003
SOL (min) 47.0 (44.5)‐59.6 (80.3) .187 0.19 31.7 (35.2)‐24.6 (28.2) .079 0.24 4.03 .047
WASO (min) 140.6 (68.3)‐143.3 (68.3) .610 0.07 136.0 (66.7)‐134.5 (58.2) .800 0.03 0.27 .604
EMA (min) 30.7 (38.9)‐35.2 (35.5) .268 0.16 50.1 (61.1)‐40.5 (37.5) .082 0.24 4.20 .043
NoW (no.) 31.2 (11.6)‐30.3 (11.8) .404 0.12 30.0 (11.9)‐29.4 (13.5) .551 0.08 0.05 .831
Notes: TST indicates total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, waking after sleep onset; EMA, early morning awakening; NoW,
number of bouts awake.
aPaired t test, comparing values before and after the intervention (separate tests for the placebo group and the active group).
bEffect size (Cohen's d) for paired values.
cA mixed within‐between subjects 2 × 2 ANOVA comparing the placebo and active treatments.
*Pre = −7 to 0 days (baseline).
**Post = 1 to 7 days active/placebo treatment.
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TABLE 3 Effects of the placebo and active treatments on different sleep outcomes for patients with SE < 85%
Group With SE Below 85% (n = 89)
Placebo Group (n = 44) Active Group (n = 45) Interaction Effectc
Mean (SD) Pre*‐Post** P Valuea Effect Sizeb Mean (SD) Pre*‐Post** P Valuea Effect Sizeb F Value P Value
TST (min) 488.8 (97.6)‐475.3 (108.1) .107 0.25 477.7 (114.6)‐497.6 (103.9) .065 0.28 6.25 .014
SE (%) 67.5 (11.3)‐64.9 (13.3) .049 0.30 65.4 (12.4)‐69.0 (10.8) .005 0.44 12.18 .001
SOL (min) 51.9 (44.4)‐66.0 (82.4) .182 0.20 37.3 (36.5)‐28.2 (29.7) .063 0.28 4.17 .044
WASO (min) 150.7 (63.9)‐153.5 (63.5) .635 0.07 154.4 (58.3)‐148.7 (50.3) .432 0.12 0.83 .363
EMA (min) 33.7 (40.0)‐37.2 (36.3) .418 0.12 58.5 (64.5)‐45.6 (39.1) .049 0.30 4.51 .036
NoW (no.) 31.7 (11.6)‐30.5 (11.4) .339 0.15 32.5 (10.6)‐31.5 (12.3) .365 0.14 0.00 .957
Notes: TST indicates total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, waking after sleep onset; EMA, early morning awakening; NoW,
number of bouts awake.
aPaired t test, comparing values before and after the intervention (separate tests for the placebo group and the active group).
bEffect size (Cohen's d) for paired values.
cA mixed within‐between subjects 2 × 2 ANOVA comparing the buprenorphine and paracetamol groups for the patients with poor sleep efficiency.
*Pre = −7 to 0 days (baseline).
**Post = 1 to 7 days active/placebo treatment.
TABLE 4 Effects of the placebo and active treatments on different sleep outcomes for patients with pain (MOBID‐2 ≥ 3) at baseline
Group With Pain (n = 46)
Placebo Group (n = 25) Active Group (n = 21) Interaction Effectc
Mean (SD) Pre*‐Post** P Valuea Effect Sizeb Mean (SD) Pre*‐Post** P Valuea Effect Sizeb F Value P Value
TST (min) 518.3 (126.0)‐523.8 (130.7) .528 0.13 554.4 (141.8)‐565.2 (127.8) .223 0.27 0.18 .667
SE (%) 70.3 (14.9)‐69.4 (14.4) .330 0.20 74.1 (14.5)‐75.7 (13.6) .122 0.35 3.56 .066
SOL (min) 42.5 (44.7)‐49.5 (66.9) .413 0.17 25.1 (26.5)‐23.0 (24.9) .611 0.11 0.84 .362
WASO (min) 137.7 (67.1)‐140.4 (75.0) .737 0.07 128.2 (73.5)‐124.7 (70.4) .683 0.09 0.28 .595
EMA (min) 37.3 (51.4)‐36.7 (39.7) .906 0.02 34.0 (36.4)‐29.9 (30.2) .276 0.24 0.34 .559
NoW (no.) 31.3 (12.7)‐30.1 (13.3) .407 0.17 29.7 (14.2)‐30.5 (15.6) .623 0.11 0.88 .351
Notes: TST indicates total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, waking after sleep onset; EMA, early morning awakening; NoW,
number of bouts awake.
aPaired t test, comparing values before and after the intervention (separate tests for the placebo group and the active group).
bEffect size (Cohen's d) for paired values.
cA mixed within‐between subjects 2 × 2 ANOVA comparing the placebo and active treatments for the patients with pain (MOBID‐2 score ≥ 3).
*Pre = −7 to 0 days (baseline).
**Post = 1 to 7 days active/placebo treatment.
TABLE 5 Effects of the placebo and active treatments on different sleep outcomes for patients given active buprenorphine and paracetamol
Group With Active Treatment (n = 55)
Paracetamol Group (n = 25) Buprenorphine Group (n = 30) Interaction Effectc
Mean (SD) Pre*‐Post** P Valuea Effect Sizeb Mean (SD) Pre*‐Post** P Valuea Effect Sizeb F Value P Value
TST (min) 531.5 (145.5)‐518.3 (131.4) .233 0.24 502.3 (129.9)‐534.0 (110.9) .029 0.42 6.176 .016
SE (%) 72.2 (14.1)‐72.4 (12.7) .854 0.04 68.0 (15.4)‐72.1 (12.6) .027 0.42 3.252 .077
SOL (min) 34.0 (35.5)‐29.0 (33.5) .238 0.24 29.8 (35.4)‐20.9 (22.8) .181 0.25 0.241 .626
WASO (min) 121.3 (63.8)‐123.6 (52.8) .762 0.06 148.3 (67.7)‐143.5 (61.7) .610 0.09 0.333 .566
EMA (min) 42.9 (47.4)‐39.7 (39.7) .562 0.12 56.1 (70.8)‐41.2 (36.2) .101 0.31 1.173 .284
NoW (no.) 28.5 (11.8)‐28.4 (13.6) .969 0.01 31.3 (12.1)‐30.2 (13.6) .464 0.14 0.244 .624
Notes: TST indicates total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, waking after sleep onset; EMA, early morning awakening; NoW,
number of bouts awake.
aPaired t test, comparing values before and after the intervention (separate tests for the buprenorphine group and the paracetamol group).
bEffect size (Cohen's d) for paired values.
cA mixed within‐between subjects 2 × 2 ANOVA comparing the buprenorphine and paracetamol groups for the patients who received active treatment.
*Pre = −7 to 0 days (baseline).
**Post = 1 to 7 days active/placebo treatment.
BLYTT ET AL. 667
(n = 89) confirmed the main effects (see Table 3). In addition, TST
improved significantly for the active treatment group compared with
the placebo group (see Table 3). Interestingly, when analyzing the
effect of treatment for the subgroup of patients who experienced pain
at baseline (n = 46), we found no significant differences between active
and placebo treatment for any of the sleep outcomes (seeTable 4). In a
final analysis, we investigated if there were any differences within the
active treatment group (seeTable 5). We found a significant increase in
TST for patients who received active buprenorphine compared with
those who received active paracetamol (see Table 5).
4 | DISCUSSION
The results of the present study gave partial support to our hypothe-
ses. The study demonstrated that active pain treatment for people
with dementia and depression improved 3 central sleep parameters:
SE, SOL, and EMA. When we analyzed the subgroup with poor sleep
at baseline, the results were further strengthened, with an additional
improvement in TST. Moreover, the group of patients who received
the active buprenorphine transdermal patch had significantly longer
TST compared with the active paracetamol group. However, being in
pain at baseline was not associated with improved sleep after active
treatment.
To the best of our knowledge, this is the first placebo‐controlled
randomized clinical trial to investigate the efficacy of pain treatment
on sleep among NH patients with dementia and depression. The study
is of key importance for clinicians, because it provides new insight into
the complex and poorly understood relationship among pain, depres-
sion, and sleep. There is a great need for such insight, because sleep
disturbances are endemic among NH patients, and knowledge regard-
ing potential treatment is essential.
Even though the underlying mechanisms of the results are
unknown and the clinical value of the treatment effect is uncertain,
the results indicate that pain treatment may contribute to improved
sleep among some NH patients with dementia and depression. As
described above, there were patients already receiving pain medication
(paracetamol) prior to inclusion. However, our results suggest that
some of the patients might not be adequately treated, with paraceta-
mol alone or only with a low dose. Therefore, these patients may expe-
rience beneficial effects of stronger medication (eg, buprenorphine) or
an increased dose of already prescribed medication.
Interestingly, when we conducted subgroup analyses of the
patients with sleep disturbances (defined as SE < 85%), we found sig-
nificant improvement in TST in addition to SE, SOL, and EMA, indicat-
ing that the group of patients with poor sleep might derive greater
benefit from pain treatment. Husebo et al32 found that a systematic
approach to pain management significantly reduced agitation among
people with dementia and agitation. In a different study, also con-
ducted by Husebo et al,26 the results showed that mood symptoms,
including depression and sleep disturbances, improved with pain
treatment in the same patient group. This was partly attributed to
potentially untreated pain.26,32 Interestingly, in the present study, we
found no improvements in sleep in the subgroup of patients in pain
at baseline. Thus, the results do not support that the underlying
mechanism is untreated pain. It should be noted that the subgroup
analysis only included 21 patients with active treatment and pain
according to MOBID‐2. The lack of significant differences could there-
fore be due to the low sample size. It is noteworthy, however, that
Zanocchi et al33 found no association between sleep problems and
the presence of pain, although pain intensity was associated with
patients' sleep disturbances.
Furthermore, the results showed that TST increased significantly
among patients who received active buprenorphine compared with
patients who received active paracetamol. Because sedation is a
frequently reported opioid‐associated side effect, which is more likely
to occur at the onset of therapy or with dose increase,34 this may sug-
gest an opioid‐associated sedation effect. Actigraphy only records
movement, and a total lack of movement would therefore be assessed
as sleep. It is not possible to examine the question of whether there is
a sedation effect further with this study design.
In the present study, the NH patients wore the actigraph on the
dominant or mobile wrist. This choice was made because many NH
patients have limited mobility, due to medical conditions (eg, stroke
or paralysis) or general fragility and inactivity. Therefore, potential
activity would more likely to occur first in the dominant or mobile
wrist. This implies that wearing the actigraph on the dominant wrist
increases the probability of activity to be registered. There are no stan-
dards regarding the placement (dominant/nondominant wrist) of the
actigraph.35 However, in prior studies on persons with dementia, the
dominant wrist is most commonly used. For instance, Camargos
et al35 recommended using the dominant or mobile wrist. It would,
however, be valuable to assess the potential differences between
measurements on the nondominant versus the dominant wrist in
future research.
The results should be interpreted with caution because the study
design does not allow us to assess if the improvement is of subjective
value for the patient. Further research is necessary to investigate this
more extensively. However, the results of this study suggest that clini-
cians should evaluate pain, sleep, and depression by using proper
assessment tools and, based on such evaluation, consider pain treat-
ment as potentially beneficial for patients with sleep disturbances.
5 | LIMITATIONS
Our study has some limitations. The use of multiple sleep‐related out-
come measures is a potential study limitation, which can potentially
lead to type I errors. We do not correct for multiple comparisons in
our study. However, a simple Bonferroni correction would be overly
conservative and would increase the risk of type II errors.36 Therefore,
we urge the reader to take the lack of such correction into account in
the interpretation of the findings of the study.
In actigraphy recordings, immobility of the participants marks the
beginning of the sleep period. Sleep onset latency has been particularly
difficult to ascertain with actigraphy, because patients may just be
lying still in bed and it can be recorded as sleep.37 In addition, previous
studies show that actigraphy is less precise in differentiating between
sleep and wakefulness when SE is reduced.37-39 Both of these factors
may lead to an overestimation of sleep.
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The comprehensive combination of inclusion and exclusion criteria
made it difficult to recruit patients to the study. Of the 2323 patients
screened for potential eligibility, a total of 895 did not have depression
according to CSDD. In addition, there has been a change in the pre-
scription of pain medication for NH patients during the last decade
that influenced inclusion. Sandvik et al40 found that analgesic drug pre-
scription at NHs increased significantly from 2000 to 2011, and in par-
ticular the use of paracetamol and strong opioids. This impeded the
inclusion of patients in the study, as a high number of patients were
already taking high doses of opioids (n = 562) and could not be
included. This may have excluded some people with depression or
sleep problems, who could have benefited from the study intervention.
This renders the generalizability of our study questionable because our
sample may not be representative for the general NH population.
Furthermore, the subgroup analysis is based on a low number of
respondents, which implies that we cannot exclude type 2 errors.
Another central limitation in the study is that it does not include pain
assessment during the week after the intervention. As a consequence,
we do not know how pain progressed after the intervention. Future
research should include a larger sample of patients with pain at base-
line to account for a large attrition rate and follow‐up with pain assess-
ments after the intervention is given. A further limitation of our study
was that we did not conduct a priori power analyses, which would
have been beneficial for assessing if the statistical tests have sufficient
power. However, our sample is similar to or larger than samples
in comparable studies. The reader should, however, interpret the find-
ings with caution, in particular for the subgroup analyses with lower
sample sizes.
6 | CONCLUSION
Compared with placebo, pain treatment improved actigraphy‐mea-
sured sleep in NH patients with dementia and depression. This implies
that sleep, pain, and depression in NH patients should be evaluated
critically and that pain treatment should be considered as a potentially
beneficial treatment for residents with poor sleep. Future research
should focus on the underlying mechanisms and explore the subjective
value of such treatment for the NH patient.
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Objective: Previous research indicates that pain treatment may improve sleep among
nursing home patients. We aimed to investigate the long-term effect of pain treatment
on 24-h sleep patterns in patients with comorbid depression and dementia.
Design: A 13-week, multicenter, parallel-group, double-blind, placebo-controlled
randomized clinical trial conducted between August 2014 and September 2016.
Setting: Long-term patients from 47 nursing homes in Norway.
Participants: We included 106 patients with comorbid dementia and depression
according to the Mini Mental Status Examination (MMSE) and the Cornell Scale for
Depression in Dementia (CSDD).
Intervention: Patients who were not using analgesics were randomized to receive either
paracetamol (3 g/day) or placebo tablets. Those who already received pain treatment
were randomized to buprenorphine transdermal system (maximum 10 µg/h/7 days) or
placebo transdermal patches.
Measurements: Sleep was assessed continuously for 7 days by actigraphy, at baseline
and in week 13. Total sleep time (TST), sleep efficiency (SE), sleep onset latency (SOL),
wake after sleep onset (WASO), early morning awakening (EMA), and number of wake
bouts (NoW) were evaluated. In addition, daytime total sleep time (DTS) was estimated.
Pain was assessed with Mobilization-Observation-Behavior-Intensity-Dementia-2 Pain
Scale (MOBID-2).
Results: The linear mixed model analyses for TST, SE, SOL, WASO, EMA, NoW and
DTS showed no statistically significant differences between patients who received active
pain treatment and those who received placebo. Post hoc subgroup analyses showed
that there were no statistically significant differences between active treatment and
placebo from baseline to week 13 in patients who were in pain (MOBID-2 ≥ 3) at
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baseline, or in patients who had poor sleep (defined as SE < 85%) at baseline. Patients
who received active buprenorphine showed an increase in TST and SE compared to
those who received active paracetamol.
Conclusion: The main analyses showed that long-term pain treatment did not improve
sleep as measured with actigraphy. Compared to paracetamol, TST and SE increased
among patients who received buprenorphine. This could indicate that some patients
had beneficial effects from the most potent pain treatment. However, based on the
present findings, long-term pain treatment is not recommended as a strategy to improve
sleep. Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02267057.
Keywords: sleep, nursing home, actigraphy, pain treatment, depression, pain
INTRODUCTION
Approximately 46.8 million people worldwide suffer from
dementia – a number estimated to reach 131.5 million by
2050 (Prince et al., 2016). In nursing homes (NH), 50–80% of
patients have dementia (Helvik et al., 2015; Blytt et al., 2017b),
a neurodegenerative condition that results in the decline of
physical and cognitive functions (Cricco et al., 2001). Sleep
disturbances are common among NH patients with dementia,
with prevalence ranging from 24.5% (Moran et al., 2005) to 60%
(Neikrug and Ancoli-Israel, 2010; Ownby et al., 2014; Peter-
Derex et al., 2015). Dementia may induce pathophysiological
changes in the brain, which can interfere with the maintenance
of normal sleep (Moran et al., 2005; Neikrug and Ancoli-
Israel, 2010). Previous studies have reported that people with
dementia have more disturbed sleep than do patients without
dementia (Pat-Horenczyk et al., 1998). It is further noteworthy
that previous research indicates that NH patients with dementia
are rarely asleep or awake for a full hour in the 24-h cycle (Jacobs
et al., 1989). NH patients may suffer dramatic consequences from
sleep disturbances, for instance by increasing the risk of falls and
hip fractures (Stone et al., 2004; Morley, 2013; Widera, 2013)
and decreasing survival (Dew et al., 2003). Furthermore, sleep
disturbances contribute to impaired daytime functioning (Cricco
et al., 2001).
Several factors contribute to sleep disturbances among NH
patients, including pain (Chen et al., 2011; Flo et al., 2017)
and depression (Giron et al., 2002). Approximately 20–30% of
NH patients have depression, a disorder highly associated with
sleep disturbances (Potter and Steffens, 2007). Depression is a
common mental disorder, of which central symptoms are low
mood and low or loss of ability to experience pleasure (American
Psychiatric Association, 2013). Around 50% of the people with
Alzheimer disease experience depression during the course of
the disease (Lyketsos and Olin, 2002). Furthermore, nearly 60%
of NH patients experience pain every day (Husebo et al., 2010).
Pain is an unpleasant sensory and emotional experience (Onen
et al., 2005) and represents an important cause for poor sleep
among NH patients (Morley, 2013). Patients with dementia
may have reduced capacity to express symptoms, e.g., pain
or sleep disturbances. For this reason, it is essential that NH
staff strives to evaluate symptoms through appropriate methods.
Research suggests that pain and depression share common signal
pathways and neurotransmitters, which implies that they may be
responsive to comparable treatments. This intimate relationship
is denoted the pain-depression dyad (Chopra and Arora, 2014).
Medications such as atypical antipsychotics, benzodiazepines
and other GABAergic drugs are often sought to alleviate sleep
problems in people with dementia (McCleery et al., 2016).
However, previously conducted studies indicate that the source
of sleep problems might be changes in the brain caused by
dementia (Montplaisir et al., 1995, 1998; Kinnunen et al., 2017).
Therefore, the efficacy of treatment with various drugs in this
patient group is highly questionable (McCleery et al., 2016).
Meanwhile, a study conducted by Husebo et al. (2013) found
that a stepwise protocol for treating pain improved mood and
sleep, as measured with the Neuropsychiatric Inventory – Nursing
Home version (NPI-NH), in people with advanced dementia
and agitation. Furthermore, in a recently published randomized
controlled trial, based on the same dataset and respondents as the
present work, we found that compared to placebo, pain treatment
improved sleep after 1 week of treatment (Blytt et al., 2017a).
In the present study, we aim to investigate the long-term effect
of pain treatment on sleep in patients with comorbid dementia
and depression. In light of the results from Blytt et al. (2017a),
we hypothesized that long-term pain treatment would improve
sleep after 13 weeks in patients with comorbid dementia and
depression.
In additional post hoc subgroup analyses, we further aimed
to investigate if improvement of sleep from pain treatment
was larger in patients who were in pain at baseline, defined
as Mobilization-Observation-Behavior-Intensity-Dementia-2 Pain
Scale (MOBID-2) score ≥ 3, than in those who were not. In
addition, we aimed to investigate the effects of pain treatment on
different sleep outcomes for patients with poor sleep at baseline,
defined as sleep efficiency (SE) < 85%. In the last analysis,
we aimed to examine if there were any differences within the
active treatment group, i.e., between patients receiving active
buprenorphine and active placebo, respectively.
MATERIALS AND METHODS
The study is based on an actigraphy subproject in the 13-week,
multicentre, parallel-group, double-blind, placebo-controlled
randomized trial “Efficacy of Pain Treatment on Depression in
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Patients with Dementia – A Randomized Clinical Trial of Efficacy:
DEP.PAIN.DEM.” The study was conducted from August 2014
to September 2016, in Norway. We included 47 NHs from 11
municipalities, located in both urban and rural areas in Norway.
In the present study, we used sleep data collected in the week
before treatment commenced (baseline) and in week 13 of the
treatment/placebo period.
Participants and Procedures
Data collection was led by two researchers who enrolled NHs
through direct contact with NH management. If the management
agreed to be part of the project, the researchers were given access
to patient medical journals to perform a pre-screening review.
If there were no recent blood analyses (electrolytes, hemoglobin,
serum creatinine, and serum alanine aminotransferase) available,
new were requisitioned. In order to be included, patients had
to be ≥60 years, long term NH patients with >4 weeks of
stay, dementia as indicated by Mini Mental State Examination
(MMSE ≤ 20) and depression as indicated by the Cornell
Scale for Depression in Dementia (CSDD ≥ 8). Patients were
excluded from the study if they had severe medical disease that
could interfere with study participation, were using any opioid
analgesic (except buprenorphine 5 mcg/h), did not want to wear
an actigraph, were immobile or had involuntary movements.
Inclusion and exclusion criteria are covered extensively in
Blytt et al. (2017a). The patient was reassessed after written
consent was given, and a drop from ≥8 to ≥6 in CSDD was
permitted between screening and baseline. In addition to all
of the inclusion and exclusion criteria, the treatment needed
to be approved by the physician responsible for the patient
(see the flow chart in Figure 1 for an overview of enrolment
and reasons for exclusion). We assessed the patients with the
same measurements at baseline and in week 13 of the treatment
period.
A stepwise protocol, with a fixed-dose regimen, for treating
pain was used in the study period (see Table 1). Patients were
allocated either to a paracetamol group or to a buprenorphine
group and randomized to receive active treatment or placebo.
If a patient showed any signs of not tolerating the treatment
(e.g., headache, dizziness or nausea), needed to change medical
treatment, or there was anything else conflicting with the patient
taking part in the study, the patient was withdrawn from the study
FIGURE 1 | Flow chart screening and inclusion (reprinted from Blytt et al., 2017a).
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1 No analgesics or
paracetamol ≤ 1g/day
Paracetamol tablets 3 g/day
Placebo tablets Inactive placebo
2 Non-opioid
analgesics/paracetamol
> 1 g/day, and/or











∗Except low-dose acetylsalicylic acid.
and the reason was recorded. During the study period, all patients
continued their usual medical treatment.
Sleep-related outcomes were measured with Actiwatch
Spectrum (Philips Respironics). Activity was assessed continuously
for 7 days at baseline and for 7 days in week 13 of the treatment
period. The intervention started on day 8. Actigraphs were
placed on the dominant/mobile wrist. As of today, there is no
standard regarding the placement of the actigraph (Camargos
et al., 2013). However, in prior studies in which sleep is evaluated
with actigraphy, the dominant arm is most commonly used
(Camargos et al., 2013). This is based on the understanding that
many NH patients may have limited mobility and therefore any
potential activity is more likely to occur in the dominant/mobile
wrist. NH staff was instructed to push the event button on the
actigraph when the patient went to bed in the evening (lights off)
and got up in the morning (lights on). These instructions were
given both verbally and in writing, and NH staff was provided
with contact information if there were any questions regarding
this procedure. The Actiware 6 (Respironics) was used for sleep
scoring. The actigraph’s sensitivity to detect motion was set to
medium. Furthermore, sleep/waking status was determined for
each one-minute epoch. A qualified technician scored all the
activity protocols. A standardized ranked approach was applied
to set rest intervals for the actigraphy data, using: event markers
when possible, light and activity data, or light or activity data.
The scoring protocol generated data on the following outcome
variables: total sleep time (TST), sleep efficiency (SE), sleep onset
latency (SOL), wake after sleep onset (WASO), early morning
awakening (EMA), and number of wake bouts (NoW). These
parameters were estimated in the time window between lights off
in the evening and lights on in the morning. In addition, daytime
total sleep time (DTS) was estimated in the time window from
lights on to lights off using the Actiware 6 software.
Pain was measured by MOBID-2 (Husebo et al., 2007),
a validated, reliable staff-administered instrument with good
responsiveness for measuring pain in people with advanced
dementia (Husebo et al., 2007, 2014). A total score ranging from
0 to 10 was set, where 10 represented the worst possible pain. The
average score was based on all of the observations during the last
week. Clinically relevant pain is defined as a score of ≥3 (Husebo
et al., 2014).
Symptoms of depression during the last week were assessed
using the validated CSDD, an instrument that consists of 19
items measuring five domains related to depression (mood,
behavioral disturbances, physical signs, cyclic functions and
ideational disturbances). In line with previous research, which
has demonstrated that a score of 8/9 complies with the diagnosis
of depression according to ICD-10 criteria, the patient had to get
a CSDD score ≥ 8 to be included in the study (Barca et al., 2010).
The CSDD score was provided using only information from NH
staff who knew the patients well.
MMSE was used to evaluate cognitive function. MMSE is a
brief, cognitive screening test with a 30-point scale that consists
of 20 tasks. It was developed to distinguish potential dementia
from normal functioning (Perneczky et al., 2006). Scores from 0
to 10 indicate severe dementia; from 11 to 20 indicate moderate
dementia; from 21 to 25 indicate mild impairment; and from 26
to 30 indicate no dementia (Perneczky et al., 2006). A score of
≤20 was necessary to be included in the study.
Initially, 162 patients were included. By means of computer-
generated random numbers, these patients were randomly
allocated to each arm in a 1:1 ratio. A statistician produced the
randomization list without any involvement from the research
team. Stratification factors were not used. However, not all
of the patients from the main study were included in the
actigraphy subproject (see the flow chart in Figure 1 for the
reasons for inclusion/exclusion). The randomization ratio in
the actigraphy subproject was therefore not 1:1. The statistician
provided the research team with a blinded, sequential list of pack
identification numbers, in which patients were consecutively
assigned to the next pack number in the list upon inclusion.
The study was double-blinded, which implied that all researchers,
patients and NH staff were masked with regard to group
allocation.
The patient’s medical decision-making capacity was
deliberated with the patient’s primary nurse. For patients
who had reduced capacity to give consent (MMSE scores from
16 to 19), attempts were made to modify the information. Also,
the researchers contacted all of the legal guardians of eligible
patients. Legal guardians who gave presumed consent on behalf
of the patient received written and oral information together
with a consent form to sign and mail back. The Regional Ethics
Committee (REC-West 2013/1474) approved the study, and the
study’s Clinical Trial number is NCT02267057.
Statistical Analyses
Descriptive statistics (means, standard deviations and
percentages) were calculated and compared across the
experimental groups both at baseline (week 0) and post-
treatment (week 13). In order to investigate the effect of pain
treatment after 13 weeks, linear mixed models were conducted.
Mixed models allow for regression-based analyses of treatment
effects even in the case of considerable attrition, as long as data
are missing at random (Bennett, 2001). Thus, individuals with
missing data at one time point can be retained in the analyses.
The mixed model for the main effect (n = 106) was conducted
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TABLE 2 | Baseline characteristics for the different treatment groups.
Placebo
group (n = 49)
Active group
(n = 57)
Total (n = 106)
Age (mean, SD) 86.0 (6.6) 85.2 (7.8) 85.5 (7.3)
Female (%) 80 74 76
MMSE (mean, SD) 6.9 (5.8) 8.2 (6.1) 7.6 (6.0)
MOBID-2 (mean,
SD)
3.2 (2.3) 2.6 (1.9) 2.8 (2.1)
CSDD (mean, SD) 11.4 (4.1) 11.0 (3.4) 11.2 (3.7)
The table reports baseline characteristics for several central variables in the placebo
group and the active group: age, sex, mini mental status examination score
(MMSE), Mobilization-Observation-Behavior-Intensity-Dementia-2 Pain Scale score
(MOBID-2), Cornell Scale for Depression in Dementia score (CSDD). No statistical
significant differences were found between the groups.
with no covariates, with baseline as the time reference point,
and with random intercept. In addition, we conducted a 2 × 2
ANOVA analysis in which we included only data from the 58
patients who completed week 13. This was done to investigate if
the different analyses provided similar results.
In addition to the mixed model for the main effect, several
post hoc sub-group analyses were carried out. Linear mixed
model analyses were conducted for the sub-group of patients
with MOBID-2 score ≥ 3 (n = 46) at baseline and the
sub-group of patients with poor sleep at baseline, defined as
sleep efficiency < 85% (Lacks and Morin, 1992) (n = 90).
Finally, linear mixed model analyses were conducted to compare
patients receiving active paracetamol and active buprenorphine
treatment, respectively (n = 57). The statistical analyses were
conducted using IBM SPSS Statistics 24.
RESULTS
Two thousand three hundred and twenty three patients were
screened for potential inclusion and 106 patients were included
in the actigraphy subproject (see flow chart in Figure 1).
Mean age was 85.5 years and 76% of the patients were
female. Mean scores for MMSE, MOBID-2 and CSDD were
7.6, 2.8, and 11.2, respectively (see Table 2). From baseline
to week 13, 48 patients dropped out of the study (reasons
for dropout are listed in Table 3). There were no statistically
significant differences in relevant baseline characteristics (age,
sex, CSDD, MOBID-2, NPI-NH, MMSE) between the patients
who dropped out (n = 48) and the patients who completed
treatment through week 13 (n = 58) (see Table 4). This supports
the assumption that the data were missing at random. Nine
patients were using buprenorphine 5 µg/h prior to inclusion and
stayed on this treatment and were then randomized to receive
either an additional 5 µg/h (5 patients) or placebo patch (4
patients).
The main linear mixed model analyses for sleep outcomes
showed no statistically significant differences between patients
who received active pain treatment compared to those who
received placebo (see Table 5). Similarly, in the 2 × 2 ANOVA
TABLE 4 | Comparison of baseline characteristics for patients who completed the






Total (n = 106)
Age (mean, SD) 84.5 (7.1) 86.8 (7.3) 85.5 (7.3)
Female (%) 78 75 76
MMSE (mean, SD) 7.1 (5.7) 8.3 (6.3) 7.6 (6.0)
MOBID-2 (mean,
SD)
2.8 (2.0) 2.8 (2.3) 2.8 (2.1)
CSDD (mean, SD) 11.4 (3.8) 10.9 (3.7) 11.2 (3.7)
The table reports baseline characteristics for several central variables in the group
of patients who completed the study period and those who dropped out; age, sex,
MMSE, Mobilization-Observation-Behavior-Intensity-Dementia-2 Pain Scale score
(MOBID-2), Cornell Scale for Depression in Dementia score (CSDD). No statistical
significant differences were found between the groups.
TABLE 3 | Overview of dropout (n = 48) in week 13.
Placebo











Gastrointestinal 0 0 0 4 4
Neurological 0 0 0 2 2
Psychological 0 2 0 6 8
Infection 0 0 1 0 1





1 7 8 6 22
Patient refused to
take the medication
0 3 0 0 3
Change in
treatment
0 0 1 0 1
Death 0 0 1 2 3
The table reports reasons for dropout in each of the four experimental groups: active/placebo paracetamol/buprenorphine.
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analyses with only the 58 patients who had complete data in
week 13, there were no significant differences between active pain
treatment and placebo. Table 5 also shows descriptive statistics
of sleep characteristics for both the placebo group and the active
group, as measured at baseline and in week 13 of the treatment
period.
Table 6 reports analyses for the subgroup of patients
with pain (MOBID-2 score ≥ 3) at baseline. There were no
statistically significant differences between the patients who
received active treatment and those who received placebo.
Table 7 shows analyses for the subgroup of patients with sleep
efficiency < 85% at baseline. Again, there were no statistically
significant differences between the patients who received active
treatment and those who received placebo.
Table 8 reports analyses for the subgroup of patients
receiving the two different types of active pain treatment –
paracetamol and buprenorphine, respectively. In this linear
mixed model, there were significant effects on TST (p < 0.01)
and SE (p < 0.05), which revealed that TST and SE were
both improved after 13 weeks for patients who received active
buprenorphine compared with patients who received active
paracetamol.
DISCUSSION
This is the first placebo-controlled trial to investigate the long-
term efficacy of paracetamol and buprenorphine on sleep in
patients with comorbid dementia and depression. Previous
studies have found that depression among NH patients with
dementia may be related to untreated pain (Leong and Nuo,
2007). Moreover, it is well established that pain is associated
with sleep disturbances (Chen et al., 2011; Flo et al., 2017).
Based on our findings in Blytt et al. (2017a) that pain treatment
improved sleep in NH patients with comorbid dementia and
depression after one week of pain treatment, we hypothesized
that pain treatment would continue to improve sleep after
13 weeks in this patient group. Contrary to our hypothesis,
the main mixed model analyses for the full sample showed no
statistically significant differences between active and placebo
treatment.
There were, however, interesting significant effects in one
of the post hoc sub-group analyses: TST improved for patients
who received active buprenorphine, compared to those who
received active paracetamol. In the active paracetamol group,
TST was reduced by about 10 min, while it increased by
more than one hour in the active buprenorphine group.
Furthermore, we found that SE was reduced in the group
who received active paracetamol, while it increased by about
9% in the group who received active buprenorphine. Thus,
patients who received active buprenorphine seemed to benefit
from the treatment. These results are in line with Blytt et al.
(2017a), wherein we also found that the group of patients
who received active buprenorphine had significantly improved
TST compared to the active paracetamol group after one
week of treatment. However, the underlying mechanisms are
unclear.
Sedation is a frequently reported opioid-associated side
effect (McNicol et al., 2003). Usually, symptoms of sedation
decline after a few days in more healthy adults. However,
among people with comorbidity, sedation may persist (McNicol
et al., 2003). In Blytt et al. (2017a), we highlight that the
positive effect on TST after one week of treatment could be
attributed to such a side-effect. There is a lack of studies
that investigate how symptoms of sedation may persist among
older people with comorbidity, and we cannot exclude sedation
TABLE 5 | Linear mixed model analyses investigating the long-term effect of pain treatment on sleep outcomes (n = 106).
Sleep outcomes Treatment effect Pre-post sleep; mean (SD)
Active Placebo
TST (min) C −2.52 515.2 (139.3) – 538.5 (142.4) 509.9 (113.6) – 498.3 (146.8)
p 0.90
SE (%) C −0.78 70.0 (15.0) – 73.0 (15.3) 70.0 (13.1) – 68.5 (18.2)
p 0.76
SOL (min) C 5.68 33.0 (37.3) – 31.3 (43.0) 47.0 (44.5) – 52.2 (63.5)
p 0.61
WASO (min) C −7.27 134.5 (66.4) – 116.9 (51.7) 140.6 (68.3) – 133.7 (69.8)
p 0.58
EMA (min) C 11.73 48.9 (60.4) – 44.4 (54.9) 30.7 (38.9) – 42.8 (45.5)
p 0.22
NoW (no) C −0.38 30.3 (12.5) – 28.1 (11.5) 31.2 (11.6) – 30.7 (11.0)
p 0.90
DTS (min) C 26.27 191.7 (124.0) – 206.2 (130.3) 215.8 (104.2) – 254.5 (106.5)
p 0.15
The table reports linear mixed model analyses for the following outcome variables: TST, total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, wake after
sleep onset; EMA, early morning awakening; NoW, number of wake bouts; DTS, daytime total sleep time. The column “Treatment effect” reports the interaction effect
between treatment and time, i.e., the main result of the clinical trial, with baseline as the reference time point. C refers to coefficients and p refers to p-values. The column
“Pre-post sleep; mean (SD)” reports descriptive sleep characteristics for the active and placebo groups from baseline to week 13, with standard deviations in parentheses.
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TABLE 6 | Linear mixed model analyses for the subgroup of patients with pain (MOBID-2 score ≥ 3) at baseline (n = 46).
Sleep outcomes Treatment effect Pre-post sleep; mean (SD)
Active Placebo
TST (min) C −9.71 563.5 (139.1) – 635.1 (152.2) 517.8 (122.2) – 500.8 (151.8)
p 0.80
SE (%) C −1.17 75.2 (14.4) – 80.4 (16.0) 70.5 (14.4) – 67.9 (18.4)
p 0.77
SOL (min) C 7.85 23.5 (25.8) – 17.7 (32.7) 40.5 (43.6) – 49.0 (55.2)
p 0.50
WASO (min) C 1.12 124.3 (71.2) – 91.7 (61.4) 138.7 (65.5) – 142.1 (73.0)
p 0.97
EMA (min) C −1.02 32.2 (35.2) – 43.5 (60.0) 36.6 (49.6) – 43.4 (51.6)
p 0.95
NoW (no) C 2.03 32.2 (15.8) – 25.3 (16.0) 32.8 (15.2) – 32.5 (13.8)
p 0.75
DTS (min) C 28.33 251.3 (140.3) – 253.4 (126.5) 226.8 (114.6) – 254.5 (101.6)
p 0.39
The table reports linear mixed model analyses for the subgroup of patients with pain (MOBID-2 score ≥ 3) for the following outcome variables: TST, total sleep time; SE,
sleep efficiency; SOL, sleep onset latency; WASO, wake after sleep onset; EMA, early morning awakening; NoW, number of wake bouts; DTS, daytime total sleep time.
The column “Treatment effect” reports the interaction effect between treatment and time, i.e., the main result of the clinical trial, with baseline as the reference time point.
C refers to coefficients and p refers to p-values. The column “Pre-post sleep; mean (SD)” reports descriptive sleep characteristics for the active and placebo groups from
baseline to week 13, with standard deviations in parentheses.
TABLE 7 | Linear mixed model analysis for the subgroup of patients with poor sleep (sleep efficiency < 85%) at baseline (n = 90).
Sleep outcomes Treatment effect Pre-post sleep; mean (SD)
Active Placebo
TST (min) C −4.81 477.1 (116.7) – 463.2 (104.9) 490.2 (95.3) – 470.4 (130.3)
p 0.85
SE (%) C −1.54 65.5 (12.5) – 65.7 (13.6) 67.7 (11.0) – 65.2 (16.9)
p 0.64
SOL (min) C −0.24 38.7 (38.7) – 45.7 (47.5) 50.1 (43.6) – 58.5 (65.0)
p 0.99
WASO (min) C 3.93 153.0 (57.5) – 136.4 (40.2) 151.3 (62.5) – 147.1 (64.3)
p 0.81
EMA (min) C 14.11 56.8 (63.6) – 57.7 (64.1) 33.3 (36.8) – 46.8 (46.8)
p 0.27
NoW (no) C −1.58 32.7 (11.1) – 32.0 (10.0) 32.7 (11.1) – 32.0 (12.1)
p 0.61
DTS (min) C 7.74 161.6 – 167.5 (105.7 – 110.4) 205.2 (98.9) – 240.5 (110.7)
p 0.72
The table reports linear mixed model analyses for the subgroup of patients with sleep efficiency < 85% for the following outcome variables: TST, total sleep time; SE,
sleep efficiency; SOL, sleep onset latency; WASO, wake after sleep onset; EMA, early morning awakening; NoW, number of wake bouts; DTS, daytime total sleep time.
The column “Treatment effect” reports the interaction effect between treatment and time, i.e., the main result of the clinical trial, with baseline as the reference time point.
C refers to coefficients and p refers to p-values. The column “Pre-post sleep; mean (SD)” reports descriptive sleep characteristics for the active and placebo groups from
baseline to week 13, with standard deviations in parentheses.
as a potential explanation of the results from the present
study.
Importantly, we found no clear causal effect on the active
group with clinically significant pain (MOBID-2 score ≥ 3),
compared to placebo. This is contrary to previous studies on older
people, in which sleep disturbances have been linked to untreated
pain (Chen et al., 2011). In addition, pain has previously been
shown to reduce SE and to increase WASO and stage 1 sleep at
the expense of slow wave sleep and REM sleep (Onen et al., 2005).
It is, however, noteworthy that in the subgroup analysis including
patients with clinically significant pain, all of the sleep parameters
(except EMA) showed indication of improvement, compared
to placebo. However, no statistically significant differences were
found. This could, however, be attributed to the low number of
patients with pain at baseline (n = 46), and we cannot exclude
type 2 errors.
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TABLE 8 | Linear mixed model analysis for the subgroup of patients receiving the two different types of active pain treatment – paracetamol and buprenorphine (n = 57).
Sleep outcomes Treatment effect Pre-post sleep; mean (SD)
Paracetamol Buprenorphine
TST (min) C 68.56 522.9 (149.1) – 511.4 (141.9) 508.7 (132.6) – 580.6 (140.7)
p 0.01
SE (%) C 7.32 71.4 (14.4) – 70.2 (15.0) 68.7 (15.7) – 77.4 (15.8)
p 0.03
SOL (min) C −20.66 37.9 (40.0) – 41.4 (48.4) 29.0 (35.0) – 15.6 (28.8)
p 0.14
WASO (min) C −14.91 121.6 (62.5) – 118.8 (38.4) 145.3 (68.7) – 113.9 (70.3)
p 0.54
EMA (min) C −19.93 42.1 (46.7) – 48.2 (57.2) 54.7 (70.1) – 38.5 (54.0)
p 0.26
NoW (no) C −10.17 28.0 (11.7) – 30.8 (8.24) 32.2 (13.0) – 23.7 (14.7)
p 0.07
DTS (min) C 44.04 173.2 (127.0) – 167.1 (124.6) 207.2 (121.3) – 267.0 (120.9)
p 0.10
The table reports linear mixed model analyses for the subgroup of patients receiving active paracetamol and active buprenorphine, respectively, for the following outcome
variables: TST, total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, wake after sleep onset; EMA, early morning awakening; Now, number of wake
bouts; DTS, daytime total sleep time. The column “Treatment effect” reports the interaction effect between type of treatment and time, i.e., the main result of the clinical
trial, with baseline as the reference time point. C refers to coefficients and p refers to p-values. P-values printed in bold denote statistical significance. The column “Pre-post
sleep; mean (SD)” reports descriptive sleep characteristics for the active and placebo groups from baseline to week 13, with standard deviations in parentheses.
Limitations and Strengths
Due to the considerable attrition of patients at week 13, we
conducted linear mixed model analyses. These analyses are
appropriate to handle missing data and can take into account the
dependency of the observations (Bennett, 2001).
There was a drop-out of 22 patients in the group who received
active buprenorphine, suggesting that many patients did not
tolerate such treatment (see Table 3). This large drop-out may
have hindered our ability to detect a positive effect from the active
treatment compared to placebo. Furthermore, it should be noted
that the assignment to paracetamol or buprenorphine was not
a result of randomization, but of whether the patients qualified
for allocation to either paracetamol or buprenorphine at baseline
(and then were randomized to either active or placebo treatment).
This may produce bias by indication, since the choice of drug
might be related to the outcome.
In addition, during the last decade, there has been a change
in the prescription of pain medication for NH patients. Sandvik
et al. (2016) found that the use of paracetamol and strong opioids
increased significantly from 2000 to 2011. This affected the
inclusion of patients, since patients already taking opioids could
not be included in the study. Prior to inclusion, nine patients
were using buprenorphine, of which five patients received active
treatment and four patients received placebo treatment. This is
not a source of bias since the comparison was between baseline
data (pre-treatment) and week 13 (post-treatment). Therefore,
any potential effects measured in week 13 will be additional effects
of the treatment. However, the large drop-out in combination
with the difficulty to recruit patients to the study is a threat to
the generalizability of the study and we cannot exclude selection
bias.
Measuring sleep with actigraphy has its limitations.
Actigraphy only records movement, and a lack of movement
would therefore be assessed as sleep. The study population
had low SE, and previous studies show that actigraphy
is less accurate in distinguishing sleep from wakefulness
when SE is reduced (Sivertsen et al., 2006). Actigraphy
recordings may therefore overestimate sleep relative to
sleep diaries (Kushida et al., 2001; Sivertsen et al., 2006).
It is therefore recommended that clinicians use sleep
diaries/logs in addition to actigraphy, when evaluating sleep
in NH patients. This would have strengthened the study
design.
An additional limitation of the study was that we did not
conduct a priori power analyses. The lack of this renders us
unable to assess whether the statistical analyses had sufficient
power. It is, however, noteworthy that our sample of patients
with actigraphy was similar or larger than samples in comparable
studies (Fetveit and Bjorvatn, 2005; Dowling et al., 2008;
Camargos et al., 2014).
Compared to placebo, pain treatment did not improve sleep
in the full sample of patients, as measured with actigraphy.
However, we found a significant effect on TST and SE, when
we compared the different types of active pain treatment.
These results indicate that some patients may experience
beneficial effects of pain treatment. However, the underlying
mechanisms are unclear. The results could be an indication
that some of the patients in fact experience pain, and
hence had a positive effect of more potent pain treatment.
Future research should investigate this further, with a larger
sample size and including patients with clinically significant
pain.
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Appendix 9: Error notice – paper 3 
 
In paper 3 included in this thesis, Long-Term Pain Treatment Did Not Improve Sleep 
in Nursing Home Patients with Comorbid Dementia and Depression: A 13-Week 
Randomized Placebo-Controlled Trial (Frontiers of Psychology, 2018), there is a 
minor error in the Introduction section. 
 
On p. 2, in the final paragraph prior to the heading “Materials and Methods”, the final 
sentence reads: 
 
“In the last analysis, we aimed to examine if there were any differences within the 
active treatment group, i.e., between patients receiving active buprenorphine and 
active placebo, respectively.” 
 
Here, the word “placebo” was supposed to be “paracetamol”, as this refers to 
the comparison between active buprenorphine and active paracetamol. Thus, 
the sentence should read: 
 
“In the last analysis, we aimed to examine if there were any differences within the 
active treatment group, i.e., between patients receiving active buprenorphine and 
active paracetamol, respectively.”   
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